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1. Objective 1 (chapter 2) - Statistical analysis (Studies designed and conducted by 
collaborators) 
2. Objective 2 (chapter 3) - DNA extraction, PCR amplification and Sanger sequencing of 
three of the twelve Plasmodium falciparum antimalarial drug resistance markers (k13, 
ap2mu and falcipain-2a). The remaining drug resistance markers (crt, mdr1, dhps, nfs, 
ubp-1, as well as four artemisinin resistance predisposing mutations; arps10 codon 
V127M, crt codon I356T, fd codon D193Y and mdr2 codon T484I) were amplified and 
sequenced by members of Dr. Lynette Isabella Ochola-Oyier’s group. 
3. Objective 3 (chapter 4) - DNA extraction, PCR amplification and deep-sequencing of P. 
falciparum ama1 gene. 
4. The analysis, interpretation and presentation of all work contained here is the 
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Asymptomatic infections and anti-malarial drug resistance are impediments to malaria 
elimination. Markedly, asymptomatic infections often go undetected and untreated and this 
creates a parasite reservoir that fuels malaria transmission as well as being a risk factor for 
febrile malaria. On the other hand, drug-resistance renders antimalarial drugs ineffective and 
has been associated with increased morbidity and mortality in the past. 
Using longitudinal malaria monitoring data and Plasmodium falciparum positive samples from 
Kilifi, Kenya, (i) an evaluation was conducted to assess the impact of age and malaria 
transmission intensity on the risk of developing febrile malaria in individuals harbouring 
asymptomatic infections, (ii) amplicon deep-sequencing was used to evaluate P. falciparum 
genetic diversity in asymptomatic and febrile infections and (iii) the diversity of twelve drug-
resistance markers (crt, mdr1, dhps, nfs, k13, ap2mu, falcipain-2a, ubp-1, as well as four 
artemisinin resistance predisposing mutations; arps10 codon V127M, crt codon I356T, fd 
codon D193Y and mdr2 codon T484I) in Kilifi was evaluated using Sanger sequencing, 
including a neutral marker (serine-tRNA ligase) that is not under drug-pressure. 
Analyses of the data revealed that in the moderate and high transmission intensity settings, 
asymptomatic infections were associated with a reduced risk of febrile malaria in older 
children (>3 years), while in the lower transmission setting, asymptomatic infections were 
associated with an increased risk of febrile malaria in children of all ages. Amplicon deep-
sequencing revealed that P. falciparum genetic diversity in asymptomatic and febrile 
infections differ significantly, similar to previous reports. Also, a majority of the febrile cases 
(86%) were due to the introduction of P. falciparum clones that were not detected in the 
preceding asymptomatic episode. Regarding the analysis of antimalarial drug resistance 
markers, none of kelch 13 (k13) validated markers of artemisinin resistance were detected in 
the population, nonetheless, a single k13 allele, K189T, was maintained at a stable high 
frequency (>10%) over time. There was a distinct shift from chloroquine resistant transporter 
(crt)-76, multi-drug resistant gene 1 (mdr1)-86 and mdr1-1246 chloroquine (CQ) resistance 
alleles to a 99% prevalence of CQ sensitive alleles in the population, following the withdrawal 





(437G and 540E) associated with sulfadoxine-pyrimethamine (SP) resistance was maintained 
at a high frequency (>75%), after a change from SP to artemisinin combination therapies 
(ACTs). The novel cysteine desulfurase (nfs) K65 allele, implicated in resistance to 
lumefantrine in a West African study, showed a gradual significant decline in allele frequency 
pre- and post-ACT introduction (from 38% to 20%), suggesting evidence of directional 
selection in Kenya, potentially not due to lumefantrine. The frequency of AP-2 complex 
subunit mu (ap2-mu) S160N allele, a mutation that has been associated with directional 
selection after artemisinin combination therapy, was stable over time indicating that it is not 
under drug-pressure. On the other hand, the ubiquitin carboxyl-terminal hydrolase 1 (ubp-1) 
mutation at codon E1528D, also associated with directional selection after artemisinin 
combination therapy, was not detected. The S69Stop mutation in falcipain-2a that has been 
associated with artemisinin resistance, in vitro, was not detected and none of the artemisinin 
resistance predisposing mutations were identified. 
Asymptomatic infections were found to be modified by transmission intensity and age, 
altering the risk of developing febrile episodes and this suggested that host immunity plays a 
prominent role in mediating this process. The differences in P. falciparum genetic diversity 
between asymptomatic and febrile malaria infections can be attributed to the broader 
spectrum of immunological memory in the form of antibodies that has been found to be 
higher in asymptomatic infections compared to febrile malaria infections. While evidence of 
apparent protection from developing febrile episodes was observed in children with 
asymptomatic infections, amplicon deep-sequencing revealed that this protection was offset 
when a new infection occurred. Lastly, due to lack of the validated molecular markers of 
artemisinin resistance, there appears to be no problem of resistance in the population, 
however, continued surveillance remains a requirement. To conclude, P. falciparum genetic 
epidemiology revealed the ability to characterise P. falciparum complexity of infection (COI), 
a proxy that can be used to characterise malaria transmission intensity. Additionally, frequent 
sampling of P. falciparum positive samples from a hospital setting coupled with the molecular 
genotyping of drug resistance markers revealed the utility of P. falciparum genetic 
epidemiology in surveillance of antimalarial drug resistance.
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Chapter 1 : General Introduction 
1.1 Background 
Malaria in humans is caused by six species of unicellular protozoan parasite of the genus 
Plasmodium (the species include: falciparum, vivax, malariae, ovale curtisi, ovale wallikeri and 
knowlesi) and it is considered one of the most important infectious diseases still affecting 
mankind today. Moreover, while nearly half of the world’s population is at risk of malaria, 
sub-Saharan Africa (SSA) continues to bear the greatest burden of Plasmodium falciparum 
malaria, the species associated with the most serious morbidity and mortality worldwide 
(WHO 2018a). For this reason, efforts to reduce or eliminate malaria burden in SSA remain a 
priority. Between 2000 and 2015, the implementation of infection control measures such as 
insecticide-treated mosquito nets (ITNs) and artemisinin-based combination therapies (ACTs) 
in SSA resulted in the aversion of more than 663 million clinical cases and over 6 million deaths 
(Bhatt et al. 2015). However, while significant progress has been made, equally significant 
challenges persist. Notably, In 2017 there were an estimated 219 million malaria cases and 
approximately 435,000 deaths globally and SSA accounted for most of the global malaria 
cases (92%) and deaths (93%) (WHO 2018a). Therefore, this calls for more research to be 
done to inform malaria elimination efforts. 
1.2 The life cycle of P. falciparum 
P. falciparum, the focus of this work, is the most prevalent Plasmodium species in SSA and is 
responsible for the greatest burden of malaria (WHO 2018a). The P. falciparum life cycle 
commences when an infected female Anopheles mosquito injects Plasmodium sporozoites 
into the host during a blood meal (Figure 1.1). Some sporozoites then enter the host’s blood 
circulamon or lymphamc system and traffic to the liver. There, the sporozoites cross the 
sinusoidal layer, primarily through Kupffer cells to access hepatocytes - liver cells (Pradel and 
Frevert 2001). Sporozoites migrate through several hepatocytes before invading a final 
hepatocyte, in which a parasitophorous vacuole is formed (Mota et al. 2001). Here, the 
sporozoites develop by a process of schizogony into merozoite forms. The parasites then 
induce death and detachment of their host hepatocytes, followed by the budding of parasite-





Approximately 30,000 merozoites rupture from an infected liver cell to invade red blood cells 
(RBCs). Some Plasmodium spp. such as P. vivax also develop into a small number of latent 
stage forms called "hypnozoites". These latent-stages can revert to acmve infecmve parasites 
that cause clinical relapses of malaria within weeks or months of the original infecmon 
(Cogswell 1992). Upon the invasion of RBCs, merozoites first develop into ‘ring’ trophozoites, 
then mature into trophozoites and finally into a schizont containing up to 32 new merozoites. 
These schizont-infected RBCs synchronously rupture to release merozoites, which can invade 
new RBCs, resulmng in an exponenmal increase in parasite biomass. This mulmplicamon and 
invasion of RBCs lead to illness and complicamons of malaria. 
The Plasmodium life cycle conmnues when some merozoites develop into the sexual parasite 
stages, male and female gametocytes, the form that is taken up by the mosquito host 
(Silvestrini, Alano and Williams 2000; Smith et al. 2000). The mechanism underlying 
commitment to sexual differentiation in P. falciparum was only recently shown to be an 
epigenetically regulated process. Two recent studies showed that the AP2 domain 
transcription factor (AP2-G) is a key regulator of gametocytogenesis, as in the absence of AP2-
G parasites do not produce gametocytes, both in P. falciparum (Kafsack et al. 2014) and its 
murine relative, P. berghei (Sinha et al. 2014). Following gametocytogenesis, male and female 
gametocytes emerge from within their infected erythrocytes and undergo fermlisamon, zygote 
formamon and development into the momle ookinete which infect the mosquito’s midgut 
(Angrisano et al. 2012). From here, they develop into oocysts that burst to release sporozoites 








Figure 1.1. The P. falciparum life cycle. The figure shows the cycle in the human host which 
commences with sporozoites invading the liver, the sporozoites then mature and rapture to 
release merozoites. These merozoites invade red blood cells to begin the asexual cycle, 
accompanied by clinical manifestations of malaria. This is followed by the production of male 
and female gametocytes which are transmitted back to the mosquito (during a blood meal) 
where they fuse to form oocysts that divide to create sporozoites. The sporozoites migrate to 
the mosquito’s salivary glands from where the cycle of infection starts again. Adapted from 
Michalakis and Renaud (2009). 
 
1.3 Laboratory diagnosis 
The WHO recommends the confirmation of the presence of malaria parasites in suspected 
malaria cases before antimalarial treatment. Consequently, microscopy of stained blood films 
remains the gold standard for diagnosis of malaria (WHO 2015). However, rapid diagnostic 
tests (RDTs) are now widely used as the first-line diagnostic tool and given the predominance 
of P. falciparum in Africa, a P. falciparum-only RDT is often used, which is based on the 
histidine-rich protein 2 (HRP2) specific to P. falciparum. Nonetheless, some RDTs include an 
additional Plasmodium lactate dehydrogenase (p-LDH) band for the detection of non-





deletions provide new obstacles in the path of malaria elimination and warrant regular 
surveillance for such mutations (Verma, Bharti and Das 2018). 
Microscopy, the gold standard, typically detects 50 parasites/µl in European reference 
laboratories (Bejon et al. 2006). However, this may vary in the field where detection may 
range between 50 and 100 parasites/µl because of lower quality reagents and less stringent 
protocols for slide preparation (Wongsrichanalai et al. 2007). RDTs show a sensitivity similar 
to that of good microscopy, approximately 100 parasites/µl, but even these may fail to detect 
lower density infections (Wongsrichanalai et al. 2007). Therefore, nucleic acid amplification-
based tests offer greater sensitivity and can reach limits of 0.02 parasites/µl (Mahajan et al. 
2012). That said, microscopy remains the most affordable diagnostic method for diagnosis, 
especially in the resource-limited settings of Africa.  
1.4 Manifestations of malaria 
Manifestation of P. falciparum infection ranges from asymptomatic parasitaemia, 
uncomplicated malaria, through to severe malaria. Asymptomatic malaria infections can be 
defined as infections that lack typical clinical malaria symptoms but whose parasitemia is 
detectable by microscopy, rapid diagnostic tests (RDTs) or molecular methods (Bousema et 
al. 2014). Uncomplicated malaria infections typically present with fever and without signs of 
severity or evidence (clinical or laboratory) of vital organ dysfunction and since the signs and 
symptoms of uncomplicated malaria are nonspecific, it is clinically diagnosed based on fever 
or a history of fever (WHO 2015). This, however, presents a challenge in distinguishing 
uncomplicated malaria from Dengue fever and Chikungunya (viral infections) since clinical 
presentations tend to be shared, these infections are co-endemic both in SSA and South-East 
(SE) Asia and fever is the most common symptom (Salam et al. 2018). Severe falciparum 
malaria presentations are varied and include the following:  
• cerebral malaria - unrousable coma with peripheral P. falciparum parasitaemia after 
exclusion of other causes of encephalopathy.  






• respiratory distress - pulmonary oedema or acute respiratory distress syndrome  
• renal failure - urine output of less than 400 ml in 24 h (or <12 ml/kg in children) and a 
serum creatinine >265 mmol/l (>3.0 mg/dl).  
• Hypoglycaemia - whole blood glucose <2.2 mmol/l (40 mg/dl). 
• circulatory collapse (shock) - systolic blood pressure <70 mmHg or core-skin 
temperature difference >10°C. 
• coagulation failure - spontaneous bleeding and/or laboratory evidence of 
disseminated intravascular coagulation (WHO 2000).  
The malaria disease spectrum is quite complex and is influenced by factors related to the host, 
parasite, vector and the environment. In order to effectively implement anti-malaria 
interventions, a deeper understanding of the epidemiology of malaria is crucial. 
1.5 Epidemiology of falciparum malaria 
1.5.1 The malaria burden 
According to the World Malaria Report of 2018 (WHO 2018a), 20 million fewer malaria cases 
were reported in 2017 than in 2010, but there was no significant progress in reducing global 
malaria cases for the period 2015-2017. Fifteen countries in SSA and India carried almost 80% 
of the global malaria burden and the 10 highest-burden countries in SSA reported increases 
in cases of malaria in 2017 compared with 2016. In contrast, India reported 3 million fewer 
cases in the same period, a 24% decrease compared with 2016. While SE Asia continued to 
witness a decline in incidence rates (from 17 cases per 1000 population at risk in 2010 to 7 in 
2017, a 59% decrease), the malaria incidence rate remained at 219 cases per 1000 population 
at risk in SSA for the second year in a row. P. falciparum remained the predominant parasite 
in SSA and accounted for 99% and 62% of estimated malaria cases in 2017 in SSA and SE Asia, 
respectively. In comparison, P. vivax was the predominant parasite in the South Americas, 
representing 74% of malaria cases. Approximately 80% of global malaria deaths in 2017 were 
concentrated in 17 countries in the SSA and India. Conversely, while SSA experienced the 
highest number of malaria deaths in 2017, it experienced 151,000 fewer malaria deaths 





1.5.2 Malaria endemicity 
Malaria endemicity can be used to indicate disease prevalence and may help to design, 
implement and monitor malaria control and prevention activities. Various methods exist for 
classifying malaria endemicity (Autino et al. 2012), including (i) the proportion of individuals 
in a population with a substantial enlargement of spleen (spleen rate), (ii) the proportion of 
individuals in a population with a laboratory-confirmed parasite infection (parasite rate), (iii) 
the number of infective bites per person (entomological inoculation rate) and (iv) the number 
of microscopically confirmed malaria cases detected during one year per unit population 
(annual parasite incidence). Of these, EIR best quantifies endemicity as it is more directly 
related to morbidity and mortality than the rest, however, measuring EIR requires intensive 
entomological studies over the whole annual period of malaria transmission (Beier, Killeen 
and Githure 1999). Though variable, SSA has the highest annual EIRs that range from 0.6 to 
814 (Kelly-Hope and McKenzie 2009) compared to SE Asia which has low EIRs such as 0.3 in 
India, 2.2 in Vietnam, 3 in Thailand and 0.13 in Myanmar (Chattopadhyay et al. 2004; Van 
Bortel et al. 2010; Kwansomboon et al. 2017; Chaumeau et al. 2019). 
How does the burden of malaria vary with malaria transmission intensity? In a study by 
Carneiro et al. (2010) that included 86 studies from SSA, episodes of uncomplicated malaria 
were fairly evenly distributed across all ages and this burden shifted towards younger age 
groups as transmission intensity increased. Hospital admissions due to falciparum malaria 
were found to be concentrated in younger children, as did severe cases of malaria, and these 
were more likely with increasing transmission intensity. Moreover, malaria-diagnosed 
mortality was more focused in younger children than admissions with malaria in all settings. 
All three outcomes, uncomplicated malaria, hospital admissions with falciparum malaria and 
malaria-diagnosed mortality, were biased towards younger ages.  
In a similar study, Roca-Feltrer et al. (2010) evaluated the relationship between age patterns 
and severe malaria syndromes (cerebral malaria - CM, severe malarial anaemia - SMA and 
respiratory distress - RD) from 67 studies in SSA. They observed that increasing transmission 
intensity shifted the burden of CM towards younger age groups however, this was not 





of SMA, including HIV and malnutrition, which may mask the relationship between 
transmission intensity and SMA. On the other hand, admissions of RD frequently occur with 
SMA and CM and like SMA, this may mask the relationship between transmission intensity 
and SMA. 
This shift in the malaria burden as a consequence of malaria transmission intensity is a result 
of the rapid acquisition of immune responses that limit the life-threatening effects of malaria 
due to increasing exposure to P. falciparum (Doolan, Dobaño and Baird 2009). Nevertheless, 
while declines in malaria transmission intensity have been associated with a shift in malaria 
morbidity towards older children due to reduced exposure, strategies for averting malaria 
mortality and severe morbidity in young children are still appropriate.  
1.5.3 The distribution of Anopheles species 
The Anopheles gambiae complex is the most effective and efficient of P. falciparum vectors 
and predominates if SSA, leading to some of the highest EIRs and the highest malaria 
prevalence worldwide (Guerra et al. 2008). Four principal species of An. gambiae complex 
exist, including An. gambiae, An. arabiensis, An. merus and An. melas. However, three 
additional anthropophilic vectors exist in SSA including An. funestus, An. moucheti and An. nili 
(Sinka et al. 2010). Conversely, An. Dirus and An. darlingi are considered the most important 
malaria vectors in SE Asia and South America, respectively (Obsomer, Defourny and 
Coosemans 2007; Sinka et al. 2010). 
Vector distribution is influenced by environmental factors such as rainfall patterns, 
temperature, humidity, presence of vegetation and surface water and hence impact on the 
malaria transmission cycle. Human activities such as agriculture, irrigation, deforestation, 
urbanization and population movements are also connected to transmission levels and 
malaria epidemiology (De Silva and Marshall 2012), further revealing how complex the 
malaria transmission cycle is and the need for a multi-faceted approach to tackling malaria. 
1.5.4 The distribution of Plasmodium species 
P. falciparum is prevalent in virtually all malaria-endemic countries. In SSA, P. falciparum is 





(Culleton et al. 2008). Vivax malaria is less prevalent in SSA because many individuals are 
Duffy antigen-negative, however, there have been reports of vivax infections in Duffy-
negative individuals in SSA (Zimmerman 2017). Thus, whether vivax malaria was undetected 
in SSA in the past or the parasite has adapted to infect Duffy negative individuals, it remains 
to be seen how significant vivax malaria will be in SSA. In contrast, numbers of malaria 
incidences in SE Asia and Oceania are generally lower and are caused by both P. vivax and P. 
falciparum, whereas in South America, vivax malaria cases exceed falciparum by more than 
two-fold (WHO 2018a).  
The P. ovale species is relatively less prevalent compared to other malaria parasites, occurring 
in <5% of cases associated with the parasite, however, higher prevalence has been observed 
for example in Cameroon where one study reported a prevalence greater than 10% (Collins 
and Jeffery 2005). P. malariae is spread in SSA, SE Asia and South America and its distribution 
overlaps with that of P. falciparum (Collins and Jeffery 2007). Still, the distribution of P. 
malariae is relatively sparse, variable and is endemic to West-Africa (Roucher et al. 2014), 
South America (Scopel et al. 2004), SE Asia (Zhou et al. 1998; Mohapatra et al. 2008) and the 
western Pacific region (Mueller et al. 2005). P. knowlesi is a parasite of the long-tailed and 
pig-tailed macaques (Vythilingam et al. 2008), however, it can also infect humans and 
infections are localized in SE Asia because the long-tailed and pig-tailed macaques inhabit the 
forests of SE Asia (Mason Dentinger 2016).  
1.6 Malaria case management 
For uncomplicated P. falciparum malaria, the WHO (WHO 2015) recommends treatment of 
children and adults (except pregnant women in their first trimester) with one of the following 
ACTs: artemether-lumefantrine (AL), artesunate-amodiaquine (AS-AQ), artesunate-
mefloquine (AS-MQ), dihydroartemisinin-piperaquine (DHA-PPQ) and artesunate + 
sulfadoxine-pyrimethamine (AS-SP). In low-transmission areas, a single low dose of 0.25 
mg/kg primaquine with an ACT is recommended for patients with P. falciparum malaria 
(except pregnant women, infants aged <6 months and women breastfeeding infants aged <6 
months) to reduce transmission without the need for glucose-6-phosphate dehydrogenase 





associated with haemolysis, a single low dose is associated with acceptable haemolytic risk 
(Pamba et al. 2012). 
Malaria in the first trimester of pregnancy is treated with quinine and clindamycin. However, 
in areas where clindamycin is unavailable, quinine monotherapy is prescribed. For second and 
third trimesters, AL, AS-AQ, AS-MQ and DHA-PPQ are recommended, though AL is associated 
with less adverse effects and DHA-PPQ is associated with the greatest post-treatment 
prophylaxis (WHO 2015). 
Patients presenting with severe malaria are treated with parenteral artesunate (WHO 2014a). 
Additional measures include urgent correction through blood transfusion for severe anaemia 
(haemoglobin <6g/dl) (Maitland et al. 2019). Patients with cerebral malaria should have blood 
cultures taken, a lumbar puncture performed and administered with broad-spectrum 
antibiotics, pending negative culture results and clinical improvement (WHO 2013). For 
patients presenting with respiratory distress (acidosis), reversible cause of acidosis 
(dehydration and severe anaemia) are corrected by intravenous infusion, an excess of which 
may precipitate pulmonary oedema. Hypoglycemia should be corrected with 500mg/kg of 
glucose and monitored even after successful correction, as hypoglycemia may recur (WHO 
2013). Circulatory collapse (shock) is corrected with fluids at 3–4ml/kg per hour, blood is 
taken for culture and the patient is put on appropriate broad-spectrum antibiotics 
immediately (WHO 2013). 
1.7 Immunity against malaria 
Repeated exposure to infectious mosquito bites leads to the acquisition of naturally acquired 
immunity (NAI), however, this protection is only limited to the disease and does not clear the 
blood-stage infection (Doolan et al. 2009). Nevertheless, sterile protection can be achieved 
against a homologous challenge by the inoculation of sporozoites (Roestenberg et al. 2009). 
NAI protects one from severe disease and death and is acquired within the first five years of 
life in areas of high transmission such as in SSA, whilst immunity to mild disease is acquired 
by late adolescence (Marsh and Kinyanjui 2006). Consequently, children tend to be protected 





chronic, asymptomatic infection, to which even individuals growing up in malaria-endemic 
areas remain susceptible to, for life (Doolan et al. 2009). Independent of prior exposure, 
adults acquire NAI to malaria faster than children, as was seen in a study conducted in 
Indonesia that compared immune responses between native residents of a P. falciparum-
endemic region and trans-migrants following their re-settlement from non-P. falciparum-
endemic islands (Baird et al. 1993). Hence, these findings suggest that NAI to malaria is not 
only a function of exposure but at least partly attributable to inherent age-specific host 
factors, such as a mature or fully developed immune system. 
In P. falciparum, NAI has been associated with the sequential acquisition of antibodies and P. 
falciparum erythrocyte membrane protein 1 (PfEMP1), a protein expressed on the surface of 
parasitized erythrocytes, has been implicated as the key target (Dodoo et al. 2001). This 
sequential acquisition of antibodies is the result of cumulative exposure to multiple parasite 
infections over time, yielding a diverse repertoire of strain-specific immune responses. In fact, 
P. falciparum antigens, the targets of NAI, are highly diverse. In a study conducted in Mali to 
assess the genetic diversity of apical membrane antigen 1 (ama1), Takala et al. (2009) 
identified as many as 214 distinct ama1 variants in P. falciparum infections experienced by 
100 individuals over 3 years. This poses a challenge in the design of a malaria vaccine because 
of the immense amount of antigenic diversity to be dealt with, hence there is a need to 
identify immunodominant targets that are likely to be more conserved. 
In high transmission settings such as in SSA, it may take 10 to 15 years of roughly five 
infections per year to develop NAI to malaria (Doolan et al. 2009). However, this immunity is 
lost gradually after an individual leaves an endemic area or in a population with falling 
transmission (Ghani et al. 2009). Additionally, while reducing malaria transmission is a major 
component of malaria elimination efforts, there appears to be a detrimental impact. Recent 
studies have associated declines in malaria transmission with higher rates and severity of 
clinical malaria (O’Meara et al. 2008; Griffin, Ferguson and Ghani 2014; Njuguna et al. 2019), 
something that may be attributed to declining NAI in populations. Considering this, it is 
important to prevent a re-introduction of malaria in an area that has managed to interrupt 





1.8 Malaria prevention and control 
According to the latest high-resolution falciparum-malaria maps for the period 2000-2017 
(Weiss et al. 2019), the world has witnessed a rapid decline in malaria burden between 2005 
and 2017 with clinical episodes declining by 27% and mortality declining by 42%. 
Notwithstanding a growing population in malaria-endemic regions, clinical cases declined 
between 2005 and 2017, from 232 million to 193 million. On the other hand, malaria-related 
deaths declined from 925,000 to 618,000, demonstrating the progress made in combating 
malaria. Still, this progress appears to have stalled between 2015 and 2017 as there was an 
increase in clinical cases from 214 million in 2015 to 219 million in 2017, globally. Novel 
interventions are therefore needed to reverse the curve and accelerate the decline in the 
malaria burden. 
Several factors can be attributed to the recent decline in malaria burden including, but not 
limited to, vector control, mass drug administration (MDA), as well as early diagnosis and 
treatment. The two main vector control strategies, ITNs and indoor residual spraying (IRS), 
are used to target mosquitoes indoors, but do not prevent biting for vectors that prefer to 
feed outdoors (Kenea et al. 2016). ITNs and IRS act by breaking the chain of transmission 
between the mosquito vector and the human host and both have had remarkable success in 
reducing both the malaria parasite prevalence and incidence across a range of transmission 
settings. IRS has been associated with significant disruption in malaria transmission, is known 
to eliminate malaria vectors and has enabled the reduction of malaria incidences (Pluess et 
al. 2010). With regards to ITNs, results from a systematic review using national cross-sectional 
survey datasets in SSA showed that ITN possession was associated with a 20% reduction in P. 
falciparum prevalence (from seven surveys in seven countries) and a 23% reduction in all-
cause child mortality (from 29 surveys in 22 countries) (Lim et al. 2011). Similar findings were 
reported in a more recent Cochrane review that included data from 23 trials enrolling more 
than 275,793 adults and children (1987 and 2001) (Pryce, Richardson and Lengeler 2018). ITN 
use was associated with a 17% reduction in all-cause child mortality and also reduced the 
incidence of uncomplicated clinical episodes by half. ITNs were also associated with a 17% 





Nevertheless, ITN coverage remains insufficient and efforts need to be stepped up to ensure 
universal coverage (WHO 2018a). Additionally, insecticide resistance to the four classes of 
insecticides (pyrethroids, organochlorines, organophosphates and carbamates) presents a 
major obstacle to vector control (Coleman et al. 2017).  
MDA involves the administration of a full dose of antimalarial treatment to an entire 
population in a given area, regardless of the symptoms or presence of infection - except those 
in whom the medicine is contraindicated. Also, to reduce malaria transmission, MDA aims to 
provide therapeutic concentrations of antimalarial drugs to as large a proportion of the 
population as possible to cure asymptomatic infections and to prevent re-infection during the 
period of post-treatment prophylaxis (WHO Global Malaria Programme 2015). MDA has been 
used for malaria control since the 1930s and was backed by WHO for malaria elimination and 
eradication in the 1950s (Poirot et al. 2013). Moreover, MDA has been shown to be successful 
in combination with other malaria control measures, such as vector control. For example, 
MDA with SP combined with IRS achieved high levels of malaria control in Northern Nigeria 
in 1969 (Molineaux and Gramiccia 1980), although the effect was short-lived. More recently, 
a review of published literature on MDA by Poirot et al. (2013), included areas of different 
endemicity, various antimalarials and dosages, different timings and the number of MDA 
rounds as well as the simultaneous implementation of vector-control measures. The review 
concluded that MDA appears to reduce malaria parasitaemia rapidly plus several clinical 
outcomes. However, more studies are required to assess the impact after 6 months, assess 
the barriers for community uptake and explore the potential impact on the development of 
drug resistance. To date, MDA has not been adopted as official policy in any SSA country.  
The rationale for early diagnosis and treatment (EDT) is to offer a means of reducing 
transmission of P. falciparum from febrile individuals. Thus, treating P. falciparum-infected 
patients after the onset of fever is expected to prevent further transmission of the parasite 
(Landier et al. 2016). Equally, a delay in treatment means that a patient is more likely to 
remain infectious even after being treated because gametocytes, the transmissible sexual 
forms of P. falciparum, may persist for several weeks even after clearance of asexual parasites 





primaquine to ACT regimens has been shown to target gametocytes and reduces P. 
falciparum transmission (Graves et al. 2018). In a review by Landier et al. (2016), a 
community-based EDT for malaria is made up of three main components including trained 
personnel, quality RDT and effective anti-malarial drugs. The continuous availability of these 
tools is expected to provide reliable diagnosis and effective treatment for any clinical malaria 
case from the community within 24–48 hours of fever onset. While a functioning EDT network 
embodies an essential component of any malaria elimination strategy, it may be unavailable 
in resource limited settings, such as those in SSA, and efforts should be geared towards 
establishing and sustaining them. 
1.9 Malaria elimination 
While the idea of eliminamng malaria presents methodical challenges, it comes with vast 
economic, equity and health benefits. Cermficamon of malaria eliminamon by the WHO is the 
official recognimon of a country being free of indigenous malaria cases, based on an 
independent evaluamon verifying interrupmon of transmission and the country’s ability to 
prevent re-establishment of transmission for all human malaria parasites. Addimonally, a 
country must report zero indigenous cases of malaria for 3 consecumve years (WHO 2018a). 
To achieve global malaria eliminamon, there is a need for advancements that will transform 
the malaria community’s ability to tackle the disease. 
Vector control, acmve surveillance and efficient case management have been instrumental in 
sexng several countries on the path to eliminamng malaria. Between the years 2000 and 
2017, 19 countries (three in Africa including Algeria, Egypt and Morocco) ayained zero 
indigenous cases for 3 years or more and 21 countries (six in Africa including Algeria, 
Botswana, Cape Verde, Comoros, Eswamni and South Africa) have been idenmfied as having 
the potenmal to eliminate malaria by 2020 (WHO 2018a). With the prevalence of malaria being 
heterogeneous both locally and across geographic regions, a single approach aimed at 
eliminamng the disease will not work across all sexngs with the same effecmveness. 
Therefore, the path to malaria eliminamon as recommended by the WHO (WHO 2017) is 
organised into four components: firstly, enhancing and opmmizing vector control and case 





all areas. Secondly, increasing the sensimvity and specificity of surveillance to tackle malaria 
cases and respond appropriately. Thirdly, acceleramng transmission reducmon in which 
intervenmons such as MDA are included and lastly, once very low intensity of transmission has 
been achieved, a country must be capable of finding the few remaining infecmons and any foci 
of ongoing transmission, idenmfy them and clear them. 
Even with the recent reports of declining falciparum malaria transmission globally, concerted 
efforts are smll needed to achieve complete eliminamon of malaria in SSA and SE Asia. This is 
because many regions in SSA and SE Asia smll lack significant malaria-free areas and 
transmission rates remain substanmal even azer several years of conmnuous intervenmon 
programmes. Also, while gains have been made, several challenges persist that pose 
challenges to malaria eliminamon, including insecmcide resistance, anmmalarial drug 
resistance, chronic asymptomamc infecmons and extensive parasite genemc diversity and these 
are discussed below.  
1.9.1 Insecticide resistance 
Insecticide resistance can be defined as the ability of mosquitoes to survive exposure to a 
standard dose of insecticide as a result of physiological or behavioural adaptation. Resistance 
to insecticides (pyrethroids, organochlorines, organophosphates and carbamates) is 
prevalent in Anopheles mosquitoes in all malaria-endemic countries, especially resistance to 
pyrethroids, the class of insecticides used on all ITNs (WHO 2018a).  
The mechanisms by which mosquitoes develop resistance to insecticides can be grouped into 
four distinct categories (Corbel and N’Guessan 2013) including metabolic resistance, target-
site resistance, reduced absorption and behavioural avoidance with the most common 
mechanism being metabolic resistance. This form of resistance is based on the enzyme 
systems which enables insects to detoxify naturally occurring insecticides and can result in 
high levels of insecticide resistance. The second most common resistance mechanism is 
target-site resistance. Insecticides largely act at a specific site within the insect, usually within 
the nervous system and the site of action can be modified in resistant strains of insects, hence 





modifications in the insect cuticle or digestive tract linings that prevent or slow the absorption 
of insecticides. Behavioural changes, that are not based on biochemical mechanisms, enable 
insects to escape lethal doses of insecticides in response to prolonged exposure. 
Regular monitoring for insecticide resistance is essential as it can negatively impact vector 
control. There are three main ways for detecting insecticide resistance including bioassays, 
biochemical and molecular tests (WHO 2016). Bioassays involve the exposure of samples of 
insects from a wild population to a fixed concentration of insecticide on test papers, so that 
any survivors may be assumed to be resistant. Biochemical tests have now been 
supplemented with molecular tests that are presently only available for target-site resistance, 
and resistance to pyrethroids (used in all ITNs) is associated with genetic mutations in the 
para-type sodium channel gene. These mutations cause reduced neuronal sensitivity and are 
termed knockdown resistance (kdr). Two mutations, L1014F prevalent in W. Africa and 
L1014S in E. Africa have been reported in pyrethroid-resistant An. gambiae (Torre et al. 2001; 
Stump et al. 2004; Awolola et al. 2005). 
It is worrying that pyrethroids are gradually becoming less effective at killing mosquitoes 
(Ranson and Lissenden 2016) and it is predicted that this drop in effectiveness could lead to 
increased malaria incidences (Churcher et al. 2016). However, while insecticide resistance 
may negatively impact on the use IRS, it appears that ITNs are still effective in regions where 
insecticide resistance has been documented (Kleinschmidt et al. 2018). Still, the lack of 
effective insecticides may hamper vector control interventions.  
1.9.2 Anti-malarial drug-resistance 
Antimalarial drugs have played an important role in the treatment and control of malaria. The 
major classes of antimalarial drugs include (Farooq and Mahajan 2004) quinoline that was 
developed from the structural modification of quinine and include 4-aminoquinoline 
compounds such as chloroquine (CQ) and mefloquine (MQ). The second class of drugs include 
antifolates such as proguanil, chloroproguanil, pyrimethamine and trimethoprim and sulfa 
drugs like dapsone, sulfalene, sulfamethoxazole and sulfadoxine. These drugs are used in 





The third class of drugs include artemisinin compounds (artesunate, artemether, arteether), 
components of the current first-line drugs, ACTs, are synthesised from the plant Artemisia 
annua. In 1993 Malawi became the first African country to replace CQ with SP (Kublin et al. 
2003) and other countries followed soon after including Kenya in 1999 (Shretta et al. 2000). 
However, following extensive SP resistance, ACTs replaced SP as the first-line antimalarial 
drug in all malaria endemic countries including Kenya in 2004 (Amin et al. 2007). 
Extensive use of antimalarials has exerted selective pressure on P. falciparum and caused the 
spread of resistant parasites with increased malaria morbidity and mortality (Trape et al. 
1998; Korenromp et al. 2003). To date, resistance has been reported to all the commonly 
used antimalarials, in particular, reduced efficacy of former first-line drugs (CQ and SP) and 
current first-line drugs, ACTs. The identification of P. falciparum genetic mutations associated 
with antimalarial drug-resistance has provided molecular markers for surveillance of 
resistance, both in real-time and retrospectively, to assess geographic origins and migration 
patterns of drug-resistant parasites (Cravo, Napolitano and Culleton 2015). 
1.9.2.1 Chloroquine (CQ) resistance 
Chloroquine resistance (CQR) emerged independently in SE Asia (at the Thai-Cambodian 
border) and South America (in Colombia) in the late 1950s and then spread to all malaria-
endemic regions (Dondorp et al. 2010). Although the mechanism of CQ is yet to be 
understood, it is believed to act by binding to heme molecules in the parasite food vacuole. 
Heme, a by-product of haemoglobin digestion, is toxic to the parasite hence it is detoxified 
into hemozoin, which is recognized as ‘malaria pigment’ by light microscopy. By binding to 
heme, CQ interferes with the detoxification process, leading to the killing of parasites (Orjih, 
Ryerse and Fitch 1994). CQ resistance has been associated with reduced CQ accumulation in 
the food vacuole, hence, CQ sensitive parasites (CQS) accumulate much more CQ in the 
digestive vacuole than CQR parasites. Consequently, CQ sensitive parasites (CQS) accumulate 
much more CQ in the digestive vacuole than CQR parasites (Saliba, Folb and Smith 1998). 
Moreover, point mutations in the genes encoding for the P. falciparum chloroquine resistance 
transporter (Pfcrt) and P. falciparum multidrug resistance gene (Pfmdr1) have been 





The P. falciparum chloroquine resistance transporter (crt) is the primary target gene for CQR 
by extensive mapping of a genetic cross between CQ sensitive (CQS) and resistant clones 
(Fidock et al. 2000; Djimdé et al. 2001). The crt gene encodes a protein consisting of 424 
amino acids that is localized to the parasite's food vacuole and has 10 predicted 
transmembrane domains. A mutation at codon 76 (lysine to threonine, K76T) is associated 
with CQR in P. falciparum clones from wide geographic areas (Fidock et al. 2000) and it is 
thought that increased efflux of CQ from the food vacuole mediated by crt might be 
associated with the reduction of CQ concentrations in P. falciparum resistant isolates 
(Sanchez et al. 2005).  
The geographical spread of CQR was described using polymorphic microsatellite markers 
flanking the crt gene (Wootton et al. 2002). It was revealed that a single resistant crt 
haplotype, spanning codons 72-76 (CVIET) spread to very high frequencies throughout most 
of Asia and Africa while the SVMNT haplotype emerged independently and spread in South 
America. The withdrawal of CQ from widespread use resulted in the resurgence of the CQS 
haplotype (CVMNK), in areas such as Malawi (Kublin et al. 2003) and Kenya (Okombo et al. 
2014). This has been attributed to a reduction in CQ pressure at a fitness cost to resistant 
parasites due to enhanced survival of drug-susceptible parasites. 
The P. falciparum multidrug resistance gene (pfmdr1) was identified as the second candidate 
CQ drug-resistant marker in 1989 (Foote et al. 1989; Wilson et al. 1989). The gene encodes a 
homologue of the mammalian multidrug resistance gene, termed P-glycoprotein homolog 1 
(Pgh1) (Cowman 1991). Five polymorphisms occurring at codons N86Y, Y184F,  S1034C, 
N1042D and D1246Y have been associated with CQR (Foote et al. 1990). However, earlier 
studies showed that mdr1 mutants might not directly cause CQR, but may augment CQR since 
transfection of mdr1 mutants (at codons 86, 1034, 1042 and 1246) into a susceptible CQS 
clone did not produce a pronounced change in response to CQ (Haruki et al. 1994). 
Subsequently, it has been shown that the 86Y mutation in mdr1 increases the CQ IC50 in P. 
falciparum parasites harbouring crt-76T (Babiker et al. 2001). In Kenya, the triple mutant 





ACT introduction but has since not been detected in the population, similar to the crt CQR 
haplotypes (Okombo et al. 2014). 
1.9.2.2 Sulfadoxine-Pyrimethamine (SP) resistance 
Sulfadoxine and pyrimethamine belong to a class of antimalarial drugs called antifolates 
because they target the parasites folate pathway (Ross and Fidock 2019). SP replaced CQ as 
CQR was associated with a significant increase in mortality (Trape et al. 1998). Soon after, 
resistance to SP emerged, spread and was also associated with an increase in malaria-related 
mortality (Korenromp et al. 2003). For this reason, SP is no longer used for the treatment of 
clinical malaria, however, it continues to be used as prophylaxis and is administered routinely 
as intermittent preventive treatment in pregnant women (IPTp) (WHO 2014b). The antifolate 
effects of SP are derived from the inhibition of two enzymes in the folate synthesis pathway, 
dihydropteroate synthase (dhps) (Zhang and Meshnick 1991) by sulfadoxine and 
dihydrofolate reductase (dhfr) by pyrimethamine (Olliaro and Yuthavong 1999), eventually 
inhibiting nuclear division. 
The dhfr gene encodes a bifunctional protein, consisting of the dhfr domain in the first 231 
amino acids and the TS domain in the last 288 residues, separated by 89 residues of the inter-
junction region between them (Bzik et al. 1987). Multiple mutations in dhfr at codons 50, 51, 
59, 108, and 164 have been demonstrated to be the major determinant of pyrimethamine 
resistance. However, the mutation at codon 108 appears to be the most essential for in vitro 
pyrimethamine resistance while additional mutations synergistically increase the levels of 
resistance. For example, 108N mutation increases the IC50 of pyrimethamine by up to 50 fold 
above that of the wild-type S108, while the double mutants S108N+N51I or S108N+C59R, 
increase resistance by up to 16 fold over the 108N single mutant (Peterson, Walliker and 
Wellems 1988; Foote, Galatis and Cowman 1990). Other studies have shown that triple 
mutants (N51I+C59R+S108N and C59R+S108N+I164R) demonstrate higher IC50 to 
pyrimethamine compared to double mutants (Peterson, Walliker and Wellems 1988; Foote, 
Galatis and Cowman 1990; Basco et al. 1995) while others find that the quadruple mutant 






The dhps gene is the target of sulfadoxine and is encoded by a single copy gene and dhps 
mutations confer resistance to sulfadoxine by decreasing affinity for the enzyme (Triglia et al. 
1997). To date, five mutations have been associated with sulfadoxine resistance, including 
436, 437, 540, 581, and 613 in a stepwise manner. In an earlier study (Triglia et al. 1998), the 
mutation at codon A437G was found to confer a 4.8-fold increase in the IC50 to sulfadoxine 
over wild-type parasites. However, an additional mutation at codon S436A did not 
significantly increase the IC50 to sulfadoxine at either codon S436A or A581G. On the other 
hand, triple dhps mutants conferred a substantial increase in sulfadoxine resistance, a 9.8-
fold increase over wild-type (S436A+A437G+K540E) and a 24-fold increase over wild-type 
(S436A+A437G+A613S). The mechanism by which these mutations confer resistance is not 
yet fully understood, but one study suggested that the mutations may result in lowered 
affinity of sulfadoxine for the active site (de Beer, Louw and Joubert 2006). 
Similar to other sites in Africa, Kenya has a high frequency of SP resistance markers (Mwai et 
al. 2009b; Okombo et al. 2014) even though SP was withdrawn as first-line treatment and 
highlights the need for ongoing surveillance since SP is still recommended for IPTp. 
1.9.2.3 Artemisinin combination therapy resistance 
The WHO recommends ACTs as first-line treatment for falciparum malaria, following 
widespread resistance to former first-line treatments (CQ and SP) (WHO 2015). Sufficient 
parasitological and clinical therapy by ACT drugs is dependent on the rapid reduction in 
parasite biomass by the short-acting but potent artemisinin component followed by the 
elimination of residual parasites by the longer-acting partner drug (White, Van Vugt and Ezzet 
1999). Various combinations of ACTs exist, but artemether-lumefantrine (AL) and artesunate-
amodiaquine (AL+AQ) are the first-line treatment policies used in most SSA countries, with 
some countries adding dihydroartemisinin-piperaquine (DHA+PPQ) as second-line treatment 
(WHO 2018b). The success of ACT use is evident as substituting failing treatments of 
chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) with ACTs has been associated with 
reduced malaria-related morbidity and mortality (Bhatt et al. 2015; Gething et al. 2016). 
However, the emergence and spread of artemisinin resistance in SE Asia (Noedl et al. 2008; 





and SP were imported to Africa from Asia (Wootton et al. 2002; Roper et al. 2004; Mita et al. 
2011). Nonetheless, some studies have shown that some dhps, dhfr and mdr1 alleles emerged 
independently in Africa based on typing of microsatellite markers (Alam et al. 2011). 
1.9.2.3.1 Artemisinin 
The mode of action of artemisinin is believed to involve iron-catalysed scission of its 
endoperoxide bridge that leads to widespread alkylation and oxidative damage inside the 
asexual blood stage parasite (Wang et al. 2015a; Ismail et al. 2016). The primary source of 
iron that is required to activate artemisinin is mainly derived from parasite-mediated 
digestion of host haemoglobin digestion (Xie et al. 2016). The clinical derivatives of 
artemisinin (dihydroartemisinin, artemether and artesunate) have the potential to reduce the 
biomass of a drug-sensitive infection by up to 10,000-fold every 48-hour asexual blood-state 
cycle. However, artemisinin’s half-life in plasma is very short, only 1–2 h (White 1997, 1999). 
For this reason, artemisinin derivatives are paired in artemisinin combination therapy (ACT) 
with a longer-acting partner drug including, lumefantrine, amodiaquine, piperaquine, SP, 
mefloquine and pyronaridine (Ross and Fidock 2019). This, however, means that after 
artemisinin is eliminated in the blood, there is an increased risk of partner-drug resistance 
since the partner drug remains as a monotherapy. 
The earliest reports of delayed response to artemisinins in P. falciparum parasites were from 
western Cambodia in 2008 to 2009, leading to the identification of the hallmark of artemisinin 
resistance, slow parasite clearance in vivo (Noedl et al. 2008; Dondorp et al. 2009). By 2014, 
slow parasite clearance had become common across countries in the Greater Mekong 
Subregion, that includes Cambodia, China, Laos, Myanmar, Thailand and Viet Nam (Ashley et 
al. 2014). The development of in vitro ring-stage survival assays (RSAs) with synchronized P. 
falciparum rings exposed to dihydroartemisinin (DHA) treatment at 6 hour intervals, led to a 
clearer definition of artemisinin resistance (Witkowski et al. 2013). These assays revealed that 
the 0-3 hour rings were less susceptible to dihydroartemisinin in artemisinin-resistant 
parasites, since artemisinins act on young ring-stage parasites (White 2017) and were 
therefore used as an in vitro correlate for artemisinin resistance. Later studies showed that a 





protein (Pfk13) that correlated with parasite survival rates in vitro and day 3 parasitemia in 
therapeutic efficacy studies and this led to the identification of k13 as the molecular marker 
for artemisinin resistance (Ariey et al. 2014). 
The Pfk13 gene encodes a protein containing a conserved N-terminal domain followed by a 
BTB/POZ and finally a 6-blade propeller domain in the C-terminus (codons 441–725) (Ariey et 
al. 2014). Mutations in the propeller domain have been associated with artemisinin 
resistance, but few have been validated to date including F446I, N458Y, M476I, Y493H, R539T, 
I543T, P553L, R561H and C580Y (Ariey et al. 2014; Ashley et al. 2014). k13 mutations 
associated with artemisinin resistance arose independently along the Myanmar-Thai (Takala-
Harrison et al. 2015) and Cambodia-Thai (Miotto et al. 2013) border regions. Consequently, 
whole-genome studies of artemisinin-resistant parasites in SE Asia were shown to accumulate 
artemisinin resistance predisposing mutations at other genetic loci, namely codon V127M in 
apicoplast ribosomal protein S10 precursor (arps10), codon I356T in crt, codon D193Y in 
ferredoxin (fd) and codon T484I in multidrug resistance (mdr) protein 2 (Miotto et al. 2015). 
One mutation, however, C580Y, has gone on to be the most dominant and studies have 
shown that it first arose in western Cambodia before it spread to Thailand and Laos (Imwong 
et al. 2017). Worryingly, it appears that some parasites carrying this mutation have gone on 
to acquire partner drug-resistance to piperaquine, characterized by amplification of a gene 
called plasmepsin-2, and have spread from Cambodia to Thailand and Laos (Imwong et al. 
2017). As a consequence, Cambodia has adopted AS-MQ as the first-line treatment due to 
widespread DHA-PPQ, while Thailand and Vietnam are reviewing current policy and 
procedures (WHO 2018b). Numerous subgroups of highly related parasites have also 
emerged within this co-lineage of multi-drug resistant parasites with diverse geographical 
distributions (Hamilton et al. 2019), hence a ‘firewall’ of containing artemisinin resistance 
may not work and calls for the elimination of this increasingly drug-resistant parasite co-
lineage. 
Pfk13 mutations associated with artemisinin resistance have not been observed in Africa 
(Kamau et al. 2015; Taylor et al. 2015; Ménard et al. 2016; WWARN K13 Genotype-Phenotype 





mutations in low frequencies (<0.1%) (MalariaGEN Plasmodium falciparum Community 
Project 2016). Also, though lacking the validated k13 mutations associated with artemisinin 
resistance, parasites with high artemisinin survival rates have been identified in Equatorial 
Guinea and Uganda (Lu et al. 2017; Ikeda et al. 2018). In contrast, some studies have reported 
artemisinin resistance in isolates that did not harbour k13 mutations, termed “discordant” 
parasites. In a study conducted by Mukherjee et al. (2017) using the samples collected from 
Cambodia, the authors reported a significant positive correlation between the k13-C580Y 
mutation and in vivo parasite clearance half-life values. However, four of the thirty-six isolates 
were reported to have high in vitro RSA survival rates (>1%) compared to artemisinin sensitive 
isolates, yet they lacked k13 mutations. While this small data set was underpowered to 
identify novel mutations using a genome-wide strategy, the authors used a candidate-gene 
approach and identified SNPs in other genes including dhps, dhfr, mdr2 
and phosphatidylinositol-4-phosphate 5-kinase (PIP5K). In another study, Demas et al. (2018) 
carried out long-term in vitro selection in two recently isolated Senegalese parasites with 
increasing concentrations of DHA over a 4-year period. The authors isolated two parasite 
clones, one from each original isolate, that exhibited enhanced survival to DHA in the RSA and 
these clones harboured up to 10 SNPs that were selected for, in vitro. Notably, the only 
candidate drug resistance gene to be identified in both clones was the actin-binding protein 
coronin (Pfcoronin) with polymorphisms at codons R100K, E107V and G50E in the absence of 
k13 mutations. These two studies present evidence to show that other genes other than k13 
may be involved in conferring artemisinin resistance. Therefore, k13 alone might not be 
enough to track artemisinin resistance especially in regions such as in SSA where resistance is 
yet to be reported. 
A mutation (S69Stop) in the cysteine proteinase falcipain-2a gene has previously been 
selected for after artemisinin in vitro selection pressure, using a parasite isolate from Africa. 
Previous work has shown that artemisinin activity is dependent on haemoglobin uptake and 
digestion. Pffalcipain-2a encodes a cysteine protease that is involved in this pathway and its 
deletion has been significantly associated with decreased artemisinin sensitivity (Klonis et al. 





thereby modulating artemisinin resistance. A clinical trial conducted in Western Kenya, 
revealed that 2-3 days of ACT treatment selected for parasites with either the 160N or 160T 
alleles in the AP-2 complex subunit mu gene (Pfap2-mu, S160N/T) and the allele 1528D in the 
ubiquitin carboxyl-terminal hydrolase 1 gene (Pfubp-1, E1528D) (Henriques et al. 2014). Both 
Pfap2-mu and Pfubp-1 are likely to also be involved in haemoglobin digestion (Birnbaum et 
al. 2020) and just like Pfap2-mu, mutations in these two genes are likely to interfere with their 
functions and render parasites less sensitive to artemisinin. 
1.9.2.3.2 Lumefantrine 
Some of the partner drugs used with artemisinin include lumefantrine, a drug that belongs to 
the aryl-amino alcohols class of antimalarials. This combination, artemether-lumefantrine 
(AL) is the most widely used antimalarial in endemic countries, accounting for approximately 
75% of all procured ACTs (UNITAID 2018). Lumefantrine’s mode of action is not well 
understood and its main target remains unsolved, but it is thought to interfere with haem 
detoxification (Combrinck et al. 2013) or to directly inhibit mdr1 (Martin, Shafik and Richards 
2018). Several recent studies have associated some polymorphisms associated with 
lumefantrine pressure and warrant further investigation. AL has been shown to select for the 
Pfcrt-K76 allele and the Pfmdr1 NFD haplotype (N86/184F/D1246) (Sisowath et al. 2005, 
2009; Humphreys et al. 2007; Henriques et al. 2014). Furthermore, the Pfmdr1-NFD 
haplotype and an increase in Pfmdr1 copy number have been linked with reduced 
susceptibility to lumefantrine (LM). Recently, a temporal increase in the frequency of the K65 
allele (K65Q) in the cysteine desulfurase (nfs) gene was observed in The Gambia, six years 
after the introduction of ACTs. Moreover, the IC50 values for LM were significantly higher in 
nfs-K65 wild-type field isolates when compared to the mutant 65Q isolates (Amambua-Ngwa 
et al. 2018). Exactly how Pfcrt, Pfmdr1 and Pfnfs modulate lumefantrine resistance, is not 
known. 
1.9.2.3.3 Amodiaquine 
Artesunate-amodiaquine (ASAQ) is the second most used ACT combination drug in malaria 





in 2017, ASAQ accounted for  greater than 20 % of all ACTs (UNITAID 2018). Amodiaquine 
(AQ) has also been adopted for seasonal malaria chemoprevention in the Sahel region, in 
combination with SP (Coldiron, Von Seidlein and Grais 2017). The mode of action of AQ is 
similar to CQ, as it accumulates in the parasite’s digestive vacuole where it binds the toxic 
haem, preventing its detoxication into the inert form hemozoin (Kaur et al. 2010). AQ 
resistance has been associated with point mutations in the Pfcrt and Pfmdr1 genes, and the 
same mutations as those for CQ resistance (Pfcrt 76T and Pfmdr1 86Y) have been shown to 
be the main determinant of decrease susceptibility to AQ in vitro and in vivo (Duraisingh et 
al. 1997; Holmgren et al. 2006; Yeka et al. 2016). 
1.9.2.3.4 Piperaquine 
The combination of dihydroartemisinin and piperaquine (DP) is an e in effective drug most 
malaria endemic settings (Achan et al. 2013) and has been used in some countries in 
Southeast Asia and Africa (WHO 2018a). This combination is increasingly being considered for 
malaria prevention in pregnancy (Kakuru et al. 2016) as well as mass drug administration 
(MDA) in near-elimination settings in Africa (Eisele et al. 2016; Mwesigwa et al. 2019). The 
mode of action of PQ is yet to be understood, but it has been linked to the inhibition of 
haemoglobin degradation pathway (Dhingra et al. 2017). DP is failing in the sub-Mekong 
region due to resistance to piperaquine (PQ) and decreased susceptibility to artemisinin 
derivatives (Amaratunga et al. 2016; Amato et al. 2017). More recently, PQ resistance has 
been associated with copy number variation in Pfplasmepsin-II and III (Witkowski et al. 2017) 
and point mutations in Pfcrt (Agrawal et al. 2017; Dhingra et al. 2017; Ross et al. 2018). in vivo 
assays are limited in the assessment of phenotypic resistance to PQ, however, a PQ survival 
assay (PSA) has been established to assess changes in parasite strains’ susceptibility to PQ 
(Witkowski et al. 2017). 
1.9.2.3.5 Sulfadoxine Pyrimethamine 
Notwithstanding widespread resistance to SP in most malaria endemic settings, the 
combination artesunate and SP (ASSP) is still used in a some countries for malaria treatment 





amodiaquine for seasonal malaria chemoprevention (SMC) (Coldiron, Von Seidlein and Grais 
2017). The mechanism of resistance to SP has been described earlier in this chapter. 
1.9.2.3.6 Mefloquine 
The combination of artesunate and mefloquine (ASMQ) was the first ACT introduced in 
Southeast Asia to halt resistance to mefloquine (MQ) monotherapy in the early 1990s 
(Trenholme 1993). Noteworthy, the use of this combination has historically been restricted 
to Southeast Asia, the Pacific region and South America, but was not used in Africa (WHO 
2019). With widespread resistance to MQ and decreased susceptibility to artemisinin 
derivatives, ASMQ is now used only in a few countries (WHO 2019). The mode of action of 
MQ is still unclear, but the drug may inhibit haem detoxification (Fitch 2004; Combrinck et al. 
2013) or directly inhibit pfmdr1 (Cowman, Galatis and Thompson 1994). MQ resistance has 
also been linked to copy number variations in Pfmdr1 (Price et al. 2004) as well as 
polymorphisms in Pfmrp1 and Pfmrp2 (Veiga et al. 2011, 2014; Woodland et al. 2018). More 
recently, the cytoplasmic ribosome (Pf80S) of the asexual blood-stage parasite has been 
suggested as the main target of MQ (Wong et al. 2017). 
1.9.2.3.7 Pyronaridine 
The combination of artesunate and pyronaridine (ASPY) is not yet recommended by the WHO, 
but is the only ACT indicated for the blood stage treatment of both P. falciparum and P. vivax 
(Medicines for Malaria Venture). The combination has shown high efficacy in Africa and was 
non-inferior to AL and DP (Sagara et al. 2016, 2018), and in Eastern Cambodia (Leang et al. 
2019). The mode of action of PY is not well known, however, it is thought to interfere with 
the hemozoin formation (Auparakkitanon et al. 2006). Resistance to PY has not been 
reported, however, ex vivo assessment has shown an association between decreased 
susceptibility to PY and the Pfcrt-76T mutation (Madamet et al. 2016). The findings 
highlighted herein, underscore the need for continued surveillance of artemisinin and partner 
drug resistance markers in Africa, where the burden of malaria is the highest, should it 






1.9.3 Chronic asymptomatic infections 
Asymptomatic falciparum infections are prevalent in malaria-endemic SSA, reaching over 90% 
in children (Okell et al. 2009). A large proportion of asymptomatic infections are associated 
with sub-microscopic infections that are not detected in routine microscopy tests and hence 
go untreated, which can result in a major parasite reservoir that can fuel malaria transmission 
and negatively impact on malaria elimination efforts (Alves et al. 2005). Accordingly, the use 
of sensitive nucleic acid-based techniques (PCR) has shown that the prevalence of 
asymptomatic infections is approximately two-fold compared to those identified with 
conventional diagnostics, such as microscopy (Okell et al. 2009) and RDT (Wu et al. 2015). 
Due to high herd immunity and premunition in the population, asymptomatic infections are 
expected to be common in high malaria transmission areas. However, sensitive PCR-based 
diagnostics have revealed that asymptomatic infections are also common in low-endemic 
areas despite residents having less NAI compared to those living in areas of high malaria 
transmission (Okell et al. 2012). The interest in asymptomatic infections has focussed both on 
their impact on health as well their role in malaria transmission and elimination as highlighted 
below. 
One major obstacle in the study of asymptomatic malaria is the lack of standard 
definition. Infected individuals may be in a pre-symptomatic period with parasitaemia and 
end up presenting with symptoms of malaria at a later date (Coura, Suárez-Mutis and Ladeia-
Andrade 2006). Alternatively, studies that do not incorporate an individual’s clinical history 
may fail to capture those that may have experienced symptoms briefly and took medication 
that suppressed parasitaemia and symptoms. The most widely-used criteria for defining 
asymptomatic malaria is the presence of P. falciparum parasites in peripheral thick blood 
smears, with no symptoms indicative of malaria (Abdel-Latif et al. 2003; Males, Gaye and 
Garcia 2008). Some studies have included other criteria, such as longitudinal follow-up. 
Longitudinal follow-up is important especially for identifying infections that appear 
asymptomatic at time of diagnosis, but may subsequently become symptomatic (Krieger et 
al. 2002; Leoratti et al. 2008; Harris et al. 2010). While species-specific PCR may not always 





microscopy has been shown to detect an even greater number of asymptomatic infections, 
underscoring just how many asymptomatic infections may be misdiagnosed as negative 
(Bousema et al. 2014). The inclusion of genetic disorders such sickle cell trait, that are known 
to protect against malaria, has also been explored so as to exclude such individuals who may 
be infected but do not develop symptoms of malaria (Touré et al. 2006). The varying 
definitions of asymptomatic malaria may pose challenges in comparing the burden of 
asymptomatic infections across different geographical settings and quantifying the impact of 
control or elimination programs that target these infections (Lindblade et al. 2013). 
Asymptomatic infections are thought to be as a result of partial immunity which controls but 
does not eliminate the infection. For this reason, these infections are sometimes viewed as 
beneficial to the individual as they help to maintain a state of premunition, thereby reducing 
the risk of severe disease (Doolan, Dobaño and Baird 2009). However, there is growing 
evidence that asymptomatic infections can be detrimental to the host, with serious health, 
developmental, and productivity consequences, leading to some describing them as “chronic” 
infections that require curative treatment (Chen et al. 2016). Some studies have associated 
chronic asymptomatic infection with elevation of C-reactive protein (CRP), a biomarker of 
inflammation (de Mast et al. 2015; Peto et al. 2016), lower platelet counts and haemoglobin 
levels as well as higher levels of von Willebrand factor and platelet factor-4, markers of 
endothelial and platelet activation, respectively (de Mast et al. 2015), low birth weight and 
premature births in pregnancy (Cottrell et al. 2015), cognitive impairment (Nankabirwa et al. 
2013), malnutrition (Maketa et al. 2015) and anaemia (Matangila et al. 2014; Maketa et al. 
2015; Sifft et al. 2016).  
Regarding the impact of asymptomatic infections on transmission, the membrane feeding 
assay has been the tool used to assess the infectivity of asymptomatic individuals to 
mosquitoes. For example, one study conducted in Western Thailand assessed the infectivity 
of asymptomatic individuals harbouring P. falciparum, P. vivax, P. malariae infections and 
found that 10% (7/70), 13% (7/52), and 0% (0/6) infected mosquitoes, respectively (Coleman 
et al. 2004). In another study conducted in Western Kenya, residual parasitemia detected by 





such children had an increased capability of infecting mosquitoes (Beshir et al. 2013). These 
studies highlight the significant role played by asymptomatic infections in fuelling malaria 
transmission. 
There is conflicting literature on the role of asymptomatic infections on the risk of developing 
febrile malaria with some studies reporting that asymptomatic infections are associated with 
increased risk of febrile malaria (Henning et al. 2004; Njama-Meya, Kamya and Dorsey 2004; 
Le Port et al. 2008; Males, Gaye and Garcia 2008) while other studies have reported a reduced 
risk (Henning et al. 2004; Males, Gaye and Garcia 2008; Portugal et al. 2017; Buchwald et al. 
2018). Overall, in the high transmission settings, there is a reduced risk of developing febrile 
malaria and this could be stratified by age such that older children (>5 years) were at a 
reduced risk compared to younger children (≤5 years), while the moderate to low 
transmission settings showed an increased risk of developing febrile malaria regardless of 
age. While these earlier studies were conducted in different geographical settings and with 
varying sample sizes and age groups, they emphasise that asymptomatic infections predict 
the risk of subsequent febrile malaria infections. Still, how other factors such as age and 
transmission intensity impact on this risk is yet to be understood. 
The indication that premunition is one of the mechanisms by which asymptomatic individuals 
develop partial immunity to malaria would suggest that curing or preventing asymptomatic 
infections would then make these individuals more susceptible to clinical attacks. Various 
studies have evaluated this and it appears that there are conflicting reports with some studies 
revealing that treatment of asymptomatic infections was associated with increased risk of 
clinical attacks (Owusu-Agyei et al. 2002; Liljander et al. 2010, 2011; Ouédraogo et al. 2010; 
Tiono et al. 2013; Larsen et al. 2015) while other studies found no effect (Portugal et al. 2017). 
Given the conflicting literature regarding the role of asymptomatic infections on developing 
febrile malaria infections, further studies are needed to clarify this. 
As already highlighted, age and malaria transmission intensity modify the risk of developing 
subsequent febrile episodes, complexity of infection (COI) has also been reported to be 
associated with the risk of developing febrile episodes. In line with this, previous reports have 





genetic diversity is greater in high-transmission settings compared to low-transmission 
settings (Magesa et al. 2002; Oyedeji et al. 2013; Adjah et al. 2018). Additionally, 
asymptomatic malaria infections have been found to harbour more complex infections 
compared to febrile malaria infections (Beck et al. 1997; Magesa et al. 2002) and exhibit a 
frequent turnover of clones (Daubersies et al. 1996; Nkhoma et al. 2018). Moreover, this high 
genetic diversity within asymptomatic infections has been associated with a reduced risk of 
developing febrile malaria episodes (Al-Yaman et al. 1997; Bereczky et al. 2007; Sondén et al. 
2015), although, the inverse has also been observed (Felger et al. 1999; Branch et al. 2001; 
Ofosu-Okyere et al. 2001; Henning et al. 2004). Conversely, lower COI in febrile malaria 
episodes could be explained by the fact that most fever episodes appear to be associated with 
parasitaemia peaks (Cox et al. 1994) and this may result from the expansion of just a few or 
even single genotypes. Therefore, this could lead to sampling of only a few clones leading to 
minority clones remaining undetectable. Fever is also known to have an antiparasitic effect 
and this may result in the elimination of some genotypes from the initial parasite pool 
(Kwiatkowski 1991). One study conducted in Sudan, however, has previously reported that 
the proportion of infections with more than 1 clone was greater in febrile malaria infections 
(51%) than in asymptomatic infection (38%) (Roper et al. 1998). The authors hypothesized 
that because febrile malaria infections had higher parasite densities, sampling greater 
number of parasites increased the likelihood of detecting mixed infections. Another study 
conducted in Malawi, it was shown that polyclonal infections were more common in febrile 
malaria infections (302/477, 63.3%) compared to asymptomatic infections (180/585, 30.8%, 
p < 0.001) (Earland et al. 2019). However, this may have been as a result of the study’s inability 
to genotype samples with low parasite densities which were mainly asymptomatic samples. 
The different findings from multiple studies regarding parasite diversity in asymptomatic vs. 
febrile infections warrants the use of a more sensitive tool coupled with intermittent sampling 
so as to efficiently capture of all circulating parasite clones. 
Most malaria interventions target the febrile population because they present with clinical 
symptoms of malaria. However, the high prevalence of asymptomatic infections necessitates 





2011; Lubis et al. 2017), though, further studies are needed to clarify the impact of treating 
asymptomatic infections on the risk of subsequent febrile malaria infections. This may have a 
larger impact in preventing transmission as opposed to interventions that only target febrile 
cases, as asymptomatic infections may have long duration. As research priorities shift from 
malaria control to malaria elimination, it is important to tailor interventions that target both 
febrile and asymptomatic infections as this will not only reduce the malaria burden but also 
interrupt malaria transmission. Consequently, a deeper understanding of asymptomatic 
infections is needed. 
1.9.4 Parasite genetic diversity 
There is great genetic diversity within P. falciparum and individuals living in malaria-endemic 
regions are frequently and simultaneously infected by several distinct parasite clones (Juliano 
et al. 2010). Harbouring multiple genetically distinct parasites, termed “complexity of 
infection (COI)”, is one of the reasons for the slow acquisition of NAI leading to the view that 
humans must encounter several diverse parasite clones before they develop effective 
immunity to malaria (Doolan, Dobaño and Baird 2009). Diversity in P. falciparum is generated 
for example during fertilisation between gametes and zygote formation in the vector and 
novel parasite genotypes can arise through chromosome reassortment at meiosis and 
recombination (Sinden 2009). Consequently, single genetically distinct clones are then 
transmitted through multiple mosquito bites or via single mosquito bites with multiple clones, 
especially in areas of higher transmission. Likewise, surface antigens (targets of NAI) 
expressed by the parasite have also been shown to be highly diverse through the acquisition 
of extensive point mutations, but the precise targets that would correlate with immunity are 
unknown at present (Doolan, Dobaño and Baird 2009). 
This extensive parasite diversity, as well as interactions between genetically distinct malaria 
parasites within a single host, has been shown to impact on several outcomes including 
malaria transmission, the evolution of parasite virulence, disease progression, antimalarial 
drug resistance, immunity and promote "vaccine-resistant" clones. In a rodent model, de 
Roode et al. (2005) showed that there was a strong relationship between parasite virulence 





mixed-clone infections. Moreover, there was a direct correlation between the clone 
composition of the parasite populations in mosquitoes and that of the blood-stage parasite 
population. Bell et al. (2006) determined the pairwise competitiveness of genetically 
divergent P. chabaudi clones with a wide range of virulence in their rodent host. The study 
demonstrated that virulent clones had a competitive advantage in the acute phase of mixed 
infections. This led the authors to conclude that such models show how virulence is selected 
for, indicating the need for interventions that reduce the incidence of mixed infections. May 
et al. (2000) determined the impact of polyclonal infections on haematological parameters in 
clinically healthy children in Nigeria and revealed that 64% of the 228 children recruited were 
anaemic. The prevalence of anaemia was dependent on the number of Plasmodium clones 
detected (P < 0.0001) and the prevalence of anaemia increased gradually with the complexity 
(P < 0.003) as well as with the extent of P. falciparum parasitaemia (P < 0.0001). Wargo et al. 
(2007) studied competitive release in acute infections containing drug-susceptible and 
resistant clones following pyrimethamine treatment in a rodent model. They showed that 
there was an expansion of resistant clones and enhanced gametocyte densities after 
treatment. The number of resistant clones increased beyond that achieved when a 
competitor had never been present, thus this competitive release substantially increased the 
fitness advantage of resistant clones. Within-host parasite diversity has been found to 
correlate with immunity in a study conducted in children aged between 1-16 years in Tanzania 
(Rono et al. 2013). By measuring the number of merozoite antigens to which participants 
responded to, Rono et al. (2013) showed that the breadth of antibody responses was 
positively correlated to the number of infecting clones. Likewise, the breadth of antibody 
responses and the number of infecting clones were associated with a lower risk of malaria. 
Lastly, the RTS,S/AS01 vaccine (trade name, Mosquirix) based on the circumsporozoite 
protein (csp), expressed during the invasion of liver cells, is the foremost malaria vaccine to 
be licensed for use by the European Medicines Agency. However, the RTS,S/AS01 has been 
associated with only 18–36% vaccine efficacy against clinical malaria of (RTS-S Clinical Trials 
Partnership 2015). One of the reasons attributed to the limited efficacy of RTS,S/AS01 is based 





vaccine efficacy of RTS,S/AS01 in Phase III clinical trials was reduced from 50.3% for parasites 
with a perfect csp C-terminal sequence match to only 33.4% for parasites with any amino acid 
mismatch in this region (Neafsey et al. 2015). 
The studies presented here highlight how P. falciparum has evolved to harness genetic 
diversity to its advantage. Accordingly, a better understanding of this diversity is crucial in 
informing malaria elimination efforts. 
1.10 Genetic epidemiology of P. falciparum  
SNP genotyping methods have previously been applied to analyze parasite genetics, but this 
has been limited to research settings. Thus, their utility when incorporated in National 
Malaria Control Programmes has not yet been proven, but may help accelerate progress 
towards malaria elimination as discussed below. 
SNP genotyping methods have been used before to detect, track and provide surveillance of 
drug-resistance in P. falciparum, a feat that was made possible by the identification of drug-
resistance markers. Notably, crt, mdr1, dhps, dhfr and k13 were defined as molecular markers 
of resistance to CQ, SP and artemisinin, respectively (Peterson, Walliker and Wellems 1988; 
Foote et al. 1989; Wilson et al. 1989; Foote, Galatis and Cowman 1990; Triglia et al. 1998; 
Fidock et al. 2000; Ariey et al. 2014). Such information has been used to study natural 
populations of P. falciparum across diverse geographical regions and enabled studies to carry 
out genetic epidemiology of drug-resistance markers to CQ (Wootton et al. 2002), SP (Roper 
et al. 2004; Mita et al. 2011) and more recently, artemisinin (Ashley et al. 2014; MalariaGEN 
Plasmodium falciparum Community Project 2016; Ménard et al. 2016). In the wake of 
artemisinin resistance, drug-resistance surveillance using molecular markers offers a scalable 
tool to detect and track resistance to artemisinins especially in regions such as SSA, where it 
is yet to be reported. 
SNP genotyping methods have also been used to define within-host parasite diversity and 
transmission patterns in populations. Such information can be used to assess the effects of 
malaria interventions, such as the use of IRS, ITNS and ACTs, as they are expected to reduce 





indicator of transmission intensity since a positive correlation between the rate of polyclonal 
infections and annual parasite incidence has been observed (Fola et al. 2017). Some studies 
have reported that a reduced risk of clinical malaria was associated with polyclonal infections 
(Al-Yaman et al. 1997; Bereczky et al. 2007), while other studies reported that infections with 
one clone were associated with severe malaria compared to infections with more than one 
clone (Durand et al. 2008). In a study conducted in Senegal, Daniels et al. (2015) showed that 
parasite diversity decreased and later increased in tandem with reductions in malaria 
transmission intensity due to malaria intervention efforts and later a rebound in malaria 
cases, respectively. Following malaria intervention efforts in Malawi, Sisya et al. (2015) 
reported that parasite diversity in a single location (Blantyre) remained high, suggesting that 
only subtle gains, if any, were made in reducing malaria transmission.  
SNP genotyping has been used to identify malaria foci linking episodes based on parasite 
genetic relatedness and hence such information can aid in the identification of malaria foci 
that can inform targeted malaria intervention strategies. Following reports in Madagascar 
that there existed localities with transmission and prevalence rates up to 10-fold higher than 
the national average, Rice et al. (2016) identified the Makira region of Madagascar as a 
hotspot. In this region, a high level of genetic diversity and a high frequency of infections with 
multiple P. falciparum clones were observed, providing a pattern consistent with the high and 
stable transmission. In a study conducted in Greece, Spanakos et al. (2018) used 
microsatellites markers to attribute an outbreak of P. vivax malaria to specific villages with 
foci revived by imported malaria via migrant agricultural workers.  
Lastly, SNP genotyping has been used to determine the connectivity of parasite populations. 
In turn, parasite populations are linked across various geographic regions, facilitating a 
quantitative assessment of how much of transmission in one region is due to contributions 
from transmission in another. This information can be used to tailor malaria interventions 
that target imported cases of malaria. In a study conducted in Papua New Guinea, Fola et al. 
(2018) used microsatellite markers to investigate population structure in eight geographically 
and ecologically distinct regions of the country. Parasite populations were found to be 





infections arrived from all other populations with limited outbound flow. In another study 
conducted in Western Kenya, Omedo et al. (2017) found no barriers to the spatial movement 
of parasites in the region because the parasites exhibited no population structure. Markedly, 
this study highlighted that the high level of parasite mixing suggested that a geographically 
restricted “one-off” targeted intervention may not be currently effective in Western Kenya, 
due to the high parasite movement that is likely to lead to re-introduction of infections from 
surrounding regions.  
1.11 Molecular approaches to determine parasite diversity 
1.11.1 Size polymorphic marker and microsatellite markers 
The traditional method for characterizing P. falciparum diversity uses nested-polymerase 
chain reaction (nested PCR) with gel electrophoresis to detect polymorphisms in merozoite 
surface protein 1 and 2 (msp1 and msp2) and glutamine-rich protein (glurp) (Viriyakosol et al. 
1995). Microsatellite markers are highly polymorphic with tandem repeats of between 2-
6 base pairs (bp) that are not under selection, show no phenotypic consequences and are 
extensively distributed throughout the parasite genome (Anderson et al. 1999). These 
markers are readily amplified by PCR to estimate COI and typically, COI is determined as the 
number of alleles detected in a gel and several markers can be combined to resolve bias. 
However, the reliance on gel electrophoresis to determine allele sizes for msp1, msp2, glurp 
and microsatellite markers is limited in discriminating alleles of similar sizes (those with size 
difference less than 20 bp). Moreover, technical problems such as non-specific amplification 
(de Valk et al. 2009) and stutter peaks (de Valk, Meis and Klaassen 2007) are some of the 
obstacles to using these markers to assess COI. Consequently, these markers underestimate 
diversity, are insensitive to low-abundant variants and are not quantitative for relative 
proportions of circulating parasite clones. 
1.11.2 Sanger sequencing 
Sanger sequencing is the di-deoxy chain termination method for DNA sequencing by synthesis 
pioneered by Fred Sanger. One strand of the double-stranded DNA is used as a template to 





are incorporated. Unlabelled dNTPs are present in excess in the elongation of DNA strands, 
so the incorporation of ddNTPs into the growing DNA strand, preventing further elongation, 
is a random event. This process generates DNA fragments of different sizes ending in labelled 
ddNTPs. These fragments are separated according to their sizes on a gel where the resultant 
bands, corresponding to DNA fragments, can be visualized by an imaging system including X-
ray and UV light (Sanger and Coulson 1975) or in current practice, detection of specific 
fluorophores for each nucleotide. The major limitation of Sanger sequencing is that it cannot 
always identify multiclonal infections as well as being time and cost-prohibitive, especially 
with large sample sizes. Nonetheless, Sanger sequencing remains the gold standard for 
confirming DNA sequences due to the stability of the technology and it is still broadly used 
for targeted sequencing analysis in research and clinical laboratories (Alekseyev et al. 2018). 
1.11.3 High-throughput (HT) SNP genotyping 
Numerous panels of genome-wide SNP markers have been identified and protocols for typing 
developed. One panel includes 24 P. falciparum SNPs selected from over 112,000 SNPs of 18 
parasite genomes (Daniels et al. 2008) whose greatest power is to discriminate among clones 
compared to the traditional msp-1 and msp-2. HT-SNP genotyping can also be done on the 
Sequenom MassARRAY iPLEX platform, which can multiplex up to 40 SNPs per single reaction. 
The genotype of a parasite is determined by the SNP allelic intensity ratios, ranging between 
0 and 1. The SNP allelic intensity ratio values nearing 0 and 1 indicate a single parasite 
genotype infection, while intermediate values indicate mixed parasite genotype infections 
(Gabriel, Ziaugra and Tabbaa 2009). The TaqMan assay is another HT-SNP genotyping method 
that PCR-based. In this assay, the region flanking a SNP is amplified in the presence of two 
allele-specific fluorescent probes that allow the detection of both alleles in a single tube. 
Compared to msp1/msp2/glurp genotyping, genotypes are determined without any post-PCR 
processing because probes are included in the PCR (Hui, DelMonte and Ranade 2008). Even 
larger-scale SNP genotyping has been conducted in P. falciparum using a custom 384-SNP 
Illumina GoldenGate with the advantage of typing numerous SNPs simultaneously. Therefore, 
this technology provides a practical, rapid, robust, and inexpensive assay of genome-wide 





monoclonal infections to estimate allele frequencies, which is problematic when a large 
fraction of infections are polyclonal (Campino et al. 2011). The major challenge with HT-SNP 
genotyping is that the use of custom panels of SNPs does not allow the discovery of SNPs 
beyond those incorporated in the panel. 
1.11.4 Whole-genome sequencing 
Ever since the sequencing of the P. falciparum genome (Gardner et al. 2002), whole-genome 
sequencing (WGS) of field isolates has become common and has been used to study P. 
falciparum parasite diversity in natural populations (Manske et al. 2012). In turn, several 
algorithms have been developed to identify multiclonal infections and reconstruct haplotypes 
from sequence data. The estMOI algorithm can be used to analyze deep sequencing data for 
the estimation of COI, however, it is limited in that it requires deep whole genome shotgun 
sequence data, which is costly to generate on a large scale (Assefa et al. 2014). 
DEploid (Zhu, Almagro-Garcia and McVean 2018) is an algorithm that analyzes genome-wide 
SNP data for estimation of the number of clones, their relative proportions and the 
haplotypes present in a sample. This method can be used to infer mixed clones with 
proportions at > 20% with high accuracy, but it struggles with minor clones due to insufficient 
read coverage. Currently, DEploid is the only software available that can reconstruct 
haplotypes as well as estimate COI using genome-wide SNP data. The limitation is that it 
requires a panel of references, which should include enough different reference clones to 
cover all the haplotype structure representing the field population, something that is a 
challenge for current computational technology. 
A typical sequencing run on an Illumina NextSeq sequencer yields approximately 130 million 
reads of 150bp each. Even if a single isolate was sequenced by a single run, and even if 
coverage across the genome of 23 million bp pairs was obtained, coverage would be below 
900×. Factoring in that field isolates always contain some human DNA; coverage would be 
even lower. Thus, when COI is the main interest of a study, whole-genome sequencing is 





1.11.5 Amplicon deep sequencing 
Amplicon deep sequencing takes advantage of the fact that, in highly polymorphic amplicons, 
several SNPs may be concentrated within a locus of 100–200bp. Hence, deep sequencing of 
highly polymorphic makers has high sensitivity and specificity to detect minority clones in 
multiclonal infections. Sequencing coverage remains a challenge when estimating COI from 
whole-genome sequencing data. However, for amplicon deep sequencing, a read depth of 
1000–10,000 results in an increased power to detect of minority clones of frequencies as low 
as 0.1% in experimental mixtures of different parasite clones (Lerch et al. 2017). The major 
advantage of amplicon deep sequencing over a panel of genome-wide SNPs is that all SNPs 
occur within one amplicon. Thus, haplotypes can be directly identified without the need for 
multi-locus haplotype reconstruction and software programs such as SeekDeep aid in the 
identification of haplotypes (Hathaway et al. 2018). Some of the limitations with amplicon 
deep-sequencing include the fact that only a small genomic region is amplified and hence is 
not ideal for characterizing polymorphisms that cover large genomic regions. Like point 
mutations, indels are another form of structural variation and reads with large indels may be 
aligned incorrectly or may remain unmapped (Kadri et al. 2015). For this reason, amplicon 
deep-sequencing is better suited for point mutations and shorter indels and hence may not 
perform well to characterize hrp2 and hrp3 deletions which currently relies on WGS 
(Sepúlveda et al. 2018). Also, the threshold for accurate genotype calls may be different 
between studies due to various sequencing error rates in different sequencing platforms. 
Thus, to exclude PCR or sequencing errors, it is recommended to perform experiments in 
duplicate and use appropriate controls so as to minimize false calls (Mideo et al. 2016; 
Hathaway et al. 2018).  
In summary, asymptomatic infections provide a constant parasite reservoir that fuels malaria 
transmission and impacts on the risk of developing febrile malaria episodes. Additionally, 
prior studies have revealed that the COI within asymptomatic infections also impacts on the 
risk of developing febrile malaria. Moreover, the emergence of artemisinin and partner drug 
resistance in SE Asia is worrying as it may render the first line antimalarial drugs, ACTs, 





increased morbidity and mortality. It is worth noting that the reduction in clinical cases 
appears to have stalled globally, and in some cases clinical cases have resurged, even with the 
deployment of effective malaria control interventions (WHO 2018a). Thus, novel 
interventions are required to improve the gains made in tackling malaria. Genetic 
epidemiology offers a resourceful tool for assessing P. falciparum genetic diversity to improve 
knowledge on the parasite diversity, its transmission dynamics, mechanisms of adaptation to 
environmental and interventional pressures and enables the surveillance of antimalarial drug 
resistance (Apinjoh et al. 2019).  
This study, therefore, sought to examine the genetic epidemiology of the P. falciparum 
parasites in Kilifi, Kenya, using longitudinal P. falciparum malaria monitoring data and the 
genetic analysis of P. falciparum positive samples. This involved the examination of the 
epidemiology of asymptomatic infections with the aim of understanding the impact of 
transmission intensity and age on the risk of developing febrile malaria in asymptomatic 
individuals. Secondly, a genetic epidemiology analysis was conducted using amplicon deep 
sequencing to characterise parasite diversity in asymptomatic infections at both the 
individual and population level and to understand how this diversity changes during the shift 
to a febrile malaria episode and how it impacts of developing subsequent febrile episodes. 
Finally, while resistance to ACTs is yet to be detected in SSA, it is imperative that continued 
surveillance is carried out and molecular markers of resistance offer a resourceful tool to 
achieve this. Accordingly, an interrogation of 12 drug resistance markers over two decades of 
changing antimalarial drug policy in Kenya, was conducted. These included the validated 
marker for artemisinin resistance (k13) identified in SE Asia as well as novel markers (ap2-mu, 
falcipain-2a and ubp-1) whose impact are not yet fully understood, artemisinin resistance 
predisposing mutations in four genes (arps10, crt, fd and mdr2), validated markers of CQ (crt) 
and SP (dhps and dhfr) resistance and finally a marker (nfs) of lumefantrine resistance 
identified in The Gambia. The characterisation of such markers could help identify an ACT 
resistance genotype predictive of reduced artemisinin susceptibility in SSA, given that some 






1.12.1 Main Objective 
Genetic analysis of asymptomatic P. falciparum infections in Kilifi, Kenya, and epidemiological 
evaluation of the contribution of antimalarial drug-resistance markers under changing drug 
selection.  
1.12.2 Specific Objectives 
1. To evaluate of the risk of developing febrile malaria in P. falciparum asymptomatic 
infected compared to uninfected children in Kilifi. 
2. To use deep-sequencing to evaluate P. falciparum diversity in asymptomatic and 
febrile infections in Kilifi. 
3. To assess the genetic diversity of 12 P. falciparum drug-resistance markers (crt, mdr1, 
dhps, nfs, k13, ap2mu, falcipain-2a, ubp-1, as well as four artemisinin resistance 
predisposing mutations; arps10 codon V127M, crt codon I356T, fd codon D193Y and 
mdr2 codon T484I), over two decades of changing antimalarial drug policy in Kilifi, 
Kenya. 
1.13 Justification 
P. falciparum asymptomatic infections may negatively impact malaria elimination strategies 
since they become a constant source of parasites that fuel malaria transmission. 
Consequently, it has been suggested that in addition to targeting febrile infections, 
asymptomatic infections should also be targeted to have a significant effect on malaria 
transmission. However, there is conflicting literature on what the role of asymptomatic 
infections in on the risk of developing febrile episodes. Also, if asymptomatic infections are 
associated with a reduced risk of febrile episodes, what will the impact of clearing these 
infections be on the risk of developing febrile episodes at a population level. For this reason, 
this study sought to evaluate how asymptomatic infections impact on the risk of developing 
febrile malaria in Kilifi, as it will inform malaria intervention strategies.  
High genetic diversity has been reported to correlate with malaria transmission intensity 





malaria transmission intensity from the 1990s to 2008, however, it has since started to 
increase again (Snow et al. 2015). What effect this drop and recent increase in transmission 
intensity has had on the genetic diversity of the local parasite population, has not been 
evaluated. This study sought to use amplicon deep-sequencing to assess parasite diversity 
over time, in parallel with changing malaria transmission intensities, in both asymptomatic 
and febrile infections.  
Finally, reports of emergence and spread of artemisinin resistance in SE Asia necessitates 
continued surveillance of drug-resistance markers in regions yet to report artemisinin 
resistance, such as SSA. Studies conducted in SSA to date have not detected the k13 mutations 
that have been associated with artemisinin resistance, but some have reported mutations in 
other markers such as ap2-mu and falcipain-2a that need to be evaluated further. This study, 
therefore, sought to evaluate the prevalence of k13, ap2-mu and falcipain-2a mutations in 
Kilifi and assess how these have changed over two decades of changing antimalarial policy. 
1.14 Ethical approval 
Ethical approval for these studies was obtained from the Ethics Review Committee of the 










Chapter 2 : P. falciparum Asymptomatic Infections and the Risk of Developing Febrile 
Malaria 
2.1 Introduction 
As previously highlighted in chapter 1, asymptomatic infections are detrimental to the host, 
with serious health, developmental, and productivity consequences. Additionally, 
asymptomatic infections can later transition to febrile malaria and the factors that influence 
this are yet to be fully understood. Using microscopy for diagnosis, some studies have 
associated asymptomatic infections with a lesser risk of developing febrile malaria. This 
apparent protection has been linked to the fact that individuals living in high malaria 
transmission settings have higher levels of immunity compared to those in low transmission 
settings (Doolan, Dobaño and Baird 2009). As highlighted in section 1.9.3, there is conflicting 
literature on the role of asymptomatic infections on the risk of developing febrile malaria. In 
a study of 316 children aged 6 months to 5 years in an area of moderate malaria transmission 
in Uganda, children with asymptomatic infections were at a higher risk of febrile malaria 
compared to uninfected children within the first 30 days of detection (Njama-Meya, Kamya 
and Dorsey 2004). Likewise, in a study of 566 children aged 2 to 17 years in an area of low 
malaria transmission in Senegal, it was shown that asymptomatic infections at the beginning 
of the transmission season were associated with increased febrile malaria episodes, 
independently of age. However, this association was not observed at the end of the 
transmission season (Le Port et al. 2008). In contrast, in a study of 610 children under 6 years 
of age in an area of high malaria transmission in Tanzania, younger children (<3 years of age) 
with asymptomatic infections at baseline were observed to be at a higher risk of febrile 
malaria while older children (>3 years of age) appeared to be at a reduced risk (Henning et al. 
2004). Similarly, in a larger study of 1356 children aged 2 to 18 years in an area of high malaria 
transmission in Senegal, it was shown that children with asymptomatic infections in the dry 
season leading into the rainy season were at a lower risk of developing febrile malaria. 
Additionally, this association was age-dependent as younger children (≤5 years of age) were 
found to be at a higher risk than older children (>5 years of age) (Males, Gaye and Garcia 
2008). In a study of 695 individuals aged 6 months to 25 years in an area of high malaria 
transmission in Mali, participants with asymptomatic infections at the end of the dry season 





less febrile malaria than younger children, although no age stratification data was provided 
(Portugal et al. 2017). Finally, in a study of 120 participants aged between 1-50 years in an 
area of high malaria transmission in Malawi, participants were treated with AL at enrolment 
and followed for 2 years with monthly routine visits. It was shown that asymptomatic 
infections were associated with decreased risk of malaria illness across all ages (Buchwald et 
al. 2018).  
The above-mentioned studies have shown that in addition to asymptomatic infections having 
an impact on the risk of developing subsequent febrile episodes, malaria transmission 
intensity also appears to have a role. In line with this, it has been shown that immunity to 
malaria is acquired more rapidly with increasing transmission. Therefore, individuals 
harbouring asymptomatic infections may be protected from malaria because of increased 
exposure. Regarding the role of age and protection from malaria, there may be something 
intrinsic about age other than the constant exposure for example a maturing immunity. To 
shed light on this, one has to explore the limitations of previous studies that examined the 
impact of asymptomatic infections and risk of malaria. Notably, these studies were conducted 
in different geographical regions and with participants of varying age groups. Therefore, 
conclusions based on the assumption that differences in transmission intensity and age 
explain the opposing results, require confirmation. In this chapter, the impact of both malaria 
transmission intensity and age on the risk of developing febrile malaria in children with 
asymptomatic infections, was evaluated. These findings may provide insights into the impact 
of immunity on the risk of developing febrile malaria in asymptomatic individuals living in 
different transmission settings. 
2.2 Methods 
2.2.1 Study design and data collection 
The data used for this analysis is based on three cohorts in Kilifi of varying malaria 
transmission intensities, including Ngerenya (low transmission), Junju (moderate to high 
transmission) and Chonyi (high transmission). The data were prospectively collected between 





cohorts, children were recruited at birth for weekly clinical malaria monitoring until the age 
of 15 years (Mwangi et al. 2005; Ndungu et al. 2015). 
The transmission intensity in Kilifi was on a general decline during the study period, from 1989 
to 2010 and later started to increase (Snow et al. 2015; Mogeni et al. 2016), however, it was 
much higher in Junju and Chonyi than in Ngerenya. Data from the active weekly surveillance 
was used to determine malaria episodes and annual cross-sectional surveys to define 
asymptomatic infections and uninfected children. There are two rainy seasons per year in 
Kenya during which malaria transmission increases, the long rains that occur in May-July and 
the short rains that occur in October-November (Mwangi et al. 2005). The cross-sectional 
surveys are conducted before the long rains. 
2.2.2 Case definitions 
Asymptomatic infection was defined as having any detectable P. falciparum parasites by 
microscopy (thick and thin smears), having an axillary temperature <37.5°C and no history of 
fever during the cross-sectional survey. Additionally, the children should not have had a 
recent febrile malaria episode within the month before the survey or had a fever within the 
subsequent 7 days from the date of the survey. Uninfected children were defined as those 
without P. falciparum parasitemia and no fever during the cross-sectional survey. A febrile 
malaria episode was defined as having ≥2500 parasites/µl and an axillary temperature greater 
than 37.5°C, based on parasite cut-offs previously defined for these cohorts (Mwangi et al. 
2005). 
2.2.3 Statistical analysis 
Survival analysis was used to compare the risk of developing febrile malaria between the 
asymptomatic and uninfected children and survival times were estimated as follows: the 
baseline (time 0) was defined as the date of cross-sectional survey while the end of follow up 
was set at the last visit or at 365 days if follow up continued to the subsequent annual cross-
sectional survey; the time to first febrile malaria episode was defined as the interval between 
the baseline date and the first febrile malaria episode. Children who did not complete follow 





Kaplan-Meier curves and log-rank test were used to compare time to first febrile malaria 
episode. The Cox proportional hazards model was used to investigate the association 
between the risk of developing a febrile episode and the following covariates: transmission 
intensity and asymptomatic infections as categorical variables, age as a continuous linear and 
non-linear variable (after transformation using multiple fractional polynomials). The calendar 
year was adjusted for as a continuous variable to account for falling transmission intensity 
and the non-independence of repeated observations was accounted for using the robust 
cluster Huber-White method. The proportional hazards assumption was tested for using 
Schoenfeld residuals and finally, the model included interactions with time for the covariates 
that showed non-proportional hazards. Model fits were assessed using log-likelihood, 
Akaike's information criterion (AIC) and Bayesian information criterion (BIC) scores and the 
model with the least scores was chosen to be the one that best fit the data. 
Data cleaning, plotting of Kaplan-Meier curves and log-rank tests were carried out in R v3.5.1 
using the following R packages: data.table v1.11.4 (Dowle and Srinivasan 2018), dplyr v0.7.6 
(Wickham et al. 2018), survival v2.42-6 (Therneau 2020) and survminer v0.4.3 (Kassambara 
and Kosinski 2018). Cox regression analysis was performed in Stata v14.0. 
2.3 Results 
2.3.1 Demography 
A total of 2,644 children were recruited into the study over 17 cross-sectional surveys. 20 
children were excluded due to missing data on age, bringing the person-years of follow up to 
12,543. 1,218 person-years of follow up were excluded from the cross-sectional surveys for 
the following reasons; 249 lacked data on parasitemia or temperature, 220 had a febrile non-
malaria episode, 99 had febrile malaria, 139 asymptomatics who did not meet the criteria for 
defining an asymptomatic infection (see section 2.2.2 regarding case definitions) and 511 
lacked weekly surveillance data. Consequently, data on 2,513 children were analysed, 
representing 11,325 person-years of follow up (Figure 2.1). There was a total of 3,132 
episodes of malaria during the cross-sectional surveys, while 15.2% of children had 
asymptomatic infections across all sites (Table 2.1). Finally, Table 2.2 shows the distribution 






Figure 2.1 A flow chart showing the total number of children recruited from three cohorts of varying 
malaria transmission intensity (Ngerenya – low, Junju – moderate to high and Chonyi – high) and 


























































Total Number of children included in the study 931 989 593 
Age range [Years] >0 - 15 >0 – 15 >0 - 15 
Person years of follow-up 5,179 5,819 1,595 
Total Number of males [%] 484 [51.99] 497 [50.25] 306 [51.60] 
Total Number asymptomatic episodes [%] 419 [9.50%] 923 [17.00%] 538 [36.40%] 
Total number of children with 1 or more febrile malaria episodes [%] 162 [17.40] 371 [37.51] 119 [20.06] 
Low – low transmission, Mod-High – moderate to high transmission, High – high transmission 
 
Table 2.2. Distribution of asymptomatic and uninfected cases through the years in the three cohorts 
Year Ngerenya (Low) Junju (Mod-High) Chonyi (High) Asymptomatic Uninfected Asymptomatic Uninfected Asymptomatic Uninfected 
1999 128 360 - - 233 218 
2000 73 453 - - 143 372 
2001 125 405 - - 162 350 
2002 35 247 - - - - 
2003 33 237 - - - - 
2004 15 261 - - - - 
2005 6 245 167 - - - 
2006 - - - - - - 
2007 2 255 50 275 - - 
2008 1 270 85 242 - - 
2009 0 240 84 570 - - 
2010 0 257 128 523 - - 
2011 0 261 96 562 - - 
2012 1 259 94 574 - - 
2013 0 241 48 623 - - 
2014 - - 79 568 - - 
2015 - - 59 306 - - 
2016 - - 33 271 - - 
Totals 419 3991 923 4514 538 940 
The time-points range from 1999 through to 2016, however, in 2006 no survey was conducted as the 
malaria monitoring study transitioned to a new protocol that began in 2007. Marked with "-" are the 
2014-2016 time points for Ngerenya when no survey was conducted since malaria transmission was very 
low and surveillance switched from active to passive. Sample collection stopped in Chonyi after 2001 
and the new study site was Junju. Additionally, for the Junju 2005 time-point, the survey included 
asymptomatic children only. Low – low transmission, Mod-High – moderate to high transmission, High 






2.3.2 Risk of developing febrile malaria  
The risk of developing febrile malaria was compared between children with asymptomatic 
infections and uninfected children at baseline. Uninfected children were found to be at a 
higher risk compared to children with asymptomatic infections from the start of follow up 
and this difference in rates of developing episodes was more distinct after 90 days, when the 
two survival functions diverged to the end of follow up (Figure 2.2, p-value < 0.0001). 
 
 
Figure 2.2. A Kaplan-Meier plot showing the risk of developing febrile malaria in uninfected children 
vs. children with asymptomatic infections across three malaria transmission settings. This plot 
compares the time to first febrile malaria episode between uninfected children versus children with 
asymptomatic infections across the three cohorts of varying malaria transmission intensities over a 
one-year period. The x-axis represents the one year longitudinal follow up from cross-sectional survey 
until one developed a febrile episode while the y-axis represents the proportion of individuals that 
have not yet developed a febrile episode. The risk table shows the number of participants under 
observation at every 30-days interval across the two groups. The log-rank test was used to compare 






The effect of age and transmission intensity on the risk of developing febrile malaria in 
children with asymptomatic infections vs. uninfected children was then examined. 
Asymptomatic infections were associated with an increased risk of febrile malaria within all 
age groups in the low transmission setting. The risk of febrile malaria was not altered by 
asymptomatic infections among the younger age groups (≤ 3 years) in the moderate to high 
and in the high transmission settings. However, among the older age groups (> 3 years) in the 
moderate-high and high transmission settings, asymptomatic infections were associated with 
a reduced risk of developing febrile malaria (Figure 2.3).  
There were some variations in effect over time including, the risk among children with 
asymptomatic infections was found to decrease over time relative to the risk among children 
without asymptomatic infection. In turn, the divergence between the survival functions 
occurred in earlier time periods in settings where asymptomatic infections were associated 
with increased risk (i.e. in children of all ages in the lower transmission region) and became 
parallel in later time periods. Where asymptomatic infections were associated with reduced 
risk (i.e. in older children in the higher transmission region) the survival functions tended to 
be parallel in earlier time periods (or even showed increased risk among children with 
asymptomatic infection) and then showed decreased risk among children with asymptomatic 









Figure 2.3. Risk of developing febrile malaria between asymptomatic and uninfected children, stratified by malaria 
transmission intensity and age. This plot compares the time to the first febrile malaria episode between uninfected children 
versus children with asymptomatic infections across the three cohorts of varying malaria transmission intensities, stratified 
by three age groups, 0-3, >3-7 and >7 years old. The risk table shows the number of participants under observation at 100-
day intervals for both the uninfected (black) and asymptomatic (maroon) groups. The log-rank test was used to compare 
survival distributions. 
 
2.3.3 The impact of transmission intensity and age on the risk of developing febrile 
malaria 
The multiple fractional polynomials (MFP) approach was used to transform age as a non-
linear variable and this was found to best fit the data compared to having age as a linear 
















variable (p < 0.0001, Figure 2.4). MFP are used for modelling the influence of continuous 
variables on the outcome of interest in regression models (Royston and Altman 1994; 
Sauerbrei and Royston 1999). These models are useful when one wishes to preserve the 
continuous nature of the covariates in a regression model, but suspects that some or all of 
the relationships may be non-linear. In this case, it was suspected that the relationship 
between age and risk of subsequent malaria episodes may not follow a linear pattern, hence 
further models were constructed with the transformed age variable. 
 
 
Figure 2.4 Models comparing the relative risk of developing febrile episodes as predicted from the 
interaction between site and age as (A) linear and (B) non-linear (transformed using fractional 
polynomials). The log-likelihood, AIC and BIC scores below each respective graph show that the non-
linear model is a better fit since it had the least scores. For this reason, further models were 
constructed with non-linear age. 
 
 
After incorporating age as a non-linear variable, a Cox proportional hazards model was 
constructed to test the effect of transmission intensity, infection status (Asymptomatic vs. 
Uninfected), transformed age, gender (male vs. female), year of survey and time cut-offs 
(days where the two survival functions diverge) and their interactions. Moreover, an 





and logarithmic interactions between time and other covariates (transmission, transformed 
age, infection status and year of survey).  
The first model tested the effect of all the covariates on the risk of developing febrile malaria 
and time was included as exponential. The following covariates were associated with an 
increased risk including transmission intensity (mod-high vs. high, hazard ratio [HR] = 15.92, 
p-value < 0.0001), transformed age (HR = 5.06, p-value < 0.0001), the interaction between 
transmission intensity (low vs. high) and asymptomatic infections (HR = 2.38, p-value < 
0.0001), the interaction between asymptomatic infections and transformed age (HR = 3.44, 
p-value <0.0001), the interaction between asymptomatic infections and year of survey (HR = 
1.13, p-value <0.0001) and gender though not significant (HR = 1.06, p-value = 0.246). On the 
other hand, the following covariates were associated with a reduced risk including 
transmission intensity (low vs. high) though not significant (HR = 0.92, p-value = 0.815), the 
interaction between transmission intensity (low vs. high) and transformed age though not 
significant (HR = 0.65, p-value = 0.213), the interaction between transmission intensity (mod-
high vs. high) and transformed age (HR = 0.25, p-value < 0.0001), asymptomatic infections 
(HR = 0.16, p-value < 0.0001), the interaction between transmission (mod-high vs. high) and 
asymptomatic infections (HR = 0.24, p-value < 0.0001) and finally the year of survey (HR = 
0.92, p-value = <0.0001) (Table 2.3). 
 
Table 2.3. Multivariable analysis to test the effect of different covariates on the risk of developing febrile malaria, 









Transmission (Low vs. High) 0.92 0.32 -0.23 0.815 0.47 1.82 
Transmission (Mod-High vs. High) 15.92 5.16 8.54 <0.0001 8.44 30.06 
Transformed Age  5.06 1.40 5.86 <0.0001 2.94 8.71 
Transmission (Low vs. High) x Transformed Age  0.65 0.23 -1.24 0.213 0.33 1.28 
Transmission (Mod-High vs. High) x Transformed Age  0.25 0.08 -4.58 <0.0001 0.13 0.45 
Infection Status (Asymptomatic vs. Uninfected) 0.16 0.05 -5.75 <0.0001 0.09 0.30 
Transmission (Low vs. High) x Infection Status (Asymptomatic vs. Uninfected) 2.38 0.44 4.74 <0.0001 1.66 3.41 
Transmission (Mod-High vs. High) x Infection Status (Asymptomatic vs. 
Uninfected) 
0.24 0.06 -5.46 <0.0001 0.15 0.40 
Infection Status (Asymptomatic vs. Uninfected) x Transformed Age  3.44 0.98 4.35 <0.0001 1.97 6.02 
Gender (Male vs. Female) 1.06 0.05 1.16 0.246 0.96 1.16 
Year of Survey 0.92 0.01 -10.25 <0.0001 0.90 0.93 





The odds ratio at baseline for all the covariates are presented. Time was included as exponential. The p-values in bold represent 
those that were statistically significant (p < 0.05). The symbol x indicates an interaction between the respective covariates. 
Abbreviations: mod-high – moderate-high. 
  
From the Schoenfeld’s residuals test, the relative effect of infection status and year of survey 
on the hazard function was found to change over time. Thus, this violated the proportional 
hazards assumption which requires that a covariate effect is constant over time (Table 2.4) 
Further models, therefore, included infection status and year of survey as time-varying 
covariates. 
 
Table 2.4. Schoenfeld’s residuals for the tested covariates 
Co-variate rho chi2 df Prob>chi2 
Infection Status (Asymptomatic vs. Uninfected) -0.041 7.26 1 0.007 
Transmission (Low vs. High) -2 x 104 <0.01 1 0.99 
Transmission (Mod-High vs. High) -0.024 2.54 1 0.11 
Age -0.003 0.04 1 0.85 
Gender (Male vs. Female) -0.008 0.42 1 0.52 
Year of Survey -0.058 18.26 1 <0.0001 
Global Test   95.61 6 <0.0001 
The global p-value shows that the effect of at least one of the covariates varies over time. Looking at 
each of the covariates independently, the effects of infection status and year of survey vary over time 
as they had p-values that were below 0.05. Abbreviations: mod-high – moderate-high. 
 
The second model tested the effect of all covariates on the risk of developing febrile malaria 
and included time-varying covariates as well as time as an exponential variable. Similar effects 
of the covariates were observed as in the first model. Also, among the time varying covariates, 
both asymptomatic infections and year of survey had no impact on risk (HR = 1) (Table 2.5). 
 
Table 2.5. Multivariable analysis to test the effect of different covariates on the risk of developing febrile malaria, 










Transmission (Low vs. High) 0.99 0.35 -0.04 0.972 0.49 1.98 
Transmission (Mod-High vs. High) 16.69 5.49 8.56 <0.0001 8.76 31.80 
Transformed Age  5.37 1.53 5.90 <0.0001 3.07 9.38 
Transmission (Low vs. High) x Transformed Age  0.59 0.21 -1.51 0.132 0.29 1.18 





Infection Status (Asymptomatic vs. Uninfected) 0.21 0.07 -4.96 <0.0001 0.11 0.39 
Transmission (Low vs. High) x Infection Status (Asymptomatic vs. Uninfected) 2.47 0.46 4.89 <0.0001 1.72 3.56 
Transmission (Mod-High vs. High) x Infection Status (Asymptomatic vs. Uninfected) 0.26 0.07 -5.23 <0.0001 0.15 0.43 
Infection Status (Asymptomatic vs. Uninfected) x Transformed Age  3.33 0.94 4.25 <0.0001 1.91 5.78 
Gender (Male vs. Female) 1.06 0.05 1.17 0.241 0.96 1.16 
Year of Survey 0.95 0.01 -4.74 <0.0001 0.94 0.97 
Infection Status (Asymptomatic vs. Uninfected) x Year of Survey 1.12 0.02 5.46 <0.0001 1.08 1.17 
Time-Varying Covariates 
Infection Status (Asymptomatic vs. Uninfected) 1.00 0.00 -2.75 0.006 1.00 1.00 
Year 1.00 0.00 -6.83 <0.0001 1.00 1.00 
The odds ratio at baseline (main) for all the covariates and those that varied over time (time-varying covariates) are presented. 
Time was included as exponential. The p-values in bold represent those that were statistically significant (p < 0.05). The symbol x 
indicates an interaction between the respective covariates. Abbreviations: mod-high – moderate-high. 
 
The third model was similar to the second model; however, gender was dropped as it was 
found not to have a significant effect in the first and second models. Similar effects of the 
other covariates were observed as in the second model (Table 2.6). 
 
Table 2.6. Multivariable analysis to test the effect of different covariates on the risk of developing febrile malaria 










Transmission (Low vs. High) 0.99 0.35 -0.03 0.977 0.49 1.98 
Transmission (Mod-High vs. High) 16.58 5.46 8.52 <0.0001 8.69 31.62 
Transformed Age  5.36 1.53 5.89 <0.0001 3.07 9.38 
Transmission (Low vs. High) x Transformed Age  0.59 0.21 -1.50 0.133 0.29 1.18 
Transmission (Mod-High vs. High) x Transformed Age  0.23 0.07 -4.64 <0.0001 0.13 0.43 
Infection Status (Asymptomatic vs. Uninfected) 0.21 0.07 -4.93 <0.0001 0.11 0.39 
Transmission (Low vs. High) x Infection Status (Asymptomatic vs. Uninfected) 2.46 0.46 4.86 <0.0001 1.71 3.55 
Transmission (Mod-High vs. High) x Infection Status (Asymptomatic vs. Uninfected) 0.26 0.07 -5.25 <0.0001 0.15 0.42 
Infection Status (Asymptomatic vs. Uninfected) x Transformed Age  3.31 0.93 4.24 <0.0001 1.90 5.75 
Year 0.95 0.01 -4.73 <0.0001 0.94 0.97 
Infection Status (Asymptomatic vs. Uninfected) x Year  1.12 0.02 5.47 <0.0001 1.08 1.17 
Time-Varying Covariates 
Infection Status (Asymptomatic vs. Uninfected) 1.00 0.00 -2.74 0.006 1.00 1.00 
Year of Survey 1.00 0.00 -6.84 <0.0001 1.00 1.00 
The odds ratio at baseline (main) for all the covariates and those that varied over time (time-varying covariates) are presented. 
Also, gender was dropped as it was found not to be significant and time was included as exponential. The p-values in bold represent 
those that were statistically significant (p < 0.05). The symbol x indicates an interaction between the respective covariates. 
Abbreviations: mod-high – moderate-high. 
 
The fourth model was similar to the third model but time was log-transformed, to compare 
with time as an exponential variable and the effects of the covariates were similar to the third 





and year of survey were associated with a non-significant and significant reduced risk, 
respectively (HR = 0.81, p-value = 0.09 and HR = 0.93, p-value < 0.0001, respectively) (Table 
2.7).  
Table 2.7. Multivariable analysis to test the effect of different covariates on the risk of developing febrile malaria, 










Transmission (Low vs. High) 0.98 0.34 -0.07 0.945 0.49 1.95 
Transmission (Mod-High vs. High) 16.44 5.39 8.53 <0.0001 8.64 31.28 
Transformed Age  5.27 1.49 5.87 <0.0001 3.03 9.18 
Transmission (Low vs. High) x Transformed Age  0.60 0.21 -1.43 0.154 0.30 1.21 
Transmission (Mod-High vs. High) x Transformed Age  0.24 0.07 -4.60 <0.0001 0.13 0.44 
Infection Status (Asymptomatic vs. Uninfected) 0.26 0.10 -3.52 <0.0001 0.12 0.55 
Transmission (Low vs. High) x Infection Status (Asymptomatic vs. Uninfected) 2.42 0.45 4.76 <0.0001 1.68 3.48 
Transmission (Mod-High vs. High) x Infection Status (Asymptomatic vs. Uninfected) 0.25 0.06 -5.36 <0.0001 0.15 0.41 
Infection Status (Asymptomatic vs. Uninfected) x Transformed Age  3.33 0.94 4.26 <0.0001 1.92 5.81 
Year of Survey 1.05 0.02 2.05 0.041 1.00 1.10 
Infection Status (Asymptomatic vs. Uninfected) x Year of Survey 1.13 0.02 5.56 <0.0001 1.08 1.17 
Time-Varying Covariates 
Infection Status (Asymptomatic vs. Uninfected) 0.81 0.10 -1.69 0.09 0.63 1.03 
Year of Survey 0.93 0.01 -5.90 <0.0001 0.91 0.95 
The odds ratio at baseline (main) for all the covariates and those that varied over time (time-varying covariates) are presented. 
Also, gender was dropped as it was found not to be significant and time was included as log-transformed. The p-values in bold 
represent those that were statistically significant (p < 0.05). The symbol x indicates an interaction between the respective 
covariates. Abbreviations: mod-high – moderate-high. 
 
Time as an exponential variable was found to be a better fit for the data, compared with time 
as a log-transformed variable. Therefore, subsequent models maintained time as an 
exponential variable. Additionally, the Kaplan-Meier plots revealed that there were variations 
in effect on risk over time. As mentioned earlier, this resulted in the divergence between the 
survival functions occurring in earlier time periods in settings where asymptomatic infections 
were associated with increased risk and became parallel in later time periods. Additionally, 
where asymptomatic infections were associated with reduced risk, the survival functions 
tended to be parallel in earlier time periods and then showed decreased risk among children 
with asymptomatic infection during later time periods. Consequently, the fifth (Table 2.8), 
sixth (Table 2.9), seventh (Table 2.10) and eighth models (Table 2.11) tested the effect of all 
covariates on the risk of developing febrile malaria and included step-wise interactions 





Similar effects of the covariates were observed as in the fourth model. The comparison of 
goodness-of-fit statistics is presented in Table 2.12. 
 
Table 2.8. Multivariable analysis to test the effect of different covariates on the risk of developing febrile malaria, 










Transmission (Low vs. High) 0.94 0.33 -0.19 0.849 0.47 1.85 
Transmission (Mod-High vs. High) 15.95 5.19 8.51 <0.0001 8.43 30.18 
Transformed Age  5.09 1.42 5.84 <0.0001 2.95 8.78 
Transmission (Low vs. High) x Transformed Age  0.64 0.22 -1.27 0.204 0.32 1.27 
Transmission (Mod-High vs. High) x Transformed Age  0.25 0.08 -4.56 <0.0001 0.13 0.45 
Infection Status (Asymptomatic vs. Uninfected) 0.13 0.05 -5.83 <0.0001 0.07 0.26 
Transmission (Low vs. High) x Infection Status (Asymptomatic vs. Uninfected) 2.37 0.44 4.67 <0.0001 1.65 3.40 
Transmission (Mod-High vs. High) x Infection Status (Asymptomatic vs. Uninfected) 0.24 0.06 -5.50 <0.0001 0.14 0.40 
Infection Status (Asymptomatic vs. Uninfected) x Transformed Age  3.44 0.98 4.33 <0.0001 1.97 6.01 
Year of Survey 0.94 0.01 -5.15 <0.0001 0.92 0.96 
Infection Status (Asymptomatic vs. Uninfected) x Year of Survey  1.13 0.02 5.68 <0.0001 1.08 1.18 
Time-Varying Covariates 
Infection Status (Asymptomatic vs. Uninfected) 1.26 0.21 1.39 0.164 0.91 1.73 
Year of Survey 0.97 0.01 -2.80 0.005 0.95 0.99 
The odds ratio at baseline (main) for all the covariates and those that varied over time (time-varying covariates) are presented. 
Also, gender was dropped as it was found not to be significant, time was included as exponential with alternative cut-offs of <30 
and >30 days. The p-values in bold represent those that were statistically significant (p < 0.05). The symbol x indicates an interaction 




Table 2.9. Multivariable analysis to test the effect of different covariates on the risk of developing febrile malaria, 










Transmission (Low vs. High) 0.96 0.34 -0.11 0.912 0.48 1.92 
Transmission (Mod-High vs. High) 16.37 5.35 8.55 <0.0001 8.63 31.07 
Transformed Age  5.20 1.46 5.86 <0.0001 3.00 9.03 
Transmission (Low vs. High) x Transformed Age  0.62 0.22 -1.35 0.176 0.31 1.24 
Transmission (Mod-High vs. High) x Transformed Age  0.24 0.08 -4.57 <0.0001 0.13 0.44 
Infection Status (Asymptomatic vs. Uninfected) 0.22 0.07 -4.82 <0.0001 0.12 0.40 
Transmission (Low vs. High) x Infection Status (Asymptomatic vs. Uninfected) 2.40 0.44 4.76 <0.0001 1.67 3.45 
Transmission (Mod-High vs. High) x Infection Status (Asymptomatic vs. Uninfected) 0.25 0.06 -5.38 <0.0001 0.15 0.41 
Infection Status (Asymptomatic vs. Uninfected) x Transformed Age  3.35 0.94 4.29 <0.0001 1.93 5.82 
Year of Survey 0.96 0.01 -4.77 <0.0001 0.94 0.97 
Infection Status (Asymptomatic vs. Uninfected) x Year of Survey  1.12 0.02 5.43 <0.0001 1.08 1.17 
Time-Varying Covariates 
Infection Status (Asymptomatic vs. Uninfected) 0.72 0.08 -2.92 0.003 0.57 0.90 
Year of Survey 0.94 0.01 -6.50 <0.0001 0.92 0.96 
The odds ratio at baseline (main) for all the covariates and those that varied over time (time-varying covariates) are presented. 
Also, gender was dropped as it was found not to be significant, time was included as exponential with alternative cut-offs of <60 
and >60 days. The p-values in bold represent those that were statistically significant (p < 0.05). The symbol x indicates an interaction 





Table 2.10. Multivariable analysis to test the effect of different covariates on the risk of developing febrile malaria, 










Transmission (Low vs. High) 0.98 0.35 -0.05 0.957 0.49 1.96 
Transmission (Mod-High vs. High) 16.55 5.43 8.55 <0.0001 8.70 31.49 
Transformed Age  5.29 1.50 5.86 <0.0001 3.03 9.22 
Transmission (Low vs. High) x Transformed Age  0.60 0.21 -1.43 0.154 0.30 1.21 
Transmission (Mod-High vs. High) x Transformed Age  0.24 0.07 -4.59 <0.0001 0.13 0.44 
Infection Status (Asymptomatic vs. Uninfected) 0.21 0.07 -4.97 <0.0001 0.12 0.39 
Transmission (Low vs. High) x Infection Status (Asymptomatic vs. Uninfected) 2.43 0.45 4.81 <0.0001 1.69 3.49 
Transmission (Mod-High vs. High) x Infection Status (Asymptomatic vs. Uninfected) 0.25 0.07 -5.29 <0.0001 0.15 0.42 
Infection Status (Asymptomatic vs. Uninfected) x Transformed Age  3.32 0.93 4.27 <0.0001 1.91 5.76 
Year of Survey 0.95 0.01 -5.72 <0.0001 0.93 0.97 
Infection Status (Asymptomatic vs. Uninfected) x Year of Survey  1.12 0.02 5.35 <0.0001 1.07 1.17 
Time-Varying Covariates 
Infection Status (Asymptomatic vs. Uninfected) 0.69 0.08 -3.39 0.001 0.56 0.85 
Year of Survey 0.94 0.01 -7.34 <0.0001 0.92 0.95 
The odds ratio at baseline (main) for tall the covariates and those that varied over time (time-varying covariates) are 
presented. Also, gender was dropped as it was found not to be significant, time was included as exponential with alternative 
cut-offs of <90 and >90 days. The p-values in bold represent those that were statistically significant (p < 0.05). The symbol x 
indicates an interaction between the respective covariates. Abbreviations: mod-high – moderate-high. 
 
 
Table 2.11. Multivariable analysis to test the effect of different covariates on the risk of developing febrile malaria, with 










Transmission (Low vs. High) 0.96 0.34 -0.11 0.909 0.48 1.92 
Transmission (Mod-High vs. High) 16.18 5.30 8.49 <0.0001 8.51 30.76 
Transformed Age  5.24 1.48 5.86 <0.0001 3.01 9.12 
Transmission (Low vs. High) x Transformed Age  0.61 0.22 -1.40 0.161 0.30 1.22 
Transmission (Mod-High vs. High) x Transformed Age  0.24 0.07 -4.59 <0.0001 0.13 0.44 
Infection Status (Asymptomatic vs. Uninfected) 0.18 0.06 -5.41 <0.0001 0.10 0.34 
Transmission (Low vs. High) x Infection Status (Asymptomatic vs. Uninfected) 2.44 0.45 4.82 <0.0001 1.70 3.50 
Transmission (Mod-High vs. High) x Infection Status (Asymptomatic vs. Uninfected) 0.25 0.07 -5.29 <0.0001 0.15 0.42 
Infection Status (Asymptomatic vs. Uninfected) x Transformed Age  3.35 0.95 4.27 <0.0001 1.92 5.82 
Year of Survey 0.93 0.01 -7.84 <0.0001 0.92 0.95 
Infection Status (Asymptomatic vs. Uninfected) x Year of Survey  1.12 0.02 5.52 <0.0001 1.08 1.17 
Time-Varying Covariates 
Infection Status (Asymptomatic vs. Uninfected) 0.79 0.09 -2.03 0.042 0.64 0.99 
Year of Survey 0.95 0.01 -5.06 <0.0001 0.94 0.97 
The odds ratio at baseline (main) for all the covariates and those that varied over time (time-varying covariates) are presented. Also, gender was dropped 
as it was found not to be significant, time was included as exponential with alternative cut-offs of <120 and >120 days. The p-values in bold represent 







In the end, the model with alternative cut-offs of <90 and >90 days (Table 2.10) was found to 
best fit the data as it had the least log-likelihood, AIC and BIC scores (Table 2.12) and was 
retained as the final model. 
 
Table 2.12. Markers of goodness-of-fit for Cox proportional hazards models 
Model Reference Log-likelihood df AIC BIC 
A multivariable model with age as non-linear and its interactions, no tvc Table 2.3 -27787.36 12 55598.72 55686.73 
A multivariable model with age as non-linear and its interactions, with tvc Table 2.5 -27756.43 14 55540.86 55643.54 
A multivariable model with time-varying covariates (statistically significant covariates only) Table 2.6 -27757.68 13 55541.36 55636.71 
A multivariable model with time-varying covariates (logarithmic variations with time) Table 2.7 -27763.78 13 55553.55 55648.90 
A multivariable model with time-varying covariates (cut-offs) 30-day cut-off (Table 2.8) -27782.10 13 55590.20 55685.55 
60-day cut-off (Table 2.9) -27761.11 13 55548.23 55643.58 
90-day cut-off (Table 2.10) -27750.39 13 55526.79 55622.14 
120-day cut-off (Table 2.11) -27770.23 13 55566.47 55661.82 
The log-likelihood score is a statistical test used for comparing the goodness of fit of two models. Based on the likelihood ratio, it 
expresses how many times more likely the data are under one model than the other and smaller log-likelihood values indicate a better 
model. The AIC and the BIC scores are information-based criteria that assess the model fit. In general, BIC penalizes models with more 
parameters more than AIC does. For this reason, it leads to choosing more parsimonious models, that is, models with fewer 
parameters, than does AIC. In both cases, lower AIC and BIC scores indicate a better model. Abbreviations: df – degrees of freedom, 
tvc – time-varying covariates.  
 
In the final model, the following covariates were associated with an increased risk including 
transmission intensity (mod-high vs. high, hazard ratio [HR] = 16.55, p-value < 0.0001), 
transformed age (HR = 5.29, p-value < 0.0001), the interaction between transmission intensity 
(low vs. high) and asymptomatic infections (HR = 2.43, p-value < 0.0001), the interaction 
between asymptomatic infections and transformed age (HR = 3.32, p-value <0.0001) and the 
interaction between asymptomatic infections and year of survey (HR = 1.12, p-value <0.0001). 
On the other hand, the following covariates were associated with a reduced risk including 
transmission intensity (low vs. high) though not significant (HR = 0.98, p-value = 0.957), the 
interaction between transmission intensity (low vs. high) and transformed age though not 
significant (HR = 0.60, p-value = 0.154), the interaction between transmission intensity (mod-
high vs. high) and transformed age (HR = 0.24, p-value < 0.0001), asymptomatic infections 
(HR = 0.21, p-value < 0.0001), the interaction between transmission (mod-high vs. high) and 
asymptomatic infections (HR = 0.25, p-value < 0.0001) and year of survey (HR = 0.95, p-value 





and year of survey were associated with a reduced risk (HR = 0.69, p-value = 0.001 and HR = 
0.94, p-value < 0.0001, respectively). 
An exploratory analysis showed that every 10-fold increase in asymptomatic parasite density 
was associated with a 35% increased risk of developing febrile malaria (Hazard Ratio = 1.35, 
p-value <0.0001). Finally, a sensitivity analysis was conducted using different parasite density 
thresholds for defining febrile malaria (i.e. any parasitemia in children <1 year and ≥ 2500 
parasites/μl for older children) as per previous work (Mwangi et al. 2005) to evaluate risk. 
The effect of asymptomatic infections remained the same as when one cut-off was used to 
define febrile malaria (i.e. ≥ 2500 parasites/μl for all children) (Table 2.13).  










Transmission (Low vs. High) 1.01 0.36 0.02 0.984 0.50 2.02 
Transmission (Mod-High vs. High) 16.99 5.59 8.61 <0.0001 8.91 32.39 
Transformed Age  5.31 1.49 5.95 <0.0001 3.06 9.21 
Transmission (Low vs. High) x Transformed Age  0.59 0.21 -1.51 0.131 0.29 1.17 
Transmission (Mod-High vs. High) x Transformed Age  0.23 0.07 -4.70 <0.0001 0.13 0.43 
Infection Status (Asymptomatic vs. Uninfected) 0.20 0.06 -5.09 <0.0001 0.11 0.38 
Transmission (Low vs. High) x Infection Status (Asymptomatic vs. Uninfected) 2.44 0.45 4.85 <0.0001 1.70 3.49 
Transmission (Mod-High vs. High) x Infection Status (Asymptomatic vs. Uninfected) 0.25 0.07 -5.31 <0.0001 0.15 0.42 
Infection Status (Asymptomatic vs. Uninfected) x Transformed Age  3.42 0.96 4.38 <0.0001 1.97 5.94 
Year 0.95 0.01 -5.80 <0.0001 0.93 0.97 
Infection Status (Asymptomatic vs. Uninfected) x Year  1.12 0.02 5.37 <0.0001 1.08 1.17 
Time-Varying Covariates 
Infection Status (Asymptomatic vs. Uninfected) 0.69 0.08 -3.34 0.001 0.56 0.86 
Year 0.94 0.01 -7.29 <0.0001 0.92 0.95 
This model shows the effect of the different covariates on developing febrile episodes with alternative cut-off times of <90 and 
>90 days and included age-dependent parasite density cut-offs for defining febrile malaria. The p-values in bold represent those 
that were statistically significant (p < 0.05). The symbol x indicates an interaction between the respective covariates. 
Abbreviations: mod-high - moderate-high. 
 
2.4 Discussion 
Asymptomatic infections before the malaria transmission season predicted the risk of 
developing febrile malaria. This effect was significantly modified by transmission intensity and 
age. In the moderate to high as well as in the high transmission settings, asymptomatic 
infections were associated with a reduced risk of febrile malaria in older children (>3-15 





younger children in the moderate to high and high transmission settings. In contrast, in 
children of all ages in the lower transmission setting, asymptomatic infections were 
associated with an increased risk of febrile malaria. Moreover, the effect of asymptomatic 
infections was modified by time since ascertainment. At low transmission, asymptomatics 
were at a higher risk than uninfected children until 90 days after ascertainment, following 
which asymptomatics were at similar risk to uninfected children. On the other hand, at higher 
transmission and older age, asymptomatics were at a similar risk as uninfected children, until 
90 days after ascertainment following which asymptomatics were at a lower risk than 
uninfected children. 
This study is in agreement with studies conducted in high transmission areas where 
asymptomatic infections have previously been associated with a reduced risk of febrile 
episodes (Henning et al. 2004; Males, Gaye and Garcia 2008; Portugal et al. 2017; Buchwald 
et al. 2018), in particular among older children. Additionally, in low transmission areas, some 
studies have shown that asymptomatic infections were associated with an increased risk of 
febrile episodes (Henning et al. 2004; Njama-Meya, Kamya and Dorsey 2004; Le Port et al. 
2008; Males, Gaye and Garcia 2008), again consistent with the findings here. Thus, 
transmission intensity and age modified the effect of asymptomatic infections on the risk of 
developing febrile malaria.  
Children living in malaria-endemic regions with high transmission acquire immunity at a faster 
rate than those living in low endemic regions as they are repeatedly exposed to infections 
(Doolan, Dobaño and Baird 2009). Consequently, while immunity to malaria may not 
necessarily prevent infection, it may help an individual control parasite density and prevent 
symptoms thus leading to asymptomatic infections (Doolan, Dobaño and Baird 2009). It has 
been argued that the presence of asymptomatic parasitemia leads to resistance to further 
infection, a state that is termed “premunition” (Breman 2001). Continuous exposure to 
malaria infection may continuously prime the immune system and lower the risk of 
developing febrile malaria. However, the presence of asymptomatic infections implies a risk 
of parasites going on to cause febrile malaria and may also imply a higher degree of exposure 





malaria. In this study, older children harbouring asymptomatic infections and living in a region 
of high transmission intensity, had a reduced risk of developing febrile malaria. On the other 
hand, younger children with a naïve immune system were at a greater risk of developing 
febrile malaria if they had asymptomatic infections. The reduced risk with asymptomatic 
infections becomes more pronounced in older children, which is consistent with a prominent 
role for acquired immunity, although an additional role of premunition cannot be excluded. 
Previous studies have indicated that antibodies are predictive of reduced susceptibility to 
malaria among children with asymptomatic infections but not among uninfected children 
(Chan et al. 2012; Rono et al. 2013), implying a role for antibodies in mediating the protection 
seen in older children with asymptomatic infections. The 90-day period of increased risk 
following the ascertainment of asymptomatic infections could be due to the increased 
exposure during to the rainy season. Finally, in the cohorts under study, every 10-fold increase 
in parasite density was associated with an increased risk of developing a febrile episode. It is 
possible that higher density asymptomatic infections indicate less host immunity and 
therefore a greater risk that parasites will evade immune control. 
Limitations of this study include the reliance on microscopy diagnosis that may have missed 
a considerable number of children with sub-microscopic infections since microscopy is less 
sensitive than PCR (Wu et al. 2015). Misclassification of low-density asymptomatic infections 
as parasite negative would tend to reduce the strength of associations seen, hence this study 
may be an underestimate of the significance of asymptomatic infections. Malaria 
transmission is locally heterogeneous (Bejon et al. 2010) and hence describing a cohort as 
uniformly high or low transmission is a simplification, but necessary to study effect 
modification across groups at different transmission intensity. Episodes of malaria could have 
been missed during surveillance, either because the episode was self-limiting, or treatment 
was obtained elsewhere. In mitigation, active surveillance was used and is more sensitive than 
passive surveillance (Olotu et al. 2012). Also, assuming that surveillance is similarly 
incomplete for all children, a bias arising from this limitation would be unlikely. Host 
population dynamics such as short-term migration (Prothero 2001) and environmental 





accounted for. These may impact on how transmission intensity, age and asymptomatic 
infections influence the risk of developing febrile malaria. 
This study cannot be used to infer the effects of treating asymptomatic infections as it was 
conducted to study the natural history of asymptomatic infections rather than to make policy 
recommendations. Furthermore, the findings here may have implications on future studies 
focussing on asymptomatic infections. More work is needed to establish the role of acquired 
immunity and premunition in protecting asymptomatic individuals from subsequent febrile 
episodes. Moreover, there is a need to standardize the definition of asymptomatic infections 
to ensure that different studies obtain comparable results. For example, future studies should 
consider including longitudinal follow-up as it will be important when defining asymptomatic 
infections to exclude pre-symptomatic individuals. However, the identification of biomarkers 
that can diagnose asymptomatic infections can assist in instances where longitudinal follow 
ups are lacking.   
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Chapter 3 : Using deep-sequencing to evaluate P. falciparum diversity in asymptomatic 
and febrile malaria infections 
3.1 Introduction 
In chapter 3, it was indicated that asymptomatic infections were associated with a reduced 
risk of febrile malaria episodes (see section 1.9.3). Still, the transition from asymptomatic to 
febrile malaria is yet to be fully understood. While some individuals have been reported to 
transition due to persistent parasites (Missinou et al. 2001; Nsobya et al. 2004), a majority of 
individuals transition due to the introduction of novel parasites (Contamin et al. 1996; Babiker 
et al. 1998; Missinou et al. 2001; Ofosu-Okyere et al. 2001; Kun et al. 2002; Nsobya et al. 
2004; Buchwald et al. 2018). These previous findings are based on msp1/msp2/glurp 
genotyping, the traditional genotyping methods of characterising P. falciparum parasite 
diversity. Such methods however, may fail to generate analysable data due to complexity of 
infections and may fail to capture minority variant subpopulations.  
Amplicon deep-sequencing offers a more sensitive tool compared to traditional genotyping 
approaches and with its ability to detect minority clones, this chapter sought to examine (i) 
how parasite diversity differs between asymptomatic and febrile malaria infections, (ii) how 
this diversity changes over time and (iii) whether episodes of febrile malaria are associated 
with persistence or the introduction of novel clones compared to those involved in the prior 
asymptomatic infection. 
3.2 Methods 
3.2.1 Study design 
P. falciparum positive (microscopy and PCR) samples were obtained from the Junju cohort in 
Kilifi and details regarding this cohort have been mentioned earlier in chapter 3 under section 
2.2.1. In this cohort, samples were collected prospectively since 2007 and both asymptomatic 
and febrile infections have been defined earlier in chapter 2 under section 2.2.2. 
3.2.2 DNA extraction 
DNA was extracted from frozen blood using the QIAamp DNA Blood Mini Kit (250) (Qiagen, 
Catalogue 51106) according to the manufacturer’s instructions. All samples were equilibrated 
to room temperature (20–25°C) and all steps were carried out at room temperature. Briefly, 





of a 1.5ml microcentrifuge tube. 200μl of the whole blood sample was added to a 
microcentrifuge tube and for samples that were less than 200μl, phosphate buffer solution 
(PBS) was used to top the volume up to 200μl to have similar starting volumes across all 
samples. 200μl of Buffer AL was then added to each sample and mixed by pulse-vortexing for 
15 sec. The samples were then incubated at 56°C for 10 min. 200μl of ethanol (96–100%) was 
added to each sample, after which the samples were mixed by pulse-vortexing for 15 sec. This 
mixture was then transferred to a QIAamp Mini spin column (attached to a 2ml collection 
tube) without wetting the rim. The cap was closed and the spin column centrifuged at 6000 x 
g for 1 min. The QIAamp Mini spin column was then placed in a clean 2ml collection tube and 
the tube containing the filtrate was discarded. The QIAamp Mini spin column was uncapped 
and 500μl Buffer AW1 was added without wetting the rim. The cap was then closed and the 
spin column centrifuged at 6000 x g for 1 min. The QIAamp Mini spin column was placed in a 
clean 2ml collection tube and the tube containing the filtrate was discarded. The QIAamp Mini 
spin column was uncapped and 500μl Buffer AW2 was added without wetting the rim. The 
cap was then closed and centrifuged at full speed (20,000 x g) for 3 min. The QIAamp Mini 
spin column was placed in a new 2ml collection tube and the old collection tube with the 
filtrate was discarded. The spin-column was then centrifuged at full speed for 1 min to 
eliminate the chance of possible Buffer AW2 carry-over. The QIAamp Mini spin column was 
placed in a clean 1.5ml microcentrifuge tube and the collection tube containing the filtrate 
was discarded. The QIAamp Mini spin column was uncapped and 50μl Buffer AE was added. 
The spin-column was incubated at room temperature (20–25°C) for 1 min to increase the DNA 
yield and then centrifuged at 6000 x g for 1 min. At this step, the eluate was ready for PCR 
amplification. 
3.2.3 PCR amplification 
P. falciparum apical membrane antigen 1 (ama1, PF3D7_1133400) amplicons spanning the 
nucleotides 465-923 were generated from each sample, in duplicate, using primers designed 
in this study (Table 3.1). This region of the ama1 gene has been found to have the highest 
nucleotide diversity (Polley and Conway 2001) and hence would serve as a good marker to 






Table 3.1. List of primers for PCR amplification 
Primer  Sequence ‘5-3’ Length (bases) 
AMA1_F GAA ATG TCC AGT ATT TGG TAA AGG 24 
AMA1_R CCC ATA ATC CGA ATT TTG CAT TC 23 
PCR included the following steps: initial denaturation (98°C – 30 
sec), followed by 30 cycles of denaturation (98°C – 10 sec), 
annealing (60°C for 30 sec for all genes), extension (72°C – 30 sec), 
and final extension (72°C – 2 min). 
 
For PCR, the following were used: 1µl of template DNA (final concentration < 50ng), 0.2µl of 
Q5® High-Fidelity DNA Polymerase (final concentration 0.02U/µl, New England BioLabs), 
forward primers tagged with Roche® multiplex identifiers (MIDs, Table 3.2) that enabled the 
demultiplexing of sequence reads into separate sequence reads for each sample (1µl, final 
concentration 10mM), reverse primers (1µl, final concentration 10mM), 0.4µl of 10mM dNTPs 
(final concentration 10µM, Bioline), 4µl of 5X Q5 reaction buffer (final concentration 1X), 
12.4µl of nuclease-free water and the PCR conditions indicated in (Table 3.1).  
Table 3.2. 10-base multiplex identifier (MID) set sequences 
MID Tag Sequence MID Tag Sequence 
MID01 ACGAGTGCGT MID14 TCACGTACTA 
MID02 ACGCTCGACA MID15 CGTCTAGTAC 
MID03 AGACGCACTC MID16 TCTACGTAGC 
MID04 AGCACTGTAG MID17 TGTACTACTC 
MID05 ATCAGACACG MID18 ACGACTACAG 
MID06 ATATCGCGAG MID19 CGTAGACTAG 
MID07 CGTGTCTCTA MID20 TACGAGTATG 
MID08 CTCGCGTGTC MID21 TACTCTCGTG 
MID09 TCTCTATGCG MID22 TAGAGACGAG 
MID10 TGATACGTCT MID23 TCGTCGCTCG 
MID11 CATAGTAGTG MID24 ACATACGCGT 
MID12 CGAGAGATAC MID25 ACGCGAGTAT 
MID13 ATACGACGTA MID26 ACTACTATGT 
Amplicons were generated using forward primers tagged on the 5’ end with 
the above listed MIDs. This enabled the unique identification of sequences 
from each sample during sequence data demultiplexing.  
 
The final reaction volume was 20µl and the PCR amplification products were visualised on 1% 
agarose gels stained with RedSafe™ Nucleic Acid Staining Solution (iNtRON Biotechnology 





template DNA. Also included for sequencing were lab controls comprising of a known mixture 
of two P. falciparum isolate: 3D7 (MRA-102G, BEI Resources, Manansas, VA) and Dd2 (MRA-
150G, BEI Resources). These two parasite isolates differ since they carry the wild-type and 
mutant ama1 and mdr1 variants, respectively, hence were appropriate sequencing controls. 
From this control mixture, ama1 amplicons were generated from six replicates each of the 
following percentage ratios of 3D7 to Dd2: 50:50, 75:25, 85:15, 95:5 and 100:0. 
3.2.4 PCR product purification 
This protocol was applied to the amplified PCR products to remove of enzymes, nucleotides, 
primers and PCR buffer components as these may interfere with sequencing. The Zymo ZR-
96 DNA Clean & Concentrator-5 Kit (Zymo Research, Catalog Number D4024) was used and 
all steps were performed at room temperature (20-25°C) and centrifugation was performed 
between 3,000 - 5,000 x g at room temperature.  
Purification of the PCR products involved adding 2-7 volumes of DNA Binding Buffer to each 
volume of PCR product and the mixture was vortexed briefly. The mixture was then 
transferred to the wells of a Zymo-Spin™ I-96 Plate mounted on a collection Plate. 
Centrifugation was then conducted for 5 min until the sample mixtures were completely 
filtered, after which the flow-through was discarded. 300µl DNA Wash Buffer was then added 
to each well of the Zymo-Spin™ I-96 Plate and the mixture was centrifuged for 5 min. This was 
repeated once more, but centrifugation was done for 15 min to ensure that the DNA Wash 
Buffer was eliminated from the sample. 30µl DNA Elution Buffer was added to the column 
matrix in each well and the Zymo-Spin™ I-96 Plate was then transferred onto an Elution Plate 
and centrifuged for 3 min to elute the DNA. Finally, the DNA was quantified using Quant-iT™ 
dsDNA Assay Kit, High Sensitivity (Invitrogen). At this stage, the ultra-pure DNA was ready for 
library preparation. 
3.2.5 Sequencing library preparation 
This protocol was performed according to the manufacturer’s instructions using The KAPA 
HyperPrep Kit which comprised 3 products: KAPA Library Amplification Primer Mix (10X, 





Kit (15 µM, Roche Cat. No 08278555702, Kit Code KK8722) and KAPA Adapter Dilution Buffer 
(25 mL, Roche Cat. No 08278539001, Kit Code KK8721). Also included were magnetic 
Agencourt AMPure XP beads (60 mL, Beckman Coulter, Cat. No A63881). The essence of this 
protocol was to attach KAPA adapters to the ends of each amplicon to enable them to bind 
to a sequencing flow cell and enable sequencing of each DNA fragment. Briefly, the quantified 
PCR products were normalised by diluting in EB Buffer (Qiagen) to achieve equimolar 
concentrations of 1ng each across all samples. The equimolar amplicons were then mixed to 
come up with amplicon pools of non-overlapping MIDs and since 26 unique MIDs were used, 
this allowed up to 13 samples to be sequenced in duplicate in each sequencing library. These 
pooled amplicons were then taken through library preparation which involved attaching dual 
index adapters using the KAPA Dual-Indexed Adapter Kit (KAPA BioSystems) and the KAPA 
Hyper Prep Kit (KAPA BioSystems). 
Library preparation commenced by taking the PCR products through an end-repair and A-
tailing process, which involved creating blunt ends and adding an A-tail to the 5’ and 3’ ends 
of each amplicon. In turn, this created binding sites for the Illumina-compatible KAPA 
adapters. By incubating the products from above with the KAPA adapters, the adapters were 
ligated to the DNA fragments. Post ligation cleanup was performed using the AMPure beads 
to size-select for adapter-ligated ama1 amplicons (636bp, including 516bp of ama1 and 120 
of KAPA adapters) and this eliminated free adapters, primers, nucleotides, salts and DNA 
fragments not ligated to adapters. Library amplification was then performed to increase the 
concentration of the adapter-ligated DNA fragments in a thermal cycler and a final round of 
clean up was performed with the magnetic AMPure beads as described above. Adapter 
ligation was confirmed by running a random sample of 20 libraries on the Agilent 2200 
TapeStation System using the Agilent High Sensitivity D1000 ScreenTape System (5067-5584). 
Since adapter ligation increased the length of amplicons by 120bp, a peak of approximately 
636bp was expected on the TapeStation. Finally, the ama1 adapter ligated amplicon libraries 





3.2.6 Amplicon deep sequencing 
Paired end sequencing (2x300 bp chemistry) of the final pool was performed on the MiSeq 
platform (Illumina) using the MiSeq Reagent Kit v3 (Illumina) in two labs: a subset of 127 
asymptomatic samples were amplified and sequenced at the KEMRI-Wellcome Trust 
Research Programme (KWTRP) lab while 408 asymptomatic samples and 114 febrile malaria 
samples were amplified and sequenced at the Infectious Disease Epidemiology and Ecology 






Figure 3.1. Schematic representation of the deep-sequencing pipeline. (1) the pipeline began with 
the extraction of DNA from frozen EDTA blood so as to generate (2) separate DNA pools from each 
sample. From the extracted DNA, (3) PCR amplification of the ama1 gene was conducted using MID-
tagged forward primers and untagged reverse primers and this generated (4) separate pools of 
amplicons from each sample, in duplicate. (5) The amplicons were then grouped into pools of non-
overlapping MIDs from which sequence libraries were generated by attaching library specific adapters 
and sequencing adapters to the 5’ and 3’ ends of each amplicon. The library specific adapters and 
unique MIDs enabled the demultiplexing of sequence data to facilitate the identification of samples 
from which each sequence originated. (6) A final pool was created containing equimolar amounts of 
each sequencing library and this final pool was (7) sequenced on the MiSeq Illumina platform. (8) The 





3.2.7 Sequence and data analysis 
Sequence analysis was performed on SeekDeep v2.6.4 (Hathaway et al. 2018). In brief, three 
of SeekDeep programs were used to: (i) extractorPairedEnd – an algorithm that carries out 
sequence demultiplexing and read filtering, enabling sequence data to be separated into 
individual samples based on the MIDs. Also, the tagged forward primer reads and untagged 
reverse primer reads were combined to generate the original amplicon fragments by 
sequence matching at the regions where the two reads overlap. (ii) qluster - an algorithm that 
carries out DNA sequence clustering and frequency estimation of the variants per 
demultiplexed data subset. ama1 haplotypes were generated based on the amino acid 
residues from all the polymorphic codons of the translated DNA sequences (iii) 
processClusters - an algorithm that carries out multiple PCR replicate comparisons to 
determine if the DNA sequence variants were identified in all sample replicates, as well as 
carrying out a comparison of the DNA variant frequencies across all samples. DNA variants 
that did not occur in two sample replicates were discarded. Also, since one of the ratios of 
the lab sequencing controls included a minor variant at 5% frequency (3D7 95% vs. Dd2 5%), 
DNA variants that were detected below this frequency were discarded. However, if such 
variants were detected above 5% frequency in other samples, they were retained. So as to 
reduce the rate of calling false positives, DNA variants that were detected in only one sample 
replicate were also discarded. Chimeric reads that originate as PCR artefacts were also 
excluded. Such reads are generated when the extension of an amplicon is terminated, and 
the aborted product functions as a primer in the next PCR cycle, thereby synthesizing a single 
sequence sourced from two different templates (Haas et al. 2011). 
3.2.8 Statistical analysis 
Statistical analysis was carried in R v3.6.0 (R Core Team ,2014). COI was defined as the number 
of DNA variants in each sample and the Wilcoxon signed-rank test was used to compare the 
difference in COI between asymptomatic and febrile malaria samples using the R package, 
ggpubr v0.2 (Kassambara 2020). The Poisson regression analysis was used to examine the 
impact of age and parasitemia on COI, while a logistic regression was used to test the impact 





et al. 2019). For the first-febrile episode with “x” number of persistent ama1 variants and 
sharing a single variant of prevalence “y”, the binomial probability that this variant is found 
by chance in a subsequent infection was calculated as 1−(1−y)x. This probability reflected the 
likelihood that the persistent genotype represented a new mosquito-bite infection. In cases 
where there were multiple shared persistent variants, the combined probability that all 
shared variants would appear in a reinfection was calculated as the product of the individual 
probabilities (Lin et al. 2015). All estimates were reported as incidence rate ratios (IRR) with 
confidence intervals (C.I) and all plots were generated using the R package, ggplot2 v3.1.1 
(Wickham 2016). 
3.3 Results 
3.3.1 Reproducibility and sensitivity analysis based on control mixtures 
A total of 49.45 million reads (combined forward and reverse) were generated and 26.2 
million (52.9%) of these were discarded as the MID tags could not be identified. A further 6.2 
million (12.5%) were discarded as the primer sequences could not be detected, 9 million 
(18.2%) were discarded because the pair reads did not overlap, 55,000 (0.1%) were discarded 
because they were identified as contaminated, possibly from bacterial DNA. Finally, 1 million 
(2%) reads were discarded because they were either chimeric, represented variants that did 
not occur in two sample replicates. Therefore, a total of 6.9 million (13.9%) reads were 
retained and used for analysis.  
A total of 30 individual lab controls were sequenced, representing six replicates of 3D7 and 
Dd2 mixtures, with one failure (Table 3.3). The median read depth for detecting DNA variants 
in the lab controls was 2,877 reads (range 2,109 – 6,477). Both 3D7 and Dd2 ama1 DNA 
sequences were identified across all control mixtures with frequencies similar to those 
expected and Table 3.3 shows the frequencies of these sequences in each control replicate.  
Table 3.3. Frequencies of known ama1 DNA sequences in sequencing controls 
Control Set Replicate Lab Isolate         DNA sequence frequency [%] Expected Observed 
Set 1 
Replicate 1 3D7 50 59 Dd2 50 41 
Replicate 2 3D7 50 58 Dd2 50 42 





Dd2 50 44 
Replicate 4 3D7 50 57 Dd2 50 43 
Replicate 5 3D7 50 56 Dd2 50 44 
Replicate 6 3D7 50 Failed Sequencing Dd2 50 
Set 2 
Replicate 1 3D7 75 71 Dd2 25 29 
Replicate 2 3D7 75 72 Dd2 25 28 
Replicate 3 3D7 75 73 Dd2 25 27 
Replicate 4 3D7 75 71 Dd2 25 29 
Replicate 5 3D7 75 71 Dd2 25 29 
Replicate 6 3D7 75 73 Dd2 25 27 
Set 3 
Replicate 1 3D7 85 84 Dd2 15 16 
Replicate 2 3D7 85 82 Dd2 15 18 
Replicate 3 3D7 85 83 Dd2 15 17 
Replicate 4 3D7 85 84 Dd2 15 16 
Replicate 5 3D7 85 85 Dd2 15 15 
Replicate 6 3D7 85 82 Dd2 15 18 
Set 4 
Replicate 1 3D7 95 94 Dd2 5 6 
Replicate 2 3D7 95 96 Dd2 5 4 
Replicate 3 3D7 95 94 Dd2 5 6 
Replicate 4 3D7 95 94 Dd2 5 6 
Replicate 5 3D7 95 95 Dd2 5 5 
Replicate 6 3D7 95 94 Dd2 5 6 
Set 5 
Replicate 1 3D7 100 100 Dd2 0 0 
Replicate 2 3D7 100 100 Dd2 0 0 
Replicate 3 3D7 100 100 Dd2 0 0 
Replicate 4 3D7 100 100 Dd2 0 0 
Replicate 5 3D7 100 100 Dd2 0 0 
Replicate 6 3D7 100 100 Dd2 0 0 
Mixtures of two lab controls (3D7 and Dd2) were prepared by mixing DNA from the two isolates in the 





the frequencies at which each isolate was detected upon sequencing. Sequencing failed for replicate 
6, under Control Set 1. 
 
Table 3.4 shows the comparison between the mean expected DNA sequence frequencies 
versus the observed frequencies. Overall correlation between expected vs. observed 
frequencies was high (Pearson correlation = 0.89 and p-value < 0.001), hence, analysis of field 
samples could proceed. 
Table 3.4. Mean frequencies of known DNA sequences in sequencing controls 
Control Set Lab Isolate               Mean DNA sequence frequency [%] Expected Observed 
Set 1 Dd2 50 57 3D7 50 43 
Set 2 Dd2 25 28 3D7 75 72 
Set 3 Dd2 15 17 3D7 85 83 
Set 4 Dd2 5 5 3D7 95 95 
Set 5 Dd2 0 0 3D7 100 100 
Mixtures of two lab controls (3D7 and Dd2) were prepared by mixing DNA from the two isolates in the 
ratios indicated under the “Expected” column, six replicates per control set. The “Observed” column 
represents the mean frequencies at which each isolate was detected upon sequencing. 
 
3.3.2 PCR amplification and deep-sequencing of samples 
A total of 535 asymptomatic and 114 febrile samples were included in this study. This set 
included 114 asymptomatic samples paired with the participant’s first febrile malaria sample 
(Table 3.5). 
Table 3.5. The number of samples across asymptomatic and febrile infections per year 
Asymptomatics (Cohort) Febrile (Cohort) 
Sampling Year (n) Sampling Year (n) 
        2007 – 55               - 
        2008 – 110               - 
        2009 – 96         2009 – 20 
        2010 – 223         2010 – 39 
        2011 – 27         2011 – 28 
        2012 – 2         2012 – 4 
        2013 – 3         2013 – 4 





        2015 – 4         2015 – 3 
        2016 – 1         2016 – 1 
Age Range Age Range 
        3 months – 14 years         8 months – 13 years 
Parasites/µL (Microscopy) Parasites/µL (Microscopy) 
        Median 128 (range 0 – 600,482)         Median 26,260 (range 2,560 – 550,000) 
Parasites/µL (PCR) Parasites/µL (PCR) 
       Median 503 (range 0.2 – 2,069,633)               - 
Gender Gender 
       Females – 266        Females – 54 
       Males – 271        Males – 60 
Entries marked with “-” under sampling year indicate time-points that were not included in the study, 
while for parasites/µL (PCR), this indicates data was not available. Microscopy negative 
asymptomatic samples were positive by PCR. 
 
177/535 asymptomatic, 98/114 febrile, 30/114 paired asymptomatic-febrile malaria samples 
had good quality data for analysis. The median read depth for detecting DNA variants in 
asymptomatic and febrile malaria samples was 8,941 reads (range 427 – 199,885) and 3,934 
reads (range 810 – 8,032), respectively. For the samples that were successfully sequenced, 
the median age for asymptomatic participants was 6.9 years (range 1-12 years), 7.5 years 
(range 9 months – 13 years) for participants with febrile malaria and 7 years (range 1-11 years) 
for the participants with the paired asymptomatic-febrile malaria samples (Table 3.6). 
Table 3.6. Summary of PCR and sequencing success for 
asymptomatic and febrile malaria samples. 
Asymptomatics 
Year Total Failed PCR Failed Sequencing Successfully Sequenced 
2007 55 29 2 24 
2008 110 49 17 44 
2009 96 51 18 27 
2010 223 140 14 69 
2011 27 16 4 7 
2012 2 0 0 2 
2013 3 2 0 1 
2014 16 10 1 5 
2015 4 3 1 0 
2016 1 1 0 0 
Symptomatics 
2009 20 1 1 18 
2010 39 1 2 36 
2011 28 3 1 24 
2012 4 0 1 3 
2013 4 0 1 3 
2014 15 0 0 15 





2016 1 0 0 1 
Failed PCR represents samples that were unsuccessfully amplified while failed 
sequencing represents samples that were unsuccessfully sequenced. 
 
Table 3.7 shows the summary of the distribution of parasitemia by microscopy and PCR for 
the samples that were successfully sequenced and those that failed. Overall, the geometric 
mean parasitemia per microliter was higher in samples that were successfully sequenced 
compared to those that failed. Moreover, 207/535 (38%) asymptomatic samples that failed 
sequencing were positive by PCR but negative by microscopy. 
Table 3.7. Distribution of parasitemia by microscopy and PCR in the samples included in this study 
Samples Parasite Positive PCR/Sequencing Microscopy and PCR Parasitemia/µl Number of Samples/n Geometric Mean  Range 
Asymptomatics 
Microscopy + PCR Successful 22/177 1,500 40 - 600,482 Failed 153/358 802 40 - 2,200,000 
PCR Only Successful 155/177 916 22 - 23,625 Failed 207/358 35 0.2 - 11,120 
Febrile Microscopy Only Successful 96/122 50,753 2,560 - 1,280,000 Failed 26/122 24,457 2,600 - 510,000 
*PCR data was not available for febrile malaria samples. Under “number of samples/n”, the denominator 177 and 358 
represent samples that were successfully and unsuccessfully sequences, respectively. 
There was a high correlation between number of samples sequenced and variants of DNA 
sequences detected (Pearson correlation = 0.96, p-value <0.0001, Table 3.8). 
Table 3.8. Total ama1 variants detected in asymptomatic and febrile infections over time 
Sampling Year Asymptomatic Infections Febrile Infections Total Samples ama1 variants Total Samples ama1 variants 
2007 24 29 - - 
2008 44 49 - - 
2009 27 34 18 21 
2010 70 59 36 40 
2011 6 7 24 27 
2012 2 4 3 5 
2013 1 1 3 5 
2014 5 7 15 22 
2015 - - 2 4 
2016 - - 1 1 
This table compares the number of samples successfully sequenced per year with the number of ama1 
variants detected. In hyphens “-” are time-points that were not successfully sequenced for 





A total of 43 SNPs were detected in the amplified region of the ama1 gene. In turn, 34 
polymorphic codons were used to generate the list of haplotypes including codons: 162, 167, 
172, 173, 175, 176, 187, 189, 190, 196, 197, 199, 200, 203, 204, 206, 207, 224, 225, 227, 228, 
230, 243, 244, 245, 267, 269, 282, 283, 285, 286, 296, 299 and 300. 23 ama1 variants were 
found to occur in only one sample each, including 13 in asymptomatic and 10 in febrile malaria 
infections, and these were excluded from subsequent analysis. Additionally, 63 samples (43 
asymptomatic and 21 febrile) were found to harbour variants with frequencies <5% (38 
variants in total). However, these variants were found to occur at frequencies ≥5% in other 
samples and were included in subsequent analysis. Consequently, a total of 72 variants (68 
haplotypes) were identified. 68 of these variants (64 haplotypes) were detected in 
asymptomatic samples, 51 variants (47 haplotypes) were detected in febrile malaria samples 
and 48 of these (44 haplotypes) occurred in both asymptomatic and febrile malaria samples 
(Table 3.9).  
Table 3.9 The frequencies of ama1 variants detected (i) across all samples, (ii) within 
asymptomatic and (iii) within febrile infections 
Variant ID Frequency [n] Haplotype Combined Asymptomatic Febrile 
PFAMA1.00 9.9 [77] 13.8 [61] 6.3 [16] KTENDNPMNGRDLKNEYMNNEDKDKEKKSQNDEE 
PFAMA1.01 6.9 [56] 5.3 [33] 11.9 [23] NTENDKLMDQRHFKDKYMINKDKDKEKISQNDEK PFAMA1.68 0.2 [2] 0.3 [2] - 
PFAMA1.02 5.6 [43] 5.8 [29] 7.2 [14] NKGNDELIDDRDFKNEYMNNQYEYKQKISQNDEK 
PFAMA1.03 2.9 [39] 1.8 [16] - NTGNYKLMDDRLLKDEDMNNKYNDKEKKSQNDEE 
PFAMA1.04 7.8 [35] 0.5 [3] - NTGNYELMDERHFKDKYMINKDKDKEKISQNDEK PFAMA1.54 0.6 [3] 1 [3] - 
PFAMA1.05 4.6 [35] 4 [24] 7.1 [11] NTENDNLINGKDFKDEDMNKEYEDNEKKSQNDEK 
PFAMA1.06 2.5 [29] 2.6 [18] 3.1 [11] NTGKDNLINGRDLKNEDMNNKDKNKQKKSQNDEK PFAMA1.37 0.7 [6] 0.7 [4] 1.1 [2] 
PFAMA1.07 3 [28] 3.1 [20] 3.7 [8] KTENDELMDDRRFKDEYMNNKYNDKEKKSQNDEK 
PFAMA1.08 2.7 [28] 4.6 [26] 0.2 [2] NTENDELMDRRDFKNEDMNKEYKDKEKKSQNDEK 
PFAMA1.09 3.2 [26] 4.4 [20] 2.1 [6] NTENDKLMDQRHFKDKYMINKDKDKQIISQNDEK 
PFAMA1.10 2.8 [24] 1.9 [15] 5.3 [9] NTENDKHMDDRLLKDEDMINKDKDKQKKSQDDEK 
PFAMA1.11 2 [20] 2 [13] 2.7 [7] NTENDKLMDQRHFKDEDMINKDKDKEKKLQNHEE 
PFAMA1.12 2 [18] 3 [16] 0.9 [2] KTENDNPMNGRDLKNEYMNNKYNDNEKKSQNDEK 
PFAMA1.13 2.2 [15] 2.9 [13] 1.6 [2] NTGKDNLINGRDLKNEDMNNKYNDKQKKLENDEE 
PFAMA1.14 1.4 [15] 2.1 [13] 0.8 [2] NTENDELMDQRHFKDKYMINKDKDKQIISQNDEK 
PFAMA1.15 1.4 [15] 1.2 [9] 2.3 [6] KTENDNPMNGRDLKNEYMNNKYNDNEKKSQNDEE 
PFAMA1.16 0.8 [14] 1.3 [11] 0.4 [3] KTENDNPMNGRDLKNEYMNNEDKDKEKKSQNDEK 
PFAMA1.17 1.4 [13] 0.6 [7] 3.4 [6] NKGNDNLINGRDFKNEYMNNKYNDKQKKLENDEE 





PFAMA1.19 1.2 [11] 1.4 [8] 1.3 [3] 
PFAMA1.20 1.6 [10] 1.7 [8] 1.9 [2] KTENDELIDQRHLKDEYMNNKYEDKEKKLENDEE 
PFAMA1.21 1 [10] 1.7 [10] - NKGNDELIDDRDFKNEYMNNQYEDKQKKSQNHEK 
PFAMA1.22 0.9 [10] 0.8 [8] 1.4 [2] NTENDELMDRRDFKNEDMNNKDKNKQKKSQNDEE 
PFAMA1.23 0.7 [10] 1.1 [8] 0.1 [2] NTGNYEHMDERHFKDKYMINKYEDKQKKLQNDEE 
PFAMA1.24 1 [9] 1.7 [7] 0.1 [2] NTENYELMDERHFKDKYMINKDKDKEKISQNDEK 
PFAMA1.25 1 [9] 0.6 [5] 1.9 [4] NKGNDELINGRDFKNEYMNKEDKDKEKKSQNDEK 
PFAMA1.26 0.8 [9] 1 [8] 0.8 [1] NTENDNLINGRDLKNEDMNNKDKNKQKKSQNDEK 
PFAMA1.27 1.2 [8] 1.4 [5] 1.3 [3] KTENDKLMDQRHFKDKYIINKDKDKEKISQNDEE 
PFAMA1.28 0.5 [8] 0.8 [6] 0.2 [2] NKGNDNLINGRDFKNEYMNNEDKDKEKKSQNDEK 
PFAMA1.29 0.4 [8] 0.6 [5] 0.2 [3] NKGNDNLINGRDFKNEYMNNKYEDKQKKLQNHEE 
PFAMA1.30 0.9 [7] 0.8 [5] 1.6 [2] KTENDELMDDRRFKDEYMNNKYNDKEKKLENDEE 
PFAMA1.31 0.8 [7] 0.6 [5] 1.4 [2] NTENYELMDERHFKDKYMINKDKDKEKKSQNDEE 
PFAMA1.32 0.8 [7] 1 [4] 0.8 [3] NTENDKLMDERHFKDKYMINKDKDKEKISQNDEK 
PFAMA1.33 0.7 [7] 0.03 [1] 2.1 [6] NTENDKLIDQRDLKNEYMNNEYKDKQKKLENDEK 
PFAMA1.34 0.6 [7] 0.6 [6] 1 [1] KTENDELIDDRDSKDEYMNNEYKDKEKKSQNDEK 
PFAMA1.35 1 [6] 1.7 [5] 0.03 [1] NTGKDNLINGRDLKNEDMNNKDKNKQKKLQNDEE 
PFAMA1.36 0.8 [6] 0.8 [4] 1.1 [2] NKGNDKLIDDRDFKNEYMNKEYKDKEKKSQNHEK 
PFAMA1.38 0.7 [6] 1.1 [6] - NKGNDNLINGRDFKNEYMNNKYNDKQKKLQNHEE 
PFAMA1.39 0.4 [5] 0.7 [5] - NTENDKLMDQRDFKNEYMNNEYKDKQKKLENHEK 
PFAMA1.40 0.4 [5] 0.1 [4] 1 [1] KTENDKLMDDRDLKNEYMNNKYNDNEKKSQNDEK 
PFAMA1.41 0.3 [5] 0.6 [5] - NTGNYEHMDERHFKDKYMINKYEDKQIISQNDEK 
PFAMA1.42 0.3 [5] 0.3 [4] 0.4 [1] NTENDNLINGKDFKDEDMNKEYEDNEKKSQNDEE 
PFAMA1.43 1.1 [4] - - NKGNDNLIDHRDFKNEYMNNKYNDKEKKSQNDEK 
PFAMA1.44 0.9 [4] 1 [3] 1 [1] KTENDELMDDRRFKDEYMNNKYNDNEKKSQNDEK 
PFAMA1.45 0.8 [4] 0.4 [1] 1.7 [3] NTGNYELMNGRDLKNEDMNNKDKNKQKKSQNDEK 
PFAMA1.46 0.7 [4] 0.8 [3] 0.9 [1] NKGNDKLIDDRDFKNEYMNNQYEDKQKKLQNHEK 
PFAMA1.47 0.4 [4] - 1.2 [4] NKGNDELIDDRDFKDEDMNKEYKDKEKKSQNDEK 
PFAMA1.48 0.3 [4] 0.3 [3] 0.5 [1] NKGNDNPMNGRDLKNEYMNNQDKDKEKKSQNDEE 
PFAMA1.49 0.3 [4] 0.5 [4] - NTENDNPMNGRDLKNEYMNNEDKDKEKKSQNDEE 
PFAMA1.50 0.3 [4] 0.5 [4] - NKGNDELIDDRDFKNEYMNNQYEDKQKKLQNDEE 
PFAMA1.51 0.2 [4] 0.4 [4] - NTVNDKLMDDRLLKDEDMINKDKDKEKKLENDEK 
PFAMA1.52 0.1 [4] 0.1 [2] 0.1 [2] KTENDNPMNGRDLKNEYMINKDKDKEKKLENDEE 
PFAMA1.53 0.7 [3] 0.6 [1] 1.2 [2] KTENDNPMNGRDLKNEDMNNKDKNKQKKSQNDEK 
PFAMA1.55 0.4 [3] 0.7 [3] - NTGNYEHMDERHFKDKYMINKYEDKQKKLQNDEK 
PFAMA1.56 0.4 [3] 0.6 [3] - NKGNDELIDQRHFKDEYMNNKYEDKQKKSQNDEK 
PFAMA1.57 0.3 [3] 0.6 [3] - NKGNDELIDDRDFKNEYMNNQYEDKQIISQNDEE 
PFAMA1.58 0.6 [2] 0.6 [1] 1 [1] NTENDNLINGKDFKDEDMNKEYKDKEKKSQNDEK 
PFAMA1.59 0.6 [2] - 2 [2] NTENDNLIDHRDSKNEYMNNQYKDKQKKSQNDEK 
PFAMA1.60 0.5 [2] 0.8 [2] - KTENDKLMDRRHLEDEYMNNEYKDKEKKLENDEK 
PFAMA1.61 0.4 [2] 0.2 [1] 0.9 [1] NTENDKHMDDRVLKDEYMNNEDKDKQKKSQNDEK 
PFAMA1.62 0.4 [2] 0.6 [1] 0.1 [1] NKGNDNLMNGRDFKNEYMNNKYNDKEKKSQNDEK 
PFAMA1.63 0.3 [2] 0.6 [2] - NTENDKLIDQRDLKNEYMNNKYNDKQKKLENDEE 
PFAMA1.64 0.3 [2] - 1 [2] NKGNDNLMNGRDFKNEYMNNKYEDKQKKLQNHEE 
PFAMA1.65 0.3 [2] 0.5 [1] 1 [1] NTENDKLIDQRDLKNEYMNNEYKDKQKKLENHEK 
PFAMA1.66 0.3 [2] 0.6 [2] - NTGKDELIDDRDFKNEYMNNQYEDKQKKSQNHEK 
PFAMA1.67 0.2 [2] 0.4 [2] - NKGNDELIDDRDFKNEYMNNKYEDKQKKLQNHEK 
PFAMA1.69 0.1 [2] 0.01 [1] 0.4 [1] NTGNYKLMDDRLLKDEDMINKDKDKEKKLENDEK 





PFAMA1.7 0.04 [2] 0.1 [2] - NTGKDNLINGKDFKDEDMNKEYEDNEKKSQNDEK 
The variable “combined” represents frequencies across both asymptomatic and febrile infections while 
n represents the number of samples. The entries marked in grey indicate entries where two unique DNA 
variants had synonymous SNPs and collapsed into the same amino acid haplotype. Entries marked with 
“-” represent variants that were not detected in the respective cases. 
 
Of all the samples sequenced, the median read depth in the asymptomatic samples 
sequenced at the KWTRP and IDEEL lab was 28,347 reads (range 895 – 199,885) and 4,947 
reads (range 427 – 29,398), respectively. Of the 177 asymptomatic samples that were 
successfully sequenced, 88 were successfully sequenced at the KWTRP lab while 89 were 
successfully sequenced at the IDEEL lab. Of the 68 ama1 variants detected in the successfully 
sequenced asymptomatic samples, 45 (66.1%) variants overlapped between the two labs, 
while 15 and 8 were detected only at KWTRP and IDEEL labs, respectively. 
Compared to SSA ama1 sequences that span the region that was amplified in this study, 61/68 
haplotypes were found to occur in a dataset of 328 haplotypes from Kilifi (Osier et al. 2010 
and unpublished data), 16/68 haplotypes were found in a dataset of 35 variants from Nigeria 
(Polley and Conway 2001), 22/68 haplotypes were found in a dataset of 122 variants from 
Mali (Takala et al. 2009) and 19/68 haplotypes were found in a dataset of 50 variants from 
The Gambia (Tetteh et al. 2009). The other haplotypes not identified in other regions appear 
to be unique to Kilifi. 
From the combined asymptomatic and febrile malaria infections data, the dominant ama1 
variant (PFAMA1.00) was detected in 77/273 samples with a population frequency of 9.9% in 
the asymptomatic and febrile infections, combined. The least dominant ama1 variant 
(PFAMA1.71) was detected in two individuals and had a population frequency of 0.04% in the 
asymptomatic and febrile infections, combined (Table 3.9). Within asymptomatic samples 
only, the most dominant ama1 variant (PFAMA1.00) was detected in 61/177 individuals with 
a population frequency of 13.8% while the least dominant variant (PFAMA1.69) was detected 
in two individuals with a population frequency of 0.01% (Table 3.9). Within the febrile malaria 





a population frequency of 11.9%, while the least dominant variant (PFAMA1.35) was detected 
in two individuals with a population frequency of 0.03% (Table 3.9).  
The median COI observed in asymptomatic and febrile malaria infections was 3 (range 1-9) 
and 2 (range 1-7), respectively, and there was a significant difference in the COI between the 
two infections (Wilcoxon test, p < 0.0001). Overall, both asymptomatic (72.9% vs. 27.1%) and 
febrile infections (53.1% vs. 46.9%,) had more samples with polyclonal infections compared 
to those with mono-infections (Figure 3.2). 
 
Figure 3.2. The distribution of complexity of infection (COI) between the asymptomatic and febrile 
malaria infections. Below the plot are the numbers 1-9 representing COI while on the right are the 
panel labels representing asymptomatic and febrile malaria samples. Above each bar is the percentage 
frequency of each of the COI in the population and no participant had a COI above 7 under the febrile 
malaria infections. 
 
3.3.3 Temporal changes in ama1 variant frequencies 
Fewer samples were obtained from 2011-2014 for asymptomatics and from 2012-2016 for 
febrile malaria infections, hence, the data from these time-points were combined. In the 
asymptomatic infections, the most prevalent variant in 2007 (PFAMA1.00) was detected 
across all time-points with frequencies ranging between 6-27% and was the most dominant 
in three of the five time-points. No other variant was detected across all time-points, 
however, three variant were detected in four of the five time-points including PFAMA1.02 





PFAMA1.09 (range 4-7%, 2008, 2009, 2010 and 2011-2014) and two variants were detected 
in two of the five time-points including PFAMA1.01 (2008-2010) and PFAMA1.08 (2007, 2008 
and 2010). All other variants were detected in less than three time-points each (Table 3.10). 
In the febrile infections, the most dominant variant in 2007 (PFAMA1.01) was detected across 
all time-points with frequencies ranging between 6-27%, and was only dominant in 2007. Two 
variants were detected in three of the four time-points including PFAMA1.00 (range 5-9%, 
2009, 2010 and 2012-2016), PFAMA1.05 (range 4-13%, 2009, 2010 and 2012-2016), 
PFAMA1.07 (range 3-4%, 2009, 2010 and 2012-2016) and PFAMA1.10 (range 4-10%, 2009, 
2011 and 2012-2016). All other variants were detected in less than three time-points each 
(Table 3.10). 
 
Table 3.10 ama1 variant frequencies in asymptomatic and febrile infections over time 
Variant ID Asymptomatic Infections First-Febrile Infections 2007 2008 2009 2010 2011-2014 2009 2010 2011 2012-2016 
PFAMA1.00 29.25 16.45 11.23 6.54 19.12 5.51 7.29 2.63 9.29 
PFAMA1.01 0.54 4.42 14.87 4.6 1.25 27.06 9.64 6.55 9.77 
PFAMA1.02 3.69 4.54 6.48 8.17 - 18.91 10.85 - 0.06 
PFAMA1.03 1.07 2.18 7.25 0.27 - - - - - 
PFAMA1.04 - - - 1.42 - - - - - 
PFAMA1.05 8.87 3.71 4.89 1.02 9.16 - 8.24 4.32 13.62 
PFAMA1.06 4.79 9.18 - 5.29 - - 0.41 - 0.17 
PFAMA1.07 1.62 4.12 2.69 1.21 6.94 0.32 5.99 4.35 0.05 
PFAMA1.08 0.87 4.2 4.41 4.95 7.14 0.22 1.37 6.93 - 
PFAMA1.09 2.65 0.45 2.7 5.25 2.16 3.68 3.32 3.86 4.17 
PFAMA1.10 4.33 1.08 0.27 1.22 7.14 5.72 2.37 10.95 4.43 
PFAMA1.11 2.29 3.02 2.6 - 7.14 1.9 2.78 1.67 4.05 
PFAMA1.12 - 3.72 2.48 4.32 - - 0.88 - 2.61 
PFAMA1.13 0.65 1.64 - 0.35 - - 3.03 10.05 - 
PFAMA1.14 2.9 1.14 - 1.64 0.04 - 0.12 - 0.83 
PFAMA1.15 - 3.3 5.13 3.24 - - 4.68 - - 
PFAMA1.16 - 1.57 - 1.74 1.61 - 2.59 3.27 2.76 
PFAMA1.17 - - 3.05 1.76 11.55 - 0.17 3.27 - 
PFAMA1.18 - 1.31 8.27 0.94 - - 0.39 - 2.53 
PFAMA1.19 4.35 - 0.12 2.81 - - 2.7 - 3.94 
PFAMA1.20 - 1.14 - 1.38 7.14 - 1.59 - 2.98 
PFAMA1.21 - 0.64 0.6 3.76 - 0.78 - 0.13 - 
PFAMA1.22 - 2.25 - 0.16 - 2.68 2.78 0.18 1.64 
PFAMA1.23 1.84 0.06 - 2.25 - 0.55 0.15 - - 
PFAMA1.24 1.66 2.91 - 0.83 4.66 - - - - 
PFAMA1.25 - 0.69 - 1.49 - - 0.47 4.35 - 
PFAMA1.26 - 0.22 1.75 0.82 - - 0.08 0.42 0.15 
PFAMA1.27 - - - 3.71 - 2.99 0.19 - 2.79 





PFAMA1.29 3.31 0.64 1.87 0.48 - - 2.17 - - 
PFAMA1.30 - - - - 0.57 0.16 0.36 4.42 4.23 
PFAMA1.31 - 1.58 1.14 0.44 - - 0.29 - 0.26 
PFAMA1.32 6.8 0.21 - - 7.14 - - 0.03 - 
PFAMA1.33 - 0.63 2.9 0.09 - 2.99 - 4.09 - 
PFAMA1.34 - 3.88 - - - - - 0.48 2.69 
PFAMA1.35 - 0.3 1.26 1.05 - - - 4.32 0.47 
PFAMA1.36 - 1.08 0.26 1.44 - - 0.07 - - 
PFAMA1.37 - - 0.14 0.81 - 1.97 - 0.03 - 
PFAMA1.38 8.76 - - - - - - - - 
PFAMA1.39 - 1.52 0.36 0.08 - - 2.8 - - 
PFAMA1.40 - 0.13 3.15 0.1 - - - - - 
PFAMA1.41 - - 0.1 0.32 - 0.13 0.37 - - 
PFAMA1.43 - - - 2.61 - 5.56 - - - 
PFAMA1.44 - - - 0.97 - - 1.17 4.3 1.04 
PFAMA1.45 - 1.32 - 0.99 - - - - 4.17 
PFAMA1.46 - - 0.13 1.89 - - 2.55 - - 
PFAMA1.47 - - - 1.43 0.07 - - - 5.15 
PFAMA1.48 - - 0.72 1.59 - - - - - 
PFAMA1.49 - - - - - - 3.3 - - 
PFAMA1.50 0.83 - 0.29 0.35 - - 1.39 - - 
PFAMA1.51 - 2.18 - - - - 0.02 - 0.02 
PFAMA1.52 0.45 - - - - - 2.78 - 4.17 
PFAMA1.53 - 0.28 - 2.34 - - - - - 
PFAMA1.54 - 2.75 - - - - - - - 
PFAMA1.55 0.45 - - 0.12 - - 2.78 - - 
PFAMA1.56 - 0.25 - 1.32 - - 0.21 - - 
PFAMA1.57 - - 3.59 0.07 - - - - - 
PFAMA1.58 4.17 - - - - - - 4.35 - 
PFAMA1.59 - - - 0.66 7.14 - - - - 
PFAMA1.60 - - - 0.53 - - 2.5 - - 
PFAMA1.61 - - - 1.43 - - - - - 
PFAMA1.62 - 0.26 - - - - - - - 
PFAMA1.63 - - - 1.54 - - - - - 
PFAMA1.64 - - - - - 5.86 - - - 
PFAMA1.65 - 2.14 - - - - 0.21 - - 
PFAMA1.66 - 0.04 - - - 5.56 - - - 
PFAMA1.67 - - - - - - 0.03 4.35 - 
PFAMA1.68 - - 2.53 0.08 - - - - - 
PFAMA1.69 - 1.67 - - - - - - - 
PFAMA1.70 - 0.03 - - - 3 - - - 
PFAMA1.71 - 1 - 0.1 - - - - - 
PFAMA1.72 0.92 - - - - - - - - 
PFAMA1.73 - - - - - - 2.78 - - 
PFAMA1.74 - - - 1.43 - - - - - 
PFAMA1.75 - - - - - - - 4.35 - 
PFAMA1.76 - - - - - - - 4.35 - 
PFAMA1.77 - 2.24 - - - - - - - 
PFAMA1.78 - - - - - - - - 4 
PFAMA1.79 - - - - - - - - 3.98 
PFAMA1.80 - - - - - - - - 3.98 
PFAMA1.81 - - 2.79 - - - - - - 





PFAMA1.83 - - - 0.96 - - - - - 
PFAMA1.84 - - - 0.93 - - - - - 
PFAMA1.85 - - - - - - - 2.01 - 
PFAMA1.86 - 0.9 - - - - - - - 
PFAMA1.87 - 0.79 - - - - - - - 
PFAMA1.88 - - - 0.42 - - - - - 
PFAMA1.89 - - - 0.39 - - - - - 
The table shows the frequencies (percentage) of different ama1 variants over time in both asymptomatic and 
febrile infections. Under “Variant ID” are the ama1 variants numbered from 00 to 89. Below both asymptomatic 
and febrile infections are the sampling timepoints and marked with “-” are timepoints where the respective 
ama1 variants were not detected. 
 
3.3.4 Temporal changes in Complexity of Infection 
A comparison of temporal changes in population COI in asymptomatic infections revealed 
that there was a significant drop in median COI from earlier time-points (2007-2010) (median 
COI = 3.5) to 2011-2014 (median COI = 1) (Kruskal-Wallis test p-value = 0.0013). Additionally, 
there was a significant drop in COI between 2009 and 2010 (COI = 3 to 2, Wilcoxon test, p < 
0.001) and 2010 and 2011-2014 (COI = 2 to 1, Wilcoxon test, p < 0.01). As for the febrile 
malaria infections, there was no significant change in median COI over time (Kruskal-Wallis 







Figure 3.3. Temporal changes in median COI in (A) asymptomatic infections and (B) febrile infections. 
A significant temporal drop in COI was observed in asymptomatic infections, however, this drop was 
not observed in febrile malaria infections. 
 
3.3.5 Transition from asymptomatic to first febrile infection 
Of the 30/114 paired asymptomatic-febrile infection samples that were successfully 
sequenced, four febrile infections were as result of an ama1 variant detected in the preceding 
asymptomatic infection. A half of these four infections involved a decrease in COI while the 
other half showed no change in COI and all four cases were from participants >5 years of age 
(Table 3.11). for all the four participants, the likelihood that the persistent variants were 
acquired from a new infectious mosquito bite was low. 
The subsequent febrile malaria episode for Participant 6 contained two DNA sequence 
variants that were persistent. This included PFAMA1.01 that decreased from 95.3% in the 
prior asymptomatic infection to 43.3% and PFAMA1.00 that increased from 0.42 to 3.22% to 
become the second most and least dominant variants, respectively. Participant 07’s 
subsequent febrile malaria episode harboured a persistent PFAMA1.07 that increased in 
frequency from 0.22% in the prior asymptomatic infection to 65.6%. Participant 13’s 
subsequent febrile infection harboured a persistent PFAMA1.14 variant as the least dominant 





finally, participant 46’s subsequent febrile infection harboured two persistent variants 
PFAMA1.01 and PFAMA1.00 that increased from 47% to 64.4% and from 5.5% to 9.8% to 
become the most dominant and least dominant variants, respectively. 
Table 3.11. Transition from asymptomatic to first febrile infection with a persistent clone 





reinfection Asymptomatic Febrile 
PID_06 
No Change in COI  
(4 to 4) 
PFAMA1.01 95.4% 43.3% Persistent 
0.21 
PFAMA1.10 0% 8.9% Novel 
PFAMA1.31 0% 44.5% Novel 
PFAMA1.03 3.7% 0% Cleared 
PFAMA1.41 0.5% 0% Cleared 
PFAMA1.00 0.4% 3.2% Persistent 
PID_07 
Decreased COI  
(3 to 2) 
PFAMA1.06 73.1% 0% Cleared 
0.06 
PFAMA1.03 26.7% 0% Cleared 
PFAMA1.07 0.2% 65.6% Persistent 
PFAMA1.02 0% 34.4% Novel 
PID_13 
Decreased COI  
(6 to 4) 
PFAMA1.21 56.1% 0% Cleared 
0.1 
PFAMA1.18 30.4% 0% Cleared 
PFAMA1.17 6.9% 0% Cleared 
PFAMA1.10 5.1% 0% Cleared 
PFAMA1.14 0.9% 5.8% Persistent 
PFAMA1.02 0.7% 0% Cleared 
PFAMA1.48 0% 49.4% Novel 
PFAMA1.00 0% 34.5% Novel 
PFAMA1.15 0% 10.3% Novel 
PID_46 
No Change in COI  
(3 to 3) 
PFAMA1.05 47.4% 0% Cleared 
0.27 
PFAMA1.00 47.1% 64.4% Persistent 
PFAMA1.01 5.5% 9.9% Persistent 
PFAMA1.53 0% 25.7% Novel 
Under the column “characteristic”, persistent represents a variant that was detected in both the 
asymptomatic and febrile malaria infections, “novel” represents a variant that was detected in the 
febrile malaria infection only, while “cleared” represents a variant that was only detected in the prior 
asymptomatic infection only. The grey cells represent points where the respective variants were not 
detected. The binomial probability of reinfection represents the likelihood that the persistent variant 
was acquired from a subsequent mosquito bite (reinfection). Entries marked with “-” indicate variants 
that were not detected. PID – Participant ID. 
 
 
26 febrile malaria infections were as a result of an ama1 variant that was not detected in the 
asymptomatic infection. Four (15.3%) of the transitions did not show a change in COI and one 
was from a participant of ≤5 years of age, while the others were from participants >5 years of 
age (Table 3.12A). Eleven of the transitions (42.3%) involved a decrease in COI and all the 





an increase in COI with four participants being ≤5 years of age while 7 were >5 years of age 
(Table 3.12C). 
For the four participants that developed a febrile malaria episode with no change in COI, none 
had a COI above three as their COI ranged between 1 and 2. For the eleven participants that 
developed a febrile malaria episode with a decrease in COI, ten participants had 
asymptomatic infections with a COI greater than two (range 3-7) while one participant had a 
COI of two. Ten of these participants then went on to develop a febrile episode with a COI of 
one, while one developed a febrile episode with a COI of two. For the eleven participants that 
developed a febrile malaria episode with an increase in COI, all participants had an 
asymptomatic infection with a COI of two and below. All these eleven participants went on 
to develop a febrile malaria episode with a COI of two and above (range 2-4) 
 
Table 3.12. Transition from asymptomatic to first febrile infection with a novel clone 
A B C 
PID COI Change Variant ID 
Frequency PID COI Change Variant ID 
Frequency PID COI Change Variant ID 
Frequency 




(1 to 1) 




(4 to 2) 




(2 to 4) 
18 99.3% 0% 




(2 to 2) 
6 98.2% 0% 2 4.8% 0% 10 0% 93.6% 
0 1.8% 0% 50 4.0% 0% 33 0% 2.9% 
20 0% 94.7% 1 0% 100% 52 0% 2.3% 




(7 to 1) 




(1 to 1) 




(1 to 2) 
36 100% 0% 




(1 to 1) 
11 100% 0% 3 3.0% 0% 2 0% 11.3% 




(1 to 3) 
27 100% 0% 
      40 0.3% 0% 2 0% 90.2% 
      12 0.3% 0% 6 0% 6.0% 
      1 0% 100% 47 0% 3.9% 




(5 to 1) 




(1 to 4) 
8 100% 0% 
      42 0.5% 0% 30 0% 78.7% 
      0 0.3% 0% 2 0% 9.4% 
      22 0.2% 0% 27 0% 6.9% 
      26 0.2% 0% 6 0% 5.0% 




(1 to 2) 
2 100% 0% 




(3 to 1) 
4 89.0% 0% 20 0% 97.1% 
      3 10.2% 0% 29 0% 2.9% 




(1 to 3) 
63 100% 0% 
      5 0% 100% 47 0% 94.2% 




(3 to 1) 
39 77.8% 0% 52 0% 4.9% 
      34 21.9% 0% 0 0% 0.9% 




(1 to 3) 
35 100% 0% 
      59 0% 100% 10 0% 51.7% 




(5 to 1) 
30 29.8% 0% 11 0% 37.8% 
      27 25.9% 0% 29 0% 10.5% 




(1 to 4) 
0 100% 0% 
      14 15.8% 0% 1 0% 41.4% 
      41 9.9% 0% 17 0% 35.1% 
      17 0% 100% 9 0% 19.7% 





      
Decreased 
COI 
(5 to 1) 




(1 to 3) 
60 100% 0% 
      1 9.9% 0% 15 0% 57.0% 
      25 6.6% 0% 45 0% 21.7% 
      12 5.9% 0% 32 0% 21.3% 




(1 to 2) 
10 100% 0% 




(6 to 1) 
42 49.8% 0% 37 0% 12.2% 
      12 16.8% 0% 11 0% 87.8% 




(1 to 2) 
19 100% 0% 
      0 9.0% 0% 17 0% 98.5% 
      1 8.5% 0% 33 0% 1.5% 
      2 6.3% 0%      
      11 0% 100%      




(3 to 2) 
14 63.4% 0%      
      7 29.4% 0%      
      33 7.2% 0%      
      45 0% 98.8%      
      1 0% 1.2%      




(2 to 1) 
5 82.2% 0%      
      0 17.8% 0%      
      36 0% 100%      




(3 to 1) 
21 65.3% 0%      
      15 22.7% 0%      
      1 12.0% 0%      
      59 0% 100%      
 
The table has been three groups that included participants who developed a febrile episode with (A) no change in COI, 
(B) decrease in COI and (C) increase in COI compared to the prior asymptomatic infection. The grey cells represent 





Median time to infection in individuals who developed a febrile episode with a persistent 
clone versus a febrile episode with a novel clone was 66.5 days and 61.5 days, respectively. A 
statistical test could however not be applied due to the limited power (4 vs 26, respectively).  
For asymptomatic infections, an increase in age was associated with a 3% increase in COI, 
however this was not significant (IRR = 1.03, 95% C.I = 0.99-1.07, p = 0.14), however, a log 
increase in parasitemia was significantly associated with a 4% increase in COI (IRR = 1.04, 95% 
C.I = 1.01-1.07, p = 0.008). For febrile malaria infections, an increase in age was associated 
with a decrease in COI, however this was not significant (IRR = 0.95, 95% C.I = 0.88-1.03, p = 
0.2) and a log increase in parasitemia was associated with an increase in COI but this was also 
not significant (IRR = 1.03, C.I = 0.96-1.11, 0.4). Finally, a unit increase in COI was significantly 
associated with a 4% increase in time to first febrile malaria episode (IRR = 1.04, 95% C.I = 
1.04-1.05, p < 0.001). 
3.4 Discussion 
In this chapter the major findings include the observation that both asymptomatic and febrile 
malaria infections harboured genetically diverse parasites with asymptomatic infections 
having higher COI compared to febrile malaria infections. The prevalence of variants detected 
changed drastically from one year to the next. Thus, some variants were observed once 
throughout the entire sampling timeframe, while others appeared and disappeared, only to 
reappear later and this was consistent even with the rare variants. Both the asymptomatic 
and febrile malaria infections shared ama1 variants, however, the most dominant ama1 
variants in both infections were distinct. Also, a temporal trend in the decrease of COI in 
asymptomatic infections was observed, however, this was not evident for febrile malaria 
infections. Few individuals maintained a persistent clone between asymptomatic and febrile 
infection pairs; hence, a large majority of the febrile infections were associated with the 
introduction of new clones. Remarkably, the median time to infection was longer in the 
individuals who developed a febrile malaria episode with a persistent clone, albeit this finding 
was made in a small sample size. Furthermore, it was not possible to ascertain whether the 





asymptomatic parasitemia at baseline was significantly associated with an increase in COI and 
an increase in asymptomatic COI at baseline was significantly associated with an increase in 
time to first febrile malaria infection. Finally, ama1 has been reported to be one of the most 
polymorphic genes in P. falciparum. This was further shown when a comparing ama1 
haplotypes from the current study with those from other regions and little overlap was 
detected even over just a 459bp region. 
This study is in agreement with previous work that showed that asymptomatic infections 
harbour more diverse parasites compared to febrile malaria infections (Beck et al. 1997; 
Magesa et al. 2002). Previous work has shown that asymptomatic individuals with a high COI 
have a broader spectrum of immunological memory compared to those with lower 
COI (Rono et al. 2013). Whether the presence of multiclonal infections leads to increased 
breadth, or whether breadth facilitates tolerance of multiclonal infections, is difficult to 
resolve. On the other hand, lower COI in febrile malaria episodes could be explained by the 
fact that most fever episodes appear to be associated with parasitaemia peaks (Cox et 
al. 1994) and this may result from the expansion of just a few or even single genotypes. 
Therefore, this could lead to sampling of only a few clones leading to minority clones 
remaining undetectable. 
Regarding temporal changes in variant frequencies, previous studies based on msp1/msp2 
genotyping (Daubersies et al. 1996; Babiker et al. 1998) and SNP genotyping (Nkhoma et al. 
2018), have revealed that asymptomatic infections exhibit a rapid turnover of clones over 
time. Daubersies et al. (1996) sampled individuals at two-week intervals over a period of three 
months and showed that alleles appeared and disappeared through time. Many alleles were 
detected over a period of 2-3 weeks, but some alleles could be detected only for a few days. 
Babiker et al. (1998) sampled individuals every two weeks for two months and subsequently 
once each month for a further 15 months and showed that single genotypes within 
multiclonal infections fluctuated considerably during this period. Finally, Nkhoma et al. (2018) 
sampled individuals over seven consecutive days and showed that even for a shorter time 
frame, the genetic diversity within individuals changed dramatically over the course of follow 





with varying sample sizes, overall, there was a rapid turnover of ama1 variants highlighting 
how heterogenous the parasite population is in asymptomatic infections. Nevertheless, using 
shorter sampling timeframes, future studies should attempt to characterise multiclonal 
infections using amplicon-deep sequencing to reveal the full extent of genetic diversity in such 
infections. 
Concerning the differences in predominant variants in asymptomatic and febrile malaria 
infections, previous studies based on msp1/msp2 genotyping have also reported differences 
in carriage of the different msp1 (K1, MAD20 and RO33) and msp2 (3D7 and FC27) alleles. 
Based on msp1-genotyping some studies have reported that the K1 allele predominates in 
febrile malaria infections (Somé et al. 2018; Sondo et al. 2019) while some have found the 
MAD20 allele do be the most dominant (Chen et al. 2018). Based on msp2-genotyping, 
previous studies have reported that the msp2-3D7 is predominant in asymptomatic infections 
(Bereczky et al. 2007; Färnert et al. 2009) while others have reported that the FC27 allele 
predominates (Sondén et al. 2015). As for febrile malaria infections, certain studies have 
reported that the 3D7 allele predominates (Bereczky et al. 2007; Mohammed et al. 2015; 
Somé et al. 2018; Sondo et al. 2019) while others have reported that the FC27 allele 
predominates (Chen et al. 2018). While the current study could not be compared to previous 
work since it was based on ama1 SNP genotyping, it does show that asymptomatic infections 
tend to be caused by clones that are predominantly distinct from those that are responsible 
for febrile malaria episodes and further work is needed to understand this.  
Previous work has found COI to be a surrogate marker for malaria transmission intensity, 
where multiple clone infections are expected to occur more frequently when transmission 
levels are higher. Using msp1/msp2 genotyping, Bendixen et al. (2001) showed that COI 
decreased from 3.5 to 1.6 when comparing villages in Tanzania in high and low malaria 
transmission intensities. Using high-throughput SNP genotyping, Nkhoma et al. (2013) 
showed that over a 10 year period (2001-2010), reduced malaria transmission was 
accompanied by a significant decrease in the frequency of multi-clonal infections (63% to 
14%) at the Thai-Burma border. Finally, using a 24 SNP barcode, a recent study conducted in 





a period of relatively high malaria transmission and samples collected during a period of 
relatively low malaria transmission, respectively (Bei et al. 2018). In agreement with these 
studies, the current study also showed decreases in COI in tandem with decreasing malaria 
transmission intensity highlighting the utility of using COI data to measure changes in P. 
falciparum transmission. 
Previous studies have reported the introduction of novel variants in febrile episodes following 
an asymptomatic infection, suggesting that the parasites causing a clinical episode are those 
against which an individual has not yet mounted an efficient protective immune response 
(Roper et al. 1998; Ofosu-Okyere et al. 2001; Kun et al. 2002; Buchwald et al. 2018). This is in 
agreement with the current study. Furthermore, previous studies have shown that after an 
asymptomatic infection, subsequent clinical malaria is associated with the same clones in 
regions of low transmission (Roper et al. 1998; Nsobya et al. 2004) and with an increase in 
COI in regions of high transmission (Ofosu-Okyere et al. 2001; Mueller et al. 2012). In contrast, 
no study was identified that showed a decrease in COI during this transition. The current study 
was conducted in a region of moderate to high malaria transmission intensity and in line with 
previous studies, it was expected that the transition from asymptomatic to febrile malaria will 
mainly be associated with an increase in COI. Conversely, patterns of no change in COI, a 
decrease and increase in COI were observed. Malaria transmission in the area under study 
has been shown to be heterogenous (Bejon et al. 2010) and the individuals who showed no 
change in COI in the subsequent febrile malaria infection could be living in homesteads where 
malaria transmission is generally lower compared to the overall malaria transmission 
intensity in the area. Indeed, while these participants were of >5 years of age, they had lower 
COI than their counterparts overall. Likewise, living in homesteads where malaria 
transmission is considerably less may have resulted in these participants acquiring less diverse 
subsequent febrile infections. For the participants that developed subsequent febrile malaria 
infection with an increase in COI, this could have been a result of a super infection after 
repeated bites from infected mosquitoes with genetically distinct parasites. For the 
participants that developed subsequent febrile malaria infection with a decrease in COI, it 





infections before developing a febrile malaria episode or getting an infection from 
mosquitoes with less COI compared to the prior asymptomatic infection. The impact of age 
on the transition from an asymptomatic to febrile infection could not be tested as there was 
an over-representation of samples in the >5 years age group (25 vs. 5). Future studies can 
mitigate this by ensuring that they have a larger sample size across different age groups. 
In previous prospective studies, asymptomatic COI detected at baseline has previously been 
shown to have an impact on the risk of developing febrile malaria. Accordingly, increasing COI 
has been associated with a reduced risk of subsequent febrile episodes (Al-Yaman et al. 1997; 
Färnert et al. 1999; Bereczky et al. 2007; Pinkevych et al. 2014; Sondén et al. 2015). However, 
some studies have reported the inverse, notably in children <5 years of age (Henning et al. 
2004). The current study, showed that increasing COI was associated with an increase in time 
to first febrile episode. However, it is worth noting that the current study was not prospective 
and hence missed out on participants who did not develop a febrile episode and this may 
have biased the findings. Nevertheless, higher COI could be an indicator of increased acquired 
immunity such that younger children (with less effective NAI) are unable to tolerate 
polyclonal infections while older children can tolerate polyclonal infections and develop 
symptoms less frequently. 
Finally, previous studies have reported increases in parasite density to be associated with 
increasing COI (Kateera et al. 2016; Nabet et al. 2016), similar to the current study. One 
hypothesis to explain this is that sampling greater number of parasites increases the 
likelihood of detecting mixed infections. 
This study had several limitations, (i) the sequencing controls enabled the detection of 
variants with >5% frequency only, in each sample. However, if a variant was identified at <5% 
frequency in one sample but at >5% in another sample, this variant was retained as this 
increased the confidence that it may be a “true” variant. It is possible that minor variants 
(<5% frequency) might exist in smaller relative proportions so as to evade immune responses. 
Consequently, it’s worth including multiple sampling timepoints to increase the likelihood of 
capturing minor variants (ii) Many samples had low parasitaemia and this resulted in fewer 





asymptomatic samples were not sequenced; hence future studies should attempt to run 
nested PCR reactions to try and increase the PCR yield for sequencing samples with low 
parasitaemia. Accordingly, an earlier study by Takala et al. (2009) employed nested PCR to 
amplify the ama1 gene in 506 falciparum infections from 100 individuals and identified 214 
unique ama1 variants. While Takala et al. (2009) amplified a larger ama1 fragment (445-
1656bp) that could have resulted in the detection of many more polymorphic loci and hence 
many more variants, it underscores the utility of nested PCR in increasing the PCR yield for 
sequencing. (iii) Sampling was conducted at only one time-point and previous studies have 
shown that a single peripheral blood sample, poorly tracks overall parasite diversity and 
should be considered as only snapshots in time (Daubersies et al. 1996; Babiker et al. 1998; 
Nkhoma et al. 2018). This may have limited the ability to describe the full extent of parasite 
diversity in asymptomatic infections. (iv) Sequencing was conducted in two separate labs and 
this may have introduced batch effects. Additionally, the KWTRP batch had higher sequencing 
depth compared to the IDEEL lab dataset. However, a majority (66.1%) of all the variants 
detected, overlapped between the two labs. For the variants that did not overlap, it is 
expected given the highly polymorphic nature of ama1 and this increases the chances that 
two samples will present with different variants. (v) The current study relied on only one 
polymorphic marker, ama1, and a recent study demonstrated that the inclusion of several 
markers can help to compare diversity from multiple targets (Lerch et al. 2017). Future studies 
should aim to include more targets to reliably describe and compare parasite diversity, 
however, the use of only one highly polymorphic is appealing as including many markers 
might be resource intensive for use as a surveillance tool. (vi) In this region of moderate to 
high transmission, it is likely that some persistent variants were acquired from new mosquito 
infections and hence falsely classified. However, we found the probability of reinfection to be 
low. That said, there is still a chance that some of the persistent variants may have been 
acquired from new infections since the median time to reporting a first febrile episode was 
more than 30 days, and this would have coincided with the peaking of the malaria 
transmission season. (vii) Lastly, half the sequence reads were discarded during the analysis 





tags and it is possible that a huge proportion of primers were unsuccessfully tagged, hence, 
any amplicons that were generated from these untagged primers would be discarded during 
sequence analysis. To avoid losing sequence data, future studies should try to quantify how 
much of their primers are actually tagged for example by sequencing the primer pool 
Taken together, the current study found that asymptomatic infections harbour more diverse 
parasite populations compared to febrile malaria infections. Additionally, higher COI in 
asymptomatic infections predict the risk of subsequent febrile malaria episodes, suggesting 
that host immunity plays a prominent role in mediating this process. This finding is particularly 
interesting as it adds to the literature already showing that host immunity impacts on the risk 
of developing febrile malaria episodes. Consequently, the identification of the correlates of 
immunity will inform the development of a malaria vaccine that will aid in malaria elimination 
efforts.   
107 
 
Chapter 4 : Surveillance of P. falciparum drug-resistance markers over two decades of 
changing anti-malarial policies 
4.1 Introduction 
In addition to chronic asymptomatic infections, drug-resistance presents another obstacle to 
malaria elimination and this chapter focussed on carrying out surveillance of antimalarial 
drug-resistance in Kilifi, Kenya. The availability of longitudinal samples collected from the Kilifi 
County hospital from 1995-2016 prompted this study into carrying out a surveillance of 
antimalarial drug-resistance markers. Within this period, antimalarial drug policies in Kenya 
changed from using CQ, followed by SP and later to the introduction of ACTs due to 
widespread resistance to CQ and SP. Such data are important for assessing the efficacy of 
antimalarial drugs and can help to detect early signs of the emergence of drug-resistance. 
There exist three main methods for assessing antimalarial drug-resistance and these include 
therapeutic efficacy studies (TES), in vitro and ex vivo phenotypic assays and finally the use of 
molecular markers of drug-resistance. TES is the gold standard used to guide treatment policy 
in malaria-endemic countries and these involve the prescription of the required doses of anti-
malarial drugs to patients with Plasmodium parasites, presenting with uncomplicated 
malaria. The patients are then followed up by parasitological and clinical assessments from 
28 to 63 days, depending upon the half-life of the medicine assessed, after which the 
treatment outcome is determined as successful or not (WHO 2009). In instances of clinical or 
parasitological failure, molecular genotyping is recommended to distinguish recrudescence 
from re-infection, using three highly polymorphic genes (msp1, msp2 and glurp) and the 
results from genotyping are routinely detected by agarose gel electrophoresis. Depending on 
the quality of the gel and technical expertise, there can be variation in the interpretation of 
gel electrophoresis leading to inaccurate estimates, especially in areas of high transmission 
intensity due to the high number of complex infections (Mugittu et al. 2006; Greenhouse et 
al. 2007). 
In vitro and ex vivo phenotypic assays test for anti‑malarial susceptibility in parasites and can 
be performed on parasites collected from patients (ex vivo) or with culture-adapted parasites 
(in vitro). Parasites are cultured in the presence of anti-malarial drugs at varying 
concentrations to determine the growth inhibitory effect of a drug, or by exposing them to a 





2013). Parasite growth is then measured using various techniques, including microscopy, 
enzyme-linked immunosorbent assays (ELISA), SYBR green fluorescence and flow cytometry. 
These results are then used to determine either the concentration that inhibits parasite 
growth by 50% (50% inhibitory concentration - IC50) (Woodrow et al. 2013) or the parasites‘ 
survival rate (Witkowski et al. 2013). The major drawback with using in vitro and ex vivo assays 
is that only a limited number of laboratories in malaria-endemic countries have access to the 
sophisticated equipment, extensive resources, training and expertise required.  
The use of molecular markers of drug resistance involves the detection of genetic 
polymorphisms associated with anti‑malarial drug resistance. This was made possible through 
the association of antimalarial drug-resistance with single nucleotide polymorphisms (SNPs) 
and amplification of genes coding for drug target proteins or transporters. Consequently, 
these have allowed for a better understanding of the emergence and spread of antimalarial 
drug resistance (Picot et al. 2009). This technique involves DNA extraction, followed by the 
amplification of the genes or loci of interest using PCR and later sequencing to detect SNPs or 
amplifications. Molecular markers have several advantages including the possibility of 
studying many isolates within a short time for example with DNA from dried blood spots (DBS) 
that are easy to collect, transport and store. Also, sample pooling strategies, advances in PCR 
and DNA sequencing technologies have improved the scalability of genotyping resistance 
markers (Taylor et al. 2013). 
The emergence of artemisinin and partner drug-resistant P. falciparum in Cambodia and its 
spread to neighbouring countries in SE Asia has added on to the growing evidence regarding 
the utility of assessing molecular markers of resistance (Hamilton et al. 2019). Consequently, 
regions outside SE Asia are encouraged to continue surveillance of drug-resistance markers 
to enable the early detection of ACT drug-resistance. One of the ways that have been 
employed to track drug-resistance markers is through genetic epidemiology of drug-
resistance markers over space and time. In turn, this enables the evaluation of the pattern of 
evolution of genes conferring resistance to antimalarials to detect parasite adaptation due to 
changing antimalarial drug policy. In Kenya, the genetic epidemiology of crt, mdr1, dhfr 





since the withdrawal of CQ and SP as first-line antimalarial treatments, chloroquine resistance 
(CQR) markers have reduced in frequency in the population while those of SP resistance have 
remained high (Okombo et al. 2014; Achieng et al. 2015). This can also be replicated to assess 
whether similar signatures have occurred with artemisinin resistance markers in Kilifi, in 
response to the adoption of ACTs as first-line antimalarial drugs in Kenya since 2004. 
crt, mdr1 and dhfr have well described selection patterns in response to the withdrawal of 
CQ and SP. Notably, there is good evidence of selection by ACT use in Kenya towards a 
predominance of wild-type alleles in crt and mdr1 and towards the fixation of the mutant dhfr 
alleles in a previous study conducted in Kilifi (Okombo et al. 2014). Additionally, evidence of 
ACT selection upon the ap2-mu and ubp-1 locus was found in a study conducted in Western 
Kenya (Henriques et al. 2014) and this has been strengthened by recent in vitro studies of 
CRISPR-Cas9-generated variants of ap2-mu and ubp-1, which both elicit significantly reduced 
artemisinin susceptibility in vitro (Henrici, van Schalkwyk and Sutherland 2019). Likewise, in 
vitro studies using a P. falciparum clone with a SSA genetic background reported selection in 
the falcipain-2a gene after artemisinin selection pressure (Ariey et al. 2014). More recently, 
a study conducted in The Gambia also reported selection in a novel marker, nfs, associated 
with lumefantrine tolerance that requires confirmation in other geographical settings 
(Amambua-Ngwa et al. 2018). Therefore, the aim of this study was to use the introduction of 
ACT as the pivotal point to test for evidence of selection in novel antimalarial drug resistance 
markers (ap2-mu, falcipain-2a, k13, nfs and ubp-1) as well as artemisinin resistance 
predisposing mutations (arps10 codon V127M, crt codon I356T, fd codon D193Y and mdr2 
codon T484I), whose impact are not yet fully understood. 
4.2 Methods 
4.2.1 Study Design 
Parasite DNA was extracted from frozen blood samples obtained from patients presenting to 
Kilifi County Hospital with uncomplicated malaria (1 month – 15 years of age) in 1995/1996, 
1999/2000, 2006/2007 and 2012/2013 from a previous study (Okombo et al. 2014) and 





samples were collected for each time-point and the samples span 24 years of changing drug 
policy, except for 2017/18 in which 109 samples were used (Figure 4.1).  
 
Figure 4.1. Schematic showing the time-points from which parasite populations were 
genotyped. Also indicated are historical highlights of antimalarial drug-resistance. 
 
4.2.2 DNA extraction and PCR amplification 
P. falciparum genomic DNA was extracted from frozen blood using the Qiagen DNA Blood 
Mini Kit (Qiagen, UK) as per the manufacturer’s instructions (see section 3.2.2). Amplicons 
were generated from the following genes using primers from previous studies and primers 
designed in this study (Table 4.1): crt (PF3D7_0709000), mdr1 (PF3D7_0523000), dhps 
(PF3D7_0810800), nfs (PF3D7_0727200), k13 (PF3D7_1347700), ap2mu (PF3D7_1218300), 
falcipain-2a (PF3D7_1347700), ubp-1 (PF3D7_0104300) and serine-tRNA ligase, putative 
(PF3D7_0717700). Additionally, four artemisinin resistance predisposing mutations; arps10 
(PF3D7_1460900), crt (PF3D7_0709000), fd (PF3D7_1318100) and mdr2 (PF3D7_1447900) 
were genotyped. For PCR, the Expand™ High Fidelity PCR System, 0.5µl of template DNA, 
primers and the conditions indicated in Table 4.1 were used. The final reaction volume was 
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RedSafe™ Nucleic Acid Staining Solution (iNtRON Biotechnology DR). PCR negative samples 
were taken through a second and final round of PCR with 0.75µl of template DNA.  
Table 4.1. List of primers for PCR and sequencing 
Gene Primer ID Primer Sequence in ‘5-3’ Orientation PCR Annealing Temperature Reference 
ap2-mu 
(full length)  
ap2mu-1F* GTT AAC ACG ATT AGC GTC ATT TG 
54°C for 2 min Henriques et al., (2014) 
ap2mu-2R GTC CTA TTA TGT ATA TGT GGA TC 
ap2mu-3F GAT ATC CAC AAA CAT TAG AAG TG 
ap2mu-4R CCA TCT GGT GGT GTG AAG G 
ap2mu-5F GCA TAT TTC ATC ATT GTG TTA CC 
ap2mu-6R* ACA CCC GAT TGA ACT ATT TAT AC 
crt 
(codon 72-76) 
F* GGT GGA GGT TCT TGTCTT GG 
52°C for 30 sec Okombo et al., (2014) 
R* ATA AAG TTG TGA GTT TCG GAT G 
dhps 
(codons A437G and 
K540E and A581G) 
F* CCT AAA CGT GCT GTT CAA AGA ATG 
58°C for 30 sec Designed in this study 
R* CAT CCA ATT GTG TGA TTT GTC CAC 
falcipain-2a 
(full length) 
fp2F* TGT AGC AAG AAC GTT TTG TGT AAA T 
56°C for 2 min Conrad et al., (2014) 
fp2NF TGT GTA AAT TAA AGA TAA AAG TGC AAA 
fp2R* GGT AAA GGA AAA ATT AGT AAG GAT GC 
fp2intR GCA TAT TGT GAT TCT ACG GAA CC 
fp2intF AAA AAG CCC TAA TGG CAA GAA 
fp2NR GGT CCC TTT TTA AAA TAC TAT TGA CA 
k13 
(full length) 
k13-F* ATG GAA GGA GAA AAA GTA AAA AC 
56°C for 30 sec Designed in this study 
k13-F2* GCA GCA AAT CTT ATA AAT GAT G 
k13-F3 GAA GCC TTG TTG AAA GAA GC 
k13-F4 CAT AGG AAA CGA TTT GATG 
k13-F1 CAA AAG CAA ATA GTA TCT CG 
k13-R CTC TTT TTT GTT GGT ATT CAT AAT TG 
k13-R1* CAC TAG CAT CAC TTA ATT CCG 
k13-R2 CAC ATA CGC CAG CAT TG 
k13-R3* CGG AGT GAC CAA ATC TGG 
k13-R4 CAT AGG AAA CGA TTT GAT G 
arps10 
(codon V127M) 
arps-F* CAC AAT ATT ATG TTT CAT TTT AG 
55°C for 30 sec 
Designed in this study 





GAT TAT CGA CAA ATT TTC TAC 
CTT TTT AAT TCT TAC GGC TAA G 
55°C for 30 sec 
fd 
(codon D193Y) 
fd-F* GAT GCT AGT GAA AGA CAG AAT G 
55°C for 30 sec 
fd-R* CAC ATA TTT TTG ATT GAG GAC 
mdr2 
(codon T484T) 
mdr2r-F* GAG GTT TGT GGT GTA TTA TTT TC 
55°C for 30 sec 
mdr2r-R* GTT AAA CCT ATA AAT AAT ACA C 
mdr1 
(codons N86Y, Y184F 
and D1246Y) 
mdr1_86/184_F* TCC CAT TAA AGC CTC TTC TA  
51°C for 30 sec Okombo et al., (2014) 
mdr1_86/184_R* ATG GGT AAA GAG CAG AAA G 
mdr1_1246_F* ATT GAT GTA AGA GAT GAT GGT 
mdr1_1246_R* TAT TCC ATC TTG TGC TGA TAA 
nfs 
F1* CTT CAA TTT TGT AAT GAA ATT TCT TC 
51°C for 30 sec Designed in this study 
R1* CAT ATT ATG TCC ATA TAA ACT TTG GA 
F2 ATG CAC GAA CAA ATC TTT TGA 
R2 AGA TTT GTT CGT GCA TCC TCC GA 





R* CCG TTT TAC CTG AAC TGT TCA GG 
serine-tRNA ligase, 
putative 
RNAligase_F1* ATG GTT TTA GAT ATA AAT TTA TTT CG 
55°C for 30 sec Designed in this study 
RNAligase_F2 AGA AAA TAG GTG GAG CTA 
RNAligase_F3 ATG ATA CAA ACA TGT GAA GA 
RNAligase_R1 TCT TGT TCA CTC CAT AAA GGG A 
RNAligase_R2* GTA ATA AGA AAC CTG CAC CTG 
All primers were used for Sanger sequencing while those marked with * were used for both PCR and sequencing. The Taq 
polymerase used in this study (Expand™ High Fidelity PCR system) has two rounds of PCR including a first-round that was set at 
10 cycles and the second set at 25 cycles. The following conditions were used including the annealing temperatures indicated 
above: denaturation (94°C – 15 sec), annealing (gene-specific), extension (72°C – 2 min), and final extension (72°C – 7 min). 
 
4.2.3 Sanger (chain-termination) sequencing 
Positive PCR products were purified using ExoSAP-IT® (Thermo Fisher Scientific) and directly 
sequenced using the primers indicated in Table 4.1 and the BigDye Terminator v3.1 Cycle 
Sequencing Kit v3.1 (Applied Biosystems, UK). Following PCR amplification, positive PCR 
products were purified using ExoSAP-IT™ Express (Thermo Fisher Scientific). This involved 
adding 1µl of ExoSAP-IT™ Express reagent into 5µl of the PCR product. This mixture was then 
incubated in a thermal cycler at 37°C for 4 min to degrade excess primers as well as 
nucleotides and another incubation at 80°C for 1 minute (min) to inactivate the ExoSAP-IT™ 
Express reagent. The PCR products were taken through a chain-termination reaction, as 
detailed below to sequence the DNA fragments. 
The chain termination reaction was conducted using the BIG DYE terminator chemistry v3.1 
kit (Applied Biosystems, UK) according to the manufacturer’s instructions. Sequencing was 
done at the International Livestock Research Institute (ILRI, Kenya) using an ABI 3730xl 
capillary sequencer (Applied Biosystems, UK). Briefly, the PCR product was combined in a tube 
with a primer, DNA polymerase, deoxynucleotide triphosphates (dNTPs) and four 
fluorescently-labelled chain-terminating di-deoxynucleotide triphosphates (ddNTPs). ddNTPs 
are dNTPs that lack a 3'-hydroxyl group and this restricts the further extension of a copied 
DNA chain. The mixture was then transferred to a thermal cycler and incubated using the 
following conditions: initial denaturation (96°C - 1 min), followed by 25 cycles of denaturation 
(96°C - 10 sec), annealing (50°C - 5 sec) and extension (60°C - 75 sec).  
During the denaturation stage, double-stranded templates are separated into single-stranded 





stage, the DNA polymerase incorporates dNTPs into growing chains of newly created DNA 
fragments that are complementary to the single-stranded template DNA. These extension 
products begin at the end of the primer and extend in the 3’ direction and chain termination 
occurs during this extension step due to the incorporation of ddNTPs. Essentially, when a 
dNTP is incorporated, the new DNA fragment will continue to grow but when a ddNTP is 
incorporated, further chain elongation is blocked and this results in a population of truncated 
products of varying lengths. Finally, the double-stranded DNA fragments are denatured into 
ssDNA by adding 10µl of Hi-Di™ Formamide and incubating the mixture in thermal Cycler for 
5 min. 
The amplified and labelled DNA fragments are then electrophoresed to enable the separation 
of the labelled fragments and their visualization. This involves the loading of these 
fluorescently-labelled DNA fragments onto the ABI 3730xl capillary sequencer and during 
electrophoresis, the DNA fragments migrate through a polyacrylamide gel and are separated 
based on their size. Towards the end of the gel, the fluorescent dyes attached to the DNA 
fragments are excited by a laser and they emit light at a wavelength specific for each dye. This 
emitted light is separated according to wavelength by a spectrograph so that all four 
fluorescent emissions can be detected by one laser pass. The data collection software collects 
these light intensities at different wavelength bands and stores them onto the sequencer’s 
computer as digital signals for processing. The analysis software then interprets the 
fluorescent intensity at each data point and assigns its base call interpretations and the data 
is finally output as chromatograms which contain the full sequence of the starting DNA 
fragment. These chromatograms are then analyzed using software for genomic sequence 
analysis. 
4.2.4 Sequence analysis 
Sequence assembly was performed in CLC Main Workbench v7.9.1 (Qiagen, UK) and SNPs 
were identified and called based on the respective 3D7 reference sequences. Nucleotide 
positions which displayed a peak within a peak in the sequence chromatograms were noted 
as ‘‘mixed’’. Consensus sequences were extracted from the sequence assemblies using CLC 





Omega v1.2.1 (Sievers and Higgins 2014). SNP frequencies were calculated per gene per time-
point and singletons were confirmed by an additional round of PCR and sequencing. 
4.2.5 Statistical analysis 
Nucleotide sequences were translated into amino acid sequences in Aliview v1.26 (Larsson 
2014). Haplotypes were then generated based on the amino acid residues from all the 
polymorphic codons that cut across all sequences and time points after excluding sequences 
with mixed bases. The difference in the prevalence of alleles and haplotypes in pre-ACT and 
post-ACT periods was evaluated using the Chi-squared test. For this analysis, 2005/06 was 
used as the point to divide the data into the pre- and post-ACT periods. Since complete ACT 
coverage is not expected following its formal introduction in 2004, data for 2005/06 was 
excluded from this part of the analysis. Chi-squared test for haplotypes was performed for 
only the sequences that had data across all loci at any time point. Additionally, the Chi-
squared test for haplotypes was conducted only for the two dominant haplotypes. Linkage 
disequilibrium (LD) analysis was conducted in DnaSP v6.12.01 (Rozas et al. 2017) and reported 
based on the D’ parameter that ranges between -1 and +1. Positive D’ values imply that two 
alleles occur together on the same haplotype more often than expected, while negative 
values imply that alleles occur together on the same haplotype less often than expected 
(Lewontin 1964). All plots were generated using ggplot2 v3.1.1 (Wickham 2016) and ggpubr 
v0.2 packages (Kassambara 2020) in R v3.6.0 (R Core Team, 2014). Ka/Ks ratio was calculated 
for k13 by dividing the number of nonsynonymous substitutions per non-synonymous site 
(Ka) by the number of synonymous substitutions per synonymous site over time. 
4.3 Results 
4.3.1 Genetic markers associated with artemisinin resistance 
The k13 codon K189T, was the only polymorphism maintained at frequencies (>10%, Table 
4.2) and the dominant allele K189 was maintained at frequencies above 75% throughout the 







Figure 4.2. k13 codon K189T frequencies over time. The two alleles appear to have stable 
frequencies from 1995/96 to 2005/06 but the frequency of K189 declines slightly to 
2012/13 while the frequency of 189T increases slightly during the same period. After 
2012/13, the frequencies of both alleles return to the frequencies observed in 1995/96. 
In grey are the 95% confidence intervals. 
 
Other than K189T, the only other polymorphism observed across all time points is the 
asparagine (Asn) repeat at codon 137. This repeat region included insertions of between one 
and four asparagine residues, though at low frequencies <3% compared to SE Asia (>60%) 
(Wang et al. 2015b; Putaporntip et al. 2016). The rest of the observed k13 alleles were rare 
including codon A578S, with frequencies barely reaching 2%. Many of the polymorphic 
codons occurred in the N-terminal region compared to the C-terminal region and from 
1995/96 to 2015/16, the Ka/Ks ratio for the whole k13 gene ranged from 2.25 to 5. 
Conversely, the Ka/Ks ratio for the N-terminal region ranged from 2 to 9, while for the C-
terminal region the Ka/Ks ratio was 1 throughout the same time period except for 2012/13 
when there were no polymorphisms in the C-terminal region. The observations in the N-
terminal region are comparable to those from other African studies, whereas fewer 
mutations were identified in SE Asian parasites (MalariaGEN Plasmodium falciparum 
Community Project 2016). Comparisons with the MalariaGEN dataset (MalariaGEN 





Madamet et al. 2014; Boussaroque et al. 2016), revealed 9 loci that were unique to the Kilifi 
population and primarily occurred at only one time point over the 24 year study period. 
Codon K189T had similar frequencies to parasites examined in East Africa 13% and West 
Africa 50%, however the frequencies were much lower in SE Asia (<0.005%) (MalariaGEN 
Plasmodium falciparum Community Project 2016). Additionally, none of the k13 mutations 
associated with resistance in SE Asia were identified and no SNPs were found to be in LD 
(Table 4.2).  
Table 4.2. k13 SNP frequencies 
Codon Nucleotide Codon [Nucleotide] Mutant Frequency % [n] Wildtype Mutant 1995/96 1998/99 2005/06 2012/13 2015/16 
38 112 S [A] C [T] 0 [132] 0 [117] 0 [133] 0 [114] 0.7 [135] 
96 287 P [C] Q [A] 0 [132] 0.7 [126] 0 [133] 0 [114] 0 [137] 
108 322 K [A] E [G] 0 [95] 0.7 [126] 0.7 [133] 0 [114] 0 [137] 
119a 355 L [T] L [C] 0.7 [132] 0 [126] 0.7 [133] 0 [114] 0 [136] 
126a 377 T [C] N [A] 0.7 [132] 0.7 [126] 0 [133] 0 [114] 0 [136] 
134 401 I [T] S [G] 0 [126] 0.7 [126] 0 [133] 0 [114] 0 [135] 
136 406 H [C] N [A] 0.7 [126] 0 [126] 0.7 [133] 1 [115] 0 [135] 
137a,b 409 Nx6 [6xAAT] Nx7 [7xAAT] 2 [124] 1 [126] 3 [133] 3 [115] 0.7 [134] 
   Nx8 [8xAAT] 3 [124] 1 [126] 0 [133] 1 [115] 1 [134] 
   Nx9 [9xTAA] 0 [124] 0 [126] 0 [133] 1 [115] 0 [134] 
   Nx10 [10xTAA] 0 [124] 0 [126] 0 [133] 1 [115] 0 [134] 
148 443 I [T] T [C] 0 [122] 0 [104] 0.7 [133] 0 [114] 0 [133] 
149a 445 T [A] S [T] 0 [122] 0.7 [127] 0 [133] 0 [114] 1 [133] 
157a 469 M [A] V [G] 0 [122] 0.7 [127] 0 [133] 0 [114] 0 [132] 
174 520 A [G] S [T] 0 [95] 0 [125] 0 [133] 0.8 [115] 0 [83] 
178a 532 I [A] L [T] 1 [86] 0 [126] 0 [128] 0 [108] 0 [68] 
182a 544 S [T] T [A] 0 [95] 3 [125] 1 [132] 0 [117] 0 [87] 
189a 566 K [A] T [C] 8 [82] 15 [126] 10.6 [132] 15 [115] 13 [71] 
 567 K [A] T [T] 0 [79] 0 [124] 0.7 [132] 0.8 [115] 0 [71] 
192b 574 T [A] A [G] 0 [72] 0 [125] 0.7 [131] 0 [104] 0 [74] 
258a 772 L [T] M [A] 1 [91] 1 [100] 0 [105] 0 [79] 0.8 [116] 
271a 813 Q [G] H [T] 0 [93] 0 [69] 0.9 [107] 0 [81] 0 [121] 
354 1060 I [A] V [G] 0.7 [132] 0 [136] 0 [126] 0 [103] 0 [138] 
417a 1251 P [C] P [T] 0.7 [135] 0 [140] 0.7 [126] 0 [105] 0 [129] 
469a 1407 C [C] C [T] 0 [138] 0 [139] 2 [126] 0 [102] 0 [139] 
487 1461 V [A] V [T] 0 [139] 0.7 [127] 0 [130] 0 [105] 0 [142] 
578a,b 1732 A [G] S [T] 1 [137] 0.7 [127] 0.7 [127] 0 [117] 0.7 [142] 
 1733 A [C] S [T] 0.7 [137] 0 [131] 0 [127] 0 [117] 0 [142] 
589a 1767 V [C] V [T] 0 [136] 0 [123] 0 [127] 0 [117] 0.7 [139] 
The number of samples successfully genotyped per timepoint include: 148 in 1995/96, 146 in 1998/99, 146 in 2005/06, 
132 in 2012/13 and 148 in 2015/16. No sequences with mixed bases were identified. Frequency is presented as the 





Polymorphisms in codons 30 to 417 fall in the N-terminal region while those from 469 to 589 fall in the C-terminal 
region. In grey are zero frequencies and marked with a and b are N-terminal SNPs that have been identified in parasites 
from Africa and SE Asia, respectively. The rest of the SNPs appear to be unique to the Kilifi parasite population. 
 
Of the 13 haplotypes, the 3D7 haplotype (PK[N6]MAISKLQ) was dominant over the entire 
sampling period with frequencies >70%. The second dominant haplotype (PK[N6]MAISTLQ), 
showed stable frequencies from 1995/96 to 2005/06 (8.8%-9.8%), however it roughly 
doubled to 19.6% in 2012/13 and then dropped back to 8.8% in 2015/16 (Table 4.3). 
Table 4.3. k13 haplotype frequencies 
Haplotype Frequency % [n] 1995/96 1998/99 2005/06 2012/13 2015/16 
PK[N6]MAISKLQ* 76.4 [34] 75 [56] 82.9 [94] 71.4 [56] 88.2 [34] 
PK[N6]MAISTLQ 8.8 [34] 12.5 [56] 9.5 [94] 19.6 [56] 8.8 [34] 
PK[N7]MAISKLQ 5.8 [34] 1.7 [56] 2.1 [94] 3.5 [56] 2.9 [34] 
PK[N6]MAISKMQ 2.9 [34] 1.7 [56] 0 [94] 0 [56] 0 [34] 
PK[N6]MALSKLQ 2.9 [34] 0 [56] 0 [94] 0 [56] 0 [34] 
PK[N8]MAISKLQ 2.9 [34] 0 [56] 0 [94] 3.5 [56] 0 [34] 
PK[N6]MAITKLQ 0 [34] 5.3 [56] 2.1 [94] 0 [56] 0 [34] 
PK[N6]VAISKLQ 0 [34] 1.7 [56] 0 [94] 0 [56] 0 [34] 
QK[N6]MAISKLQ 0 [34] 1.7 [56] 0 [94] 0 [56] 0 [34] 
PE[N6]MAISKLQ 0 [34] 0 [56] 1.0 [94] 0 [56] 0 [34] 
PK[N6]MAISNLQ 0 [34] 0 [56] 1.0 [94] 0 [56] 0 [34] 
PK[N6]MAISTLH 0 [34] 0 [56] 1.0 [94] 0 [56] 0 [34] 
PK[N6]MSISKLQ 0 [34] 0 [56] 0 [94] 1.7 [56] 0 [34] 
The following were used to define haplotypes: 10 polymorphic sites, including codons 96, 108, 137, 
157, 174, 178, 182, 189, 258 and 271. The haplotypes marked with an * indicate the 3D7 haplotype. 
Frequency is presented as the percentage of sequences that contributed to the haplotype out of the 
total number of sequences [n]. In grey are zero SNP frequencies. 
 
4.3.2 Other putative genetic markers associated with artemisinin resistance 
There were no mutations identified in arps10, crt and fd. However, a high frequency (>10%) 
SNP (I492V) was identified in mdr2 in the 1995/96 and 2015/16 time points and hence the 
three middle time points were included. Consequently, two additional polymorphisms were 
identified (I495V – 0.9% in 1998/99 and V506I – 0.7% in 2005/06) with the I492V 





Table 4.4. mdr2 SNP frequencies 
Codon Nucleotide Codon [Nucleotide] Mutant Frequency % [n] Wildtype Mutant 1995/96 1998/99 2005/06 2012/13 2015/16 
492 1474 I [A] V [G] 30.5 [131] 21 [108] 13 [132] 14 [116] 23 [130] 
495 1483 I [A] V [G] 0 [131] 0.9 [108] 0 [139] 0 [116] 0 [130] 
506 1516 V [G] I [A] 0 [129] 0 [107] 0.71 [136] 0 [115] 0 [130] 
Supplementary Table 2. Mdr2 SNP frequencies. The number of samples successfully genotyped per timepoint 
include: 131 in 1995/96, 117 in 1998/99, 134 in 2005/06, 145 in 2012/13 and 130 in 2015/16. No sequences 
with mixed bases were identified. Frequency is presented as the percentage of sequences that carried a 




In ap2-mu, the following polymorphisms were observed across all time points, I100I, S160N, 
E163E, repeat-[7N]227[6N/8N/9N/10N], repeat-[5N]320[6N/7N], S476S and V478V. In 
addition, 2 other repeat blocks were identified, [K]234[2K], and [4N]327[5N/6N]. All the 
repeat blocks had stable frequencies over time except [K]234[2K], that was at a low frequency 
of (~2%), however it was not detected in 2005/06, was later detected in 2012/13 at 10.7% 
and later dropped to 1.8% in 2015/16. No significant temporal trends were observed and only 
two polymorphisms achieved frequencies >10% across time, I100I and 
[7N]227[6N/8N/9N/10N]. Over the same period, the synonymous mutation E163E showed 
similar increases and decreases in frequency from 8.51% in 2006/06 to 16.36% in 2012/13 
and down to 4.55% in 2015/16) (Table 4.5).  
Table 4.5. ap2-mu SNP frequencies 
Codon Nucleotide     Codon [Nucleotide] Mutant Frequency % [n] Wildtype Mutant 1995/96 1998/99 2005/06 2012/13 2015/16 
44 132 E [A] E [G] 0 [93] 0 [110] 2 [48] 0 [43] 0 [77] 
92 275 F [T] S [C] 0 [87] 0 [110] 2 [48] 0 [48] 0 [81] 
100 300 I [A] I [C] 29 [86] 30 [106] 37 [37] 36 [46] 31 [86] 
127 381 V [G] V [A] 0 [74] 0 [101] 0 [21] 2 [49] 0 [92] 
144 430 T [A] A [G] 0 [75] 0 [102] 3 [27] 0 [51] 0 [90] 
146 437 R [G] K [A] 0 [74] 1 [102] 3 [27] 0 [51] 0 [91] 
149 447 Q [G] Q [A] 1 [76] 1 [101] 3 [27] 0 [52] 2 [92] 
160 479 S [G] N [A] 10 [75] 11 [102] 9 [44] 24 [44] 16 [109] 
162 486 I [T] I [C] 0 [77] 3 [103] 0 [47] 0 [55] 1 [110] 
163 489 E [A] E [G] 7 [77] 12 [102] 8 [47] 16 [55] 4 [110] 
188 564 R [A] R [G] 1 [85] 0 [104] 0 [51] 0 [57] 0 [117] 
199 596 K [A] T [C] 11 [86] 6 [102] 0 [59] 16 [60] 11 [114] 
 597 K [A] K [G] 0 [86] 0 [102] 3 [59] 0 [60] 0.8 [114] 





207 620 T [C] R [G] 1 [89] 0.9 [102] 0 [59] 0 [60] 0 [115] 
225 675 I [A] I [T] 0 [90] 0 [101] 0 [57] 1 [63] 0 [114] 
227 679 Nx7 [7xAAT) Nx6 [6xAAT] 0 [81] 0.9 [81] 0 [57] 0 [65] 0 [116] 
   Nx8 [8xAAT] 10 [81] 13.7 [81] 17 [57] 12 [65] 14 [116] 
   Nx9 [9xAAT] 6 [81] 5.8 [81] 7 [57] 1 [65] 12 [116] 
   Nx10 [10xAAT] 0 [81] 0.9 [81] 0 [57] 0 [65] 0.8 [116] 
234 700 Kx1 [AAG] Kx2 [2xAAG] 2 [91] 2 [101] 0 [57] 10 [65] 1 [111] 
235 704 T [C] I [T] 1 [89] 0 [100] 0 [52] 0 [65] 0 [112] 
236 706 A [G] T [A] 1 [88] 0 [100] 1 [51] 1 [66] 0 [112] 
254 760 Y [T] H [C] 1 [85] 0 [102] 0 [51] 0 [65] 0 [112] 
274 821 S [G] I [T] 0 [83] 0 [104] 2 [47] 0 [66] 0 [109] 
289 867 K [A] K [G] 1 [82] 0 [99] 0 [47] 0 [66] 0 [109] 
315 943 G [G] S [A] 0 [85] 0 [96] 1 [52] 0 [70] 0 [111] 
 944 G [G] D [A] 1 [85] 1 [96] 0 [52] 0 [70] 0 [111] 
320 958 Nx5 [AAC(4xAAT)] Nx6 [AAC(5xAAT)] 6 [81] 2 [76] 10 [52] 7 [69] 3 [105] 
   Nx7 [AAC(6xAAT)] 0 [81] 2 [76] 0 [52] 0 [69] 0 [106] 
327 979 Nx4 [(3xAAT)AAC] Nx5 [(4xAAT)AAC] 2 [75] 1 [84] 2 [50] 0 [66] 2 [107] 
   Nx6 [(5xAAT)AAC] 0 [75] 0 [84] 0 [50] 0 [66] 0.9 [107] 
337 1009 A [G] T [A] 0 [78] 1 [81] 0 [46] 1 [71] 0 [113] 
341 1023 S [T] S [C] 0 [77] 1 [81] 0 [45] 2 [69] 0 [113] 
437 1311 F [C] L [A] 9 [72] 0 [89] 4 [65] 4 [97] 1 [118] 
445 1334 N [A] S [G] 0 [75] 0 [91] 1 [66] 0 [97] 0 [118] 
476 1428 S [T] S [G] 1 [79] 6 [99] 2 [79] 0.9 [101] 1.6 [121] 
478 1434 V [A] V [T] 2 [78] 4 [103] 2 [79] 1.9 [101] 2.4 [121] 
491 1473 V [T] V [T] 0 [80] 0 [96] 0 [76] 0 [100] 0.8 [122] 
498 1493 I [T] T [C] 0 [80] 2 [95] 0 [74] 0 [98] 0 [121] 
517 1551 F [C] F [T] 0 [84] 1 [95] 0 [73] 0 [94] 0 [119] 
548 1644 D [C] D [T] 0 [84] 0 [86] 0 [66] 0 [89] 0.9 [111] 
586 1758 T [C] T [A] 0 [31] 0 [64] 0 [58] 0 [79] 0.9 [104] 
603 1809 Y [T] Y [C] 0 [4] 0 [47] 1 [54] 0 [72] 0 [100] 
The number of samples successfully genotyped per timepoint include: 130 in 1995/96, 134 in 1998/99, 123 in 2005/06, 110 
in 2012/13 and 135 in 2015/16. There were a total of 13, 16, 3,3 and 13 sequences with mixed bases in 1995/96, 1998/99, 
2005/06, 2012/13 and 2015/16, respectively. Frequency is presented as the percentage of sequences that carried a mutation 
out of the total number of sequences that had data for that locus [n]. In grey are zero SNP frequencies. 
 
No SNPs were found to be in LD and the prevalence of the S160N mutation was similar from 
1995/96 to 2015/16, except for a two-fold increase from 9% in 1998/99 to 24% in 2012/13 







Figure 4.3. ap2-mu codon S160N frequencies over time. The two alleles appear to have 
stable frequencies from 1995/96 to 2005/06 but the frequency of S160 declines to 
2012/13 while the frequency of 160N increases during the same period. After 2012/13, 
the frequencies of S160 increases and that of 160N decreases. In grey are the 95% 
confidence intervals. 
 
A total of 38 ap2-mu haplotypes were assembled with the 3D7 haplotype 
TRSKT[N7][Kx1]AG[N5][N4]AFI dominating across time (>39%, Table 4.6). 
Table 4.6. ap2-mu haplotype frequencies 
Haplotype Frequency % [n] 1995/96 1998/99 2005/06 2012/13 2015/16 
TRSKT[N7][Kx1]AG[N5][N4]AFI* 52.1 [46] 56.1 [73] 43.7 [16] 39.4 [38] 40.3 [62] 
TRNKT[N7][Kx1]AG[N5][N4]AFI 6.5 [46] 4.1 [73] 0 [16] 13.1 [38] 11.2 [62] 
TRSKT[N7][Kx1]AG[N5][N4]ALI 6.5 [46] 0 [73] 0 [16] 5.2 [38] 3.2 [62] 
TRSKT[N9][Kx1]AG[N5][N4]AFI 6.5 [46] 5.4 [73] 6.2 [16] 0 [38] 9.6 [62] 
TRSKT[N7][Kx1]AG[N5][N5]AFI 4.3 [46] 0 [73] 0 [16] 0 [38] 3.2 [62] 
TRSKT[N7][Kx1]AG[N6][N4]AFI 4.3 [46] 2.7 [73] 6.2 [16] 0 [38] 0 [62] 
TRSKT[N8][Kx1]AG[N5][N4]AFI 4.3 [46] 8.2 [73] 18.7 [16] 7.8 [38] 11.2 [62] 
TRSTT[N7][Kx1]AG[N5][N4]AFI 4.3 [46] 2.7 [73] 0 [16] 5.2 [38] 1.6 [62] 
TRNKT[N8][Kx1]AG[N5][N4]ALI 2.1 [46] 0 [73] 0 [16] 0 [38] 0 [62] 
TRNKT[N8][Kx1]TG[N5][N4]AFI 2.1 [46] 0 [73] 0 [16] 0 [38] 0 [62] 
TRSKR[N7][Kx1]AG[N6][N4]AFI 2.1 [46] 0 [73] 0 [16] 0 [38] 0 [62] 
TRSTT[N7][Kx2]AG[N5][N4]AFI 2.1 [46] 0 [73] 0 [16] 0 [38] 0 [62] 
TRSTT[N9][Kx1]AG[N5][N4]AFI 2.1 [46] 0 [73] 0 [16] 0 [38] 1.6 [62] 
TRNKT[N7][Kx1]AG[N6][N4]AFI 0 [46] 2.7 [73] 0 [16] 0 [38] 0 [62] 
TRSTT[N8][Kx1]AG[N5][N4]AFI 0 [46] 2.7 [73] 0 [16] 0 [38] 3.2 [62] 





TRNKT[N7][Kx1]AG[N5][N5]AFI 0 [46] 1.3 [73] 0 [16] 0 [38] 0 [62] 
TRNKT[N8][Kx1]AG[N5][N4]AFI 0 [46] 1.3 [73] 6.2 [16] 0 [38] 1.6 [62] 
TRNKT[N8][Kx1]AG[N5][N4]AFT 0 [46] 1.3 [73] 0 [16] 0 [38] 0 [62] 
TRNTT[N7][Kx1]AG[N5][N4]AFI 0 [46] 1.3 [73] 0 [16] 2.6 [38] 4.8 [62] 
TRSKT[N10][Kx1]AG[N5][N4]AFI 0 [46] 1.3 [73] 0 [16] 0 [38] 0 [62] 
TRSKT[N6][Kx2]AG[N5][N4]TFI 0 [46] 0 [73] 0 [16] 0 [38] 0 [62] 
TRSKT[N7][Kx1]AG[N7][N4]AFI 0 [46] 1.3 [73] 0 [16] 0 [38] 0 [62] 
TRSKT[N7][Kx2]AG[N6][N4]AFI 0 [46] 1.3 [73] 0 [16] 2.6 [38] 0 [62] 
TRSKT[N9][Kx1]AD[N5][N4]AFI 0 [46] 1.3 [73] 0 [16] 0 [38] 0 [62] 
TRSTT[N7][Kx1]AG[N7][N4]AFI 0 [46] 1.3 [73] 0 [16] 0 [38] 0 [62] 
ARSKT[N8][Kx1]AG[N5][N4]AFI 0 [46] 0 [73] 6.2 [16] 0 [38] 0 [62] 
TRNKT[N9][Kx1]AG[N5][N4]AFI 0 [46] 0 [73] 6.2 [16] 0 [38] 0 [62] 
TRNKT[N7][Kx2]AG[N5][N4]AFI 0 [46] 0 [73] 0 [16] 10.5 [38] 0 [62] 
TRSKT[N7][Kx1]AG[N5][N4]TFI 0 [46] 0 [73] 0 [16] 2.6 [38] 0 [62] 
TRSKT[N7][Kx2]AG[N5][N4]AFI 0 [46] 0 [73] 0 [16] 2.6 [38] 0 [62] 
TRSKT[N8][Kx1]AG[N6][N4]AFI 0 [46] 0 [73] 0 [16] 2.6 [38] 0 [62] 
TRSTT[N8][Kx1]AG[N6][N4]AFI 0 [46] 0 [73] 0 [16] 2.6 [38] 0 [62] 
TRSTT[N9][Kx1]AG[N6][N4]AFI 0 [46] 0 [73] 0 [16] 2.6 [38] 0 [62] 
TRNTT[N9][Kx1]AG[N5][N4]AFI 0 [46] 0 [73] 0 [16] 0 [38] 3.2 [62] 
TRSKT[N10][Kx1]AG[N5][N6]AFI 0 [46] 0 [73] 0 [16] 0 [38] 1.6 [62] 
TRSKT[N9][Kx1]AG[N6][N4]AFI 0 [46] 0 [73] 0 [16] 0 [38] 1.6 [62] 
TRSTT[N7][Kx1]AG[N6][N4]AFI 0 [46] 0 [73] 0 [16] 0 [38] 1.6 [62] 
The following were used to define haplotypes: 14 polymorphic sites, including codons 144, 146, 160, 199, 207, 
227, 234, 236, 315, 320, 327, 337, 437, 498. The haplotypes marked with an * indicate the 3D7 haplotype. 
Frequency is presented as the percentage of sequences that contributed to the haplotype out of the total 
number of sequences [n]. In grey are zero SNP frequencies. 
 
 
falcipain-2a was found to be the most polymorphic gene, however, the S69Stop 
polymorphism was not identified. The following polymorphic codons were observed across 
all time points N4H, A8I, A8I, P9P, H10N, E11E, Q15H, V21V, K31K, S43S, V47V, V51I, S59F, 
N173K, S228T, K255R, N257E, F260F, Y265Y, D266D, H270H, M335I, G339G, T343P, D345G, 
V350V, N358N, S373S, Q414E and L474L and had frequencies >5% (Table 4.7). Additionally, 
many SNPs under 1250bp were found to be in high LD (Figure 4.4). 
Table 4.7. falcipain-2a SNP frequencies 
Codon Nucleotide Codon [Nucleotide] Mutant Frequency % [n] Wildtype Mutant 1995/96 1998/99 2005/06 2012/13 2015/16 
4 10 N [A] H [C] 9 [91] 9 [113] 19 [73] 9 [98] 16 [109] 
8 22 A [G] I [A] 8 [93] 7 [113] 16 [74] 8 [100] 14 [110] 
 23 A [C] I [T] 8 [93] 11 [113] 17 [74] 8 [100] 15 [110] 
9 27 P [C] P [G] 8 [94] 7 [113] 17 [74] 6 [100] 14 [110] 
10 28 H [C] N [A] 8 [96] 8 [112] 17 [74] 7 [99] 14 [110] 





15 45 Q [A] H [T] 10 [98] 13 [113] 14 [78] 13 [99] 13 [113] 
21 63 V [T] V [C] 11 [98] 15 [113] 18 [79] 13 [101] 15 [112] 
31 93 K [G] K [A] 2 [99] 6 [116] 3 [82] 1 [101] 0.8 [116] 
43 129 S [T] S [A] 10 [100] 8 [116] 5 [81] 4 [102] 4 [116] 
47 141 V [T] V [A] 12 [101] 11 [115] 11 [80] 8 [103] 8 [115] 
48 142 V [G] I [A] 0 [142] 0 [115] 0 [81] 0 [103] 0.8 [115] 
51 151 V [G] I [A] 13 [104] 13 [115] 13 [81] 9 [104] 10 [118] 
59 176 S [C] F [T] 12 [105] 8 [116] 7 [80] 1 [104] 5 [118] 
60 179 R [G] K [A] 0 [105] 0 [117] 0 [79] 0.9 [102] 0.8 [119] 
82 244 L [T] L [C] 0.9 [106] 0.8 [117] 0 [81] 0.9 [103] 0 [118] 
85 255 S [C] S [T] 0 [106] 0 [119] 0 [81] 0.9 [102] 0 [118] 
86 256 P [C] T [A] 0 [106] 0 [119] 0 [81] 0 [103] 0 [118] 
87 260 N [A] N [C] 0 [106] 0.8 [119] 0 [79] 0 [102] 0 [118] 
114 340 N [A] D [G] 0 [103] 0 [120] 1 [83] 0 [101] 0 [118] 
 342 N [C] N [T] 1 [103] 0 [120] 0 [83] 0 [101] 0 [118] 
115 344 E [A] V [T] 2 [103] 3 [120] 1 [86] 0 [101] 0.8 [118] 
123 369 D [C] D [T] 0.9 [105] 0 [120] 0 [86] 0 [102] 0 [119] 
126 377 G [G] D [A] 0 [105] 3 [122] 0 [86] 0 [103] 0 [120] 
127 381 L [T] L [A] 0.9 [106] 0 [122] 0 [86] 0.9 [103] 0 [120] 
134 401 T [C] K [A] 0.9 [105] 0 [123] 0 [89] 0.9 [106] 0 [120] 
140 418 I [A] L [C] 0.9 [106] 0 [124] 0.9 [105] 0 [108] 0 [120] 
143 427 K [A] E [G] 0 [107] 0 [125] 0.9 [105] 1 [108] 0 [120] 
144 430 D [G] N [A] 0 [106] 0 [125] 0.9 [105] 1 [108] 0 [120] 
150 449 F [T] Y [A] 0 [106] 0.8 [125] 0 [105] 0 [111] 0 [120] 
167 500 M [T] T [C] 0.9 [107] 0.8 [122] 0 [98] 0 [112] 0 [120] 
169 507 I [T] I [A] 0.9 [106] 0.8 [122] 0 [98] 0 [112] 0 [120] 
173 519 N [T] K [A] 1 [105] 2 [122] 1 [98] 0.8 [112] 4 [120] 
179 537 P [A] P [G] 0 [106] 2 [123] 2 [98] 6 [112] 2 [118] 
183 549 K [G] K [A] 0 [106] 0 [122] 1 [98] 0 [114] 0 [119] 
204 612 N [T] K [G] 0 [104] 0.8 [122] 0 [98] 0 [113] 0 [122] 
210 628 E [G] Q [C] 0 [104] 0 [122] 0 [98] 0.8 [114] 4 [121] 
212 636 N [C] N [T] 0 [104] 0.8 [122] 0 [97] 0 [114] 0 [121] 
215 645 A [C] A [T] 0 [104] 0.8 [124] 0 [97] 0 [113] 0 [121] 
218 654 T [T] T [A] 0 [105] 0 [124] 0 [97] 0.8 [113] 0.8 [121] 
220 660 H [T] H [C] 0 [105] 0.8 [124] 0 [97] 0 [113] 0 [121] 
224 671 N [A] S [G] 0 [105] 0.8 [124] 0 [97] 1 [113] 0 [121] 
 672 N [C] S [T] 0 [105] 0.8 [124] 0 [97] 2 [113] 0 [121] 
227 681 L [T] L [A] 0.9 [105] 0 [124] 0 [97] 3 [113] 0 [120] 
228 683 S [G] T [C] 10 [105] 13 [124] 10 [97] 7 [113] 5 [121] 
232 696 S [A] S [G] 0 [105] 1 [124] 0 [96] 2 [113] 0 [120] 
245 735 M [G] I [A] 0 [107] 3 [126] 0 [95] 2 [113] 0 [120] 
248 744 E [A] D [C] 0 [106] 1 [126] 0 [95] 2 [113] 0 [119] 
249 746 E [A] A [C] 0 [106] 1 [126] 0 [95] 2 [113] 0 [119] 
 747 E [A] A [C] 0 [106] 1 [126] 0 [96] 2 [113] 0 [119] 
250 750 V [T] V [A] 0 [106] 1 [125] 0 [96] 2 [112] 0 [119] 
255 763 K [A] G [G] 1 [106] 0.8 [125] 0 [97] 0.9 [111] 0.8 [118] 
 764 K [A] R [G] 92 [106] 97 [125] 97 [108] 98 [111] 1 [118] 





 771 N [T] E [A] 92 [106] 96 [124] 97 [95] 96 [111] 97 [118] 
260 780 F [T] F [C] 92 [106] 96 [123] 97 [95] 96 [111] 96 [118] 
265 795 Y [T] Y [C] 92 [106] 96 [121] 97 [92] 96 [110] 96 [119] 
266 798 D [T] D [C] 92 [106] 96 [121] 97 [92] 95 [110] 95 [120] 
270 810 H [T] H [C] 92 [100] 96 [123] 97 [93] 98 [110] 98 [120] 
299 896 A [C] V [T] 2 [112] 3 [122] 2 [93] 0 [106] 0 [120] 
321 962 Y [A] S [C] 0 [108] 0.8 [120] 1 [93] 0 [94] 0 [121] 
335 1005 M [G] I [T] 2 [108] 0.8 [119] 1 [92] 1 [97] 1 [121] 
339 1017 G [G] G [A] 88 [108] 88 [120] 92 [100] 88 [97] 89 [121] 
343 1027 T [A] P [C] 90 [108] 89 [119] 93 [100] 88 [98] 90 [121] 
345 1034 D [A] G [G] 90 [108] 89 [119] 94 [100] 92 [98] 90 [122] 
350 1048 V [G] M [A] 0 [109] 0.8 [119] 0 [99] 0 [99] 0 [122] 
350 1050 V [A] V [G] 90 [109] 89 [119] 6 [96] 93 [99] 9 [122] 
358 1074 N [T] N [C] 91 [112] 86 [121] 96 [96] 10 [99] 10 [123] 
373 1119 S [C] S [T] 8 [114] 11 [123] 3 [96] 6 [7] 9 [124] 
376 1127 D [A] V [T] 0 [114] 0.7 [126] 0 [102] 0 [103] 0 [124] 
393 1177 V [G] I [A] 0.8 [116] 0 [126] 0 [101] 0 [104] 2 [124] 
400 1198 A [G] P [C] 0.8 [116] 0 [127] 0 [101] 1 [104] 2 [124] 
 1200 A [T] P [G] 0.8 [116] 0 [127] 0 [101] 2 [104] 2 [124] 
407 1221 F [C] F [T] 0.8 [116] 0 [128] 0 [101] 2 [105] 2 [123] 
414 1240 Q [C] E [G] 48 [/116] 42 [128] 33 [34] 41 [105] 41 [123] 
434 1302 T [C] T [T] 0 [114] 0 [128] 1 [99] 0.8 [122] 0 [122] 
474 1420 L [T] L [C] 0.9 [103] 0.8 [125] 3 [99] 0.9 [110]  0 [110] 
The number of samples successfully genotyped per timepoint include: 137 in 1995/96, 141 in 1998/99, 120 
in 2005/06, 125 in 2012/13 and 126 in 2015/16. There were a total of 17, 7, 11,3 and 0 sequences with mixed 
bases in 1995/96, 1998/99, 2005/06, 2012/13 and 2015/16, respectively. Frequency is presented as the 
percentage of sequences that carried a mutation out of the total number of sequences that had data for that 







Figure 4.4. Linkage disequilibrium (LD) scatter plot for falcipain-2a. (A) 1995/96, (B) 1998/99, (C) 2005/06, 
(D) 2012/13, (D) 2015/16. LD or non-random association between alleles was estimated with the D' 
parameter (y-axis) and plotted against the nucleotide distance (x-axis). The black dots represent the D’ value 
for each of the pairwise comparisons conducted at each time point. Over the entire sampling period, many 
SNPs under 1250 bp were in high LD (D’ > 0).  
 
A total of 71 falcipain-2a haplotypes were assembled and only two haplotypes exceeded 10% 
frequency across time (NAQSRNEGTIKDFMNNENSMEEREAYMPGVDVAQ and 
NAQSRNEGTIKDFMNNENSMEEREAYMPGVDVAE). Many of the haplotypes were rare, 





at any time point (Table 4.8). The only significant temporal trend observed was that of codon 
S59F (χ2 = 5.7, p-value = 0.02), with the 59F allele dropping from 13% in 1995/96 to 5% in 
2015/16. 
Table 4.8. falcipain-2a haplotype frequencies 
Haplotype Frequency % [n] 1995/96 1998/99 2005/06 2012/13 2015/16 
NAQSRNEGTIKDFMNNENSMEEREAYMPGVDVAQ 22.8 [83] 31.7 [104] 37.3 [67] 45.7 [83] 33.6 [104] 
NAQSRNEGTIKDFMNNENSMEEREAYMPGVDVAE 20.4 [83] 14.4 [104] 10.4 [67] 14.4 [83] 15.3 [104] 
HIQSRNEGTIKDFMNNENSMEEREAYMPGVDVAQ 4.8 [83] 7.6 [104] 10.4 [67] 3.6 [83] 5.7 [104] 
NAQFRNEGTIKDFMNNENSMEEREAYMPGVDVAQ 4.8 [83] 1.9 [104] 4.4 [67] 1.2 [83] 4.8 [104] 
NAQSRNEGTIKDFMNNENTMEEREAYMTDVDVAE 4.8 [83] 6.7 [104] 1.4 [67] 2.4 [83] 1.9 [104] 
NAQSRNEGTIKDFMNNENSMEEKNAYMPGVDVAE 3.6 [83] 0 [104] 1.4 [67] 0 [83] 0 [104] 
NAQSRNEGTIKDFMNNENSMEEKNAYMPGVDVAQ 3.6 [83] 1.9 [104] 0 [67] 0 [83] 0.9 [104] 
NAQSRNEGTIKDFMNNENTMEEREAYMPGVDVAQ 3.6 [83] 1.9 [104] 2.9 [67] 1.2 [83] 0 [104] 
HIQSRNEGTIKDFMNNENTMEEREAYMPGVDVAQ 2.4 [83] 0 [104] 1.4 [67] 0 [83] 0 [104] 
NAQFRNEGTIKDFMNNENSMEEREAYMPGVDVAE 2.4 [83] 0.9 [104] 2.9 [67] 0 [83] 0 [104] 
HAHSRNEGTIKDFMNNENSMEEREAYMPGVDVAQ 1.2 [83] 0 [104] 1.4 [67] 1.2 [83] 0 [104] 
HIQSRNEGTIKDFMNNENSMEEREAYMPGVDVAE 1.2 [83] 0 [104] 0 [67] 0 [83] 1.9 [104] 
HIQSRNEGTIKDFMNNENSMEEREAYMTDVDVAE 1.2 [83] 0 [104] 0 [67] 0 [83] 0 [104] 
NAHFRNEGTIKDFMNNENSMEEREAYMPGVDVAE 1.2 [83] 0.9 [104] 0 [67] 0 [83] 0 [104] 
NAHFRNEGTIKDFMNNENSMEEREAYMTDVDVAE 1.2 [83] 0 [104] 0 [67] 0 [83] 0 [104] 
NAHSRNEGKIKDFMNNENSMEEREAYMPGVDVAE 1.2 [83] 0 [104] 0 [67] 1.2 [83] 0 [104] 
NAHSRNEGTIKDFMNNENSMEEKNAYMPGVDVAQ 1.2 [83] 0 [104] 0 [67] 0 [83] 0 [104] 
NAHSRNEGTIKDFMNNENSMEEREAYIPGVDVAE 1.2 [83] 0 [104] 0 [67] 0 [83] 0 [104] 
NAHSRNEGTIKDFMNNENSMEEREAYMPGVDVAE 1.2 [83] 4.8 [104] 2.9 [67] 3.6 [83] 7.6 [104] 
NAHSRNEGTIKDFMNNENSMEEREAYMPGVDVAQ 1.2 [83] 0.9 [104] 0 [67] 1.2 [83] 0.9 [104] 
NAHSRNEGTIKDFMNNENTMEEREAYMPGVDVAE 1.2 [83] 0 [104] 2.9 [67] 2.4 [83] 0 [104] 
NAQFRNEGTIKDFMNNENSMEEGEAYMPGVDVAQ 1.2 [83] 0 [104] 0 [67] 0 [83] 0 [104] 
NAQFRNEGTIKDFMNNENSMEEREAYIPGVDVAQ 1.2 [83] 0 [104] 0 [67] 0 [83] 0 [104] 
NAQFRNEGTIKDFMNNENSMEEREAYMTDVDVAE 1.2 [83] 0.9 [104] 0 [67] 0 [83] 0 [104] 
NAQSRNEGTIKDFMKNENSMEEREAYMPGVDVAQ 1.2 [83] 0 [104] 0 [67] 0 [83] 0 [104] 
NAQSRNEGTIKDFMKNENSMEEREAYMTDVDVAE 1.2 [83] 1.9 [104] 1.4 [67] 1.2 [83] 1.9 [104] 
NAQSRNEGTIKDFMNNENSMEEREAYIPGVDVAQ 1.2 [83] 0 [104] 0 [67] 0 [83] 0.9 [104] 
NAQSRNEGTIKDFMNNENSMEEREAYMTDVDVAE 1.2 [83] 0 [104] 1.4 [67] 2.4 [83] 2.8 [104] 
NAQSRNEGTIKDFMNNENSMEEREVYMPGVDVAE 1.2 [83] 0 [104] 0 [67] 0 [83] 0 [104] 
NAQSRNEGTIKDFMNNENTMEEGEAYMPGVDVAE 1.2 [83] 0.9 [104] 0 [67] 1.2 [83] 0 [104] 
NAQSRNEGTIKDFTNNENSMEEREAYMPGVDVAQ 1.2 [83] 0 [104] 0 [67] 0 [83] 0 [104] 
NAQSRNEGTLKDFMNNENSMEEREAYMPGVDVAQ 1.2 [83] 0 [104] 1.4 [67] 0 [83] 0 [104] 
NAQSRNEDTIKDFMNNENSMEEREVYMPGVDVAE 0 [83] 3.8 [104] 0 [67] 0 [83] 0 [104] 
NAHSRNVGTIKDFMNNENSMEEREAYMPGVDVAQ 0 [83] 2.8 [104] 0 [67] 0 [83] 0.9 [104] 
NAHSRNEGTIKDFMNNENSIDAKNAYMTDVDVAE 0 [83] 1.9 [104] 0 [67] 0 [83] 0 [104] 
HAQSRNEGTIKDFMNNENSMEEREAYMPGVDVAQ 0 [83] 0.9 [104] 0 [67] 0 [83] 0 [104] 
HVQSRNEGTIKDFMNNENSMEEREAYMPGVDVAQ 0 [83] 0.9 [104] 1.4 [67] 0 [83] 0 [104] 





NAQFRNEGTIKDFMNNENSMEEREAYIPGVDVAE 0 [83] 0.9 [104] 0 [67] 0 [83] 0 [104] 
NAQSRNEGTIKDFMKNENSMEEREAYMPGVDVAE 0 [83] 0.9 [104] 0 [67] 0 [83] 0.9 [104] 
NAQSRNEGTIKDFMNKESTIEEREAYMPGVDVAQ 0 [83] 0.9 [104] 0 [67] 0 [83] 0 [104] 
NAQSRNEGTIKDFMNNENSMEEKEAYMPGVDVAQ 0 [83] 0.9 [104] 0 [67] 0 [83] 0 [104] 
NAQSRNEGTIKDFMNNENSMEEREASMPGVDVAE 0 [83] 0.9 [104] 1.4 [67] 0 [83] 0 [104] 
NAQSRNEGTIKDFMNNENSMEEREAYMPGVVVAE 0 [83] 0.9 [104] 0 [67] 0 [83] 0 [104] 
NAQSRNEGTIKDFMNNENTMEEREAYMPGVDVAE 0 [83] 0.9 [104] 1.4 [67] 1.2 [83] 0 [104] 
NAQSRNEGTIKDFTNNENTMEEREAYMPGVDVAE 0 [83] 0.9 [104] 0 [67] 0 [83] 0 [104] 
NAQSRNEGTIKDYMNNENSMEEREAYMPGVDVAE 0 [83] 0.9 [104] 0 [67] 0 [83] 0 [104] 
NVHFRNEGTIKDFMNNENSMEEREAYMPGVDVAQ 0 [83] 0.9 [104] 0 [67] 0 [83] 0 [104] 
NVQSRNEGTIKDFMNNENSMEEREAYMPGVDVAQ 0 [83] 0.9 [104] 0 [67] 0 [83] 0 [104] 
HIHSRNEGTIKDFMNNENSMEEREAYMPGVDVAE 0 [83] 0 [104] 2.9 [67] 1.2 [83] 0.9 [104] 
HIHSRNEGTIKDFMNNENSMEEREAYMPGVDVAQ 0 [83] 0 [104] 1.4 [67] 2.4 [83] 0.9 [104] 
NAHSRDEGTIKDFMNNENSMEEREAYMPGVDVAQ 0 [83] 0 [104] 1.4 [67] 0 [83] 0 [104] 
NAQSRNEGTIENFMNNENSMEEREAYMPGVDVAQ 0 [83] 0 [104] 1.4 [67] 1.2 [83] 0 [104] 
NAQSRNEGTIKDFMNNENTMEEREAYMTGVDVAE 0 [83] 0 [104] 1.4 [67] 1.2 [83] 0 [104] 
NAQSRNVGTIKDFMNNENSMEEREAYMPGVDVAQ 0 [83] 0 [104] 1.4 [67] 0 [83] 0 [104] 
NAQSRNEGTIKDFMNNENSIDAKNAYMTGVDVAE 0 [83] 0 [104] 0 [67] 2.4 [83] 0 [104] 
HIQSRNEGTIKDFMNNQNSMEEREAYMPGVDVAQ 0 [83] 0 [104] 0 [67] 1.2 [83] 5.7 [104] 
NAQSKNEGTIKDFMNNENSMEEREAYMPGVDVAE 0 [83] 0 [104] 0 [67] 1.2 [83] 0 [104] 
NAQSRNEGTIKDFMNNENSIEEREAYMPGVDVAQ 0 [83] 0 [104] 0 [67] 1.2 [83] 0 [104] 
NAQSRNEGTIKDFMNNENSMEEREAYIPGVDVAE 0 [83] 0 [104] 0 [67] 1.2 [83] 0 [104] 
NAQSRNEGTIKDFMNNENSMEEREAYMTDVDVAQ 0 [83] 0 [104] 0 [67] 1.2 [83] 0 [104] 
NAQSRNEGTIKDFMNNENSMEERNAYMTDVDVAE 0 [83] 0 [104] 0 [67] 1.2 [83] 0.9 [104] 
NAQSRNEGTIKDFMNNENSMEEREAYMPGVDIPE 0 [83] 0 [104] 0 [67] 0 [83] 2.8 [104] 
HAQSRNEGTIKDFMKNENSMEEREAYMPGVDVAQ 0 [83] 0 [104] 0 [67] 0 [83] 0.9 [104] 
HAQSRNEGTIKDFMNNENSMEEREAYMPGVDVAE 0 [83] 0 [104] 0 [67] 0 [83] 0.9 [104] 
NAHSRNEGTIKDFMNNENTMEEREAYMTGVDVAE 0 [83] 0 [104] 0 [67] 0 [83] 0.9 [104] 
NAQSKNEGTIKDFMNNENSMEEREAYMPGVDVAQ 0 [83] 0 [104] 0 [67] 0 [83] 0.9 [104] 
NAQSRNEGTIKDFMKNENSMEEREAYMPDVDVAE 0 [83] 0 [104] 0 [67] 0 [83] 0.9 [104] 
NAQSRNEGTIKDFMNNENTMEEGEAYMPGVDVAQ 0 [83] 0 [104] 0 [67] 0 [83] 0.9 [104] 
NAQSRNEGTIKDFMNNENTMEEREAYMTDVDVAQ 0 [83] 0 [104] 0 [67] 0 [83] 0.9 [104] 
NVHFRNEGTIKDFMNNENSMEEREAYIPGVDVAQ 0 [83] 0 [104] 0 [67] 0 [83] 0.9 [104] 
The following were used to define haplotypes: 35 polymorphic sites, including codons 4, 8, 15, 59, 60, 86, 114, 115, 
126, 134, 140, 143, 144, 150, 167, 173, 204, 210, 224, 228, 245, 248, 249, 255, 257, 299, 321, 335, 343, 345, 350, 
376, 393, 400, 414. The3D7 haplotype was not identified. Frequency is presented as the percentage of sequences 
that contributed to the haplotype out of the total number of sequences [n]. In grey are zero SNP frequencies. 
 
In ubp-1, the following polymorphic codons were observed across all timepoints, 
E1508Deletion, N1518N, KYD-repeat at codon 1520 and KYE-repeat at codon 1526. Only the 
polymorphism at codon 1520 and 1526 exceeded 10% frequencies across time and each had 
one stable allele. No SNPs were found to be in LD and the E1528D polymorphism observed in 
previous studies from Kenya was not identified Table 4.9.  
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Table 4.9. ubp-1 SNP frequencies 
Codon Nucleotide                            Codon [Nucleotide] Mutant Frequency %[n] Wildtype Mutant 1995/96 1998/99 2005/06 2012/13 2015/16 
1472 4415 S [C] Y [A] 0 [83] 0.8 [122] 0.8 [119] 0 [107] 0 [108] 
1484 4450 D [G] Y [T] 0 [83] 0.7 [126] 0 [125] 1.8 [110] 0 [109] 
1499 4496 R [G] H [A] 0 [83] 0.7 [136] 0 [126] 0 [112] 0.9 [110] 
1504 4511 E [A] G [G] 1.1 [84] 0 [136] 0 [127] 0 [112] 0 [110] 
1505 4515 K [A] K [G] 0 [84] 0 [136] 0.7 [127] 0 [112] 0 [110] 
1509 4525 E [GAA] Del 2.3 [83] 3.6 [132] 5.5 [127] 4.4 [112] 4.5 [110] 
1514 4540 KNEx2 [AAAAATGAAAAAAACGAA] 2xKNE [AAAAATGAAAAAAATGAA] 0 [86] 9.4 [137] 5.5 [128] 11 [112] 5.4 [112] 
   KNEKND [AAAAATGAAAAAAACGAC] 0 [86]  0.7 [128] 0 [112] 0 [112]    KNE [AAAAATGAA] 0 [86] 1.4 [137] 1.5 [128] 0 [112] 0 [112] 
   KNE [AAAAACGAA] 0 [86]  0 [127] 0.8 [112] 0.9 [112] 
1515 4545 N [T] N [C] 0 [86] 0 [137] 0 [127] 0.8 [1] 0 [111] 
1518 4554 N [C] N [T] 8.1 [135] 9.6 [13] 5.6 [123] 11 [13] 5.4 [111] 
1519 4557 Y [A] Y [C] 0 [87 0 [135] 0.8 [125] 0 [111] 0 [110] 
1520 4558 KYDx2 [AAATATGACx2] KYDx4 [AAATATGACx4] 0 [87 11 [137] 3.1 [/127] 0.8 [112] 0 [112] 
   KYDx3 [AAATATGACx3] 8.0 [87] 0 [137] 7.0 [127] 8.0 [112] 11 [112] 
   KYGKYD [AAATATGGCAAATATGAC] 0 [87 0.7 [137]] 0 [127] 0 [112] 0 [112] 
   KYD [AAATATGAC] 10 [87] 13 [137] 18 [127] 16 [112] 12 [112] 
1522 4565 D [A] G [G] 0 [87] 0.7 [137] 0 [127] 0 [112] 0 [111] 
1526 4576 KYEx2 [AAATATGAAx2] KYEKYD[KYEx2] [AAATATGAAAAATATGAC(AAATATGAAx2)] 0 [87] 0 [135] 0.7 [127] 0 [112] 0 [112] 
   KYEx3 [AAATATGAAx3] 11 [87] 14 [135] 12 [127] 10 [112] 6.3 [112] 
   KYEx3 [AAATACGAA(AAATATGAAx2)] 0 [87] 0.7 [135] 0 [127] 0 [112] 0 [112] 
   KYEKYDKYE [AAATATGAAAAATATGACAAATATGAA] 0 [87] 0 [135] 1.5 [127] 0 [112] 0 [112] 
   KYEKYV [AAATATGAAAAATATGTA] 0 [87] 0.7 [135] 0 [127] 0 [112] 0 [112] 
   KYE [AAATATGAA] 17 [15] 11 [135] 11 [14] 12 [14] 17 [112] 
1527 4581 Y [T] Y [C] 0 [87] 0.7 [133] 0 [127] 0 [112] 0 [111] 
1531 4592 E [A] V [T] 0 [72] 0.8 [122] 0 [113] 0 [98] 0 [92] 
1532 4594 KYD [AAATATGAT] KYDx2 [(2xAAATATGAT)] 1.1 [85] 0 [135] 0 [126] 0 [111] 0 [111] 
1575 4724 K [A] R [G] 0 [86] 0 [135] 0.7 [126] 0 [105] 0 [108] 
The number of samples successfully genotyped per timepoint include: 85 in 1995/96, 137 in 1998/99, 128 in 2005/06, 112 in 2012/13 and 85 in 2015/16. No 
sequences with mixed bases were identified. Frequency is presented as the percentage of sequences that carried a mutation out of the total number of 
sequences that had data for that locus [n]. In grey are zero SNP frequencies.
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Of the 23 ubp-1 haplotypes, the 3D7 haplotype dominated throughout the sampling period 
and no significant temporal trends were observed (Table 4.10). 
Table 4.10. ubp-1 haplotype frequencies 
Haplotype 
Frequency % [n] 
1995/96 1998/99 2005/06 2012/13 2015/16 
SDREE[KNEx2][KYDx2]D[KYEx2]E[KYDx1]* 66.6 [66] 62.2 [106] 58.2 [103] 62.9 [89] 70.9 [86] 
SDREE[KNEx2][KYDx1]D[KYEx2]E[KYDx1] 10.6 [66] 11.3 [106] 16.5 [103] 14.6 [89] 12.7 [86] 
SDREE[KNEx2][KYDx2]D[KYEx3]E[KYDx1] 9.0 [66] 10.3 [106] 8.7 [103] 10.1 [89] 4.6 [86] 
SDREE[KNEx2][KYDx3]D[KYEx2]E[KYDx1] 4.5 [66] 2.8 [106] 3.8 [103] 2.2 [89] 2.3 [86] 
SDRE-[KNEx2][KYDx2]D[KYEx3]E[KYDx1] 1.5 [66] 1.8 [106] 0.9 [103] 0 [89] 0 [86] 
SDRE-[KNEx2][KYDx3]D[KYEx2]E[KYDx1] 1.5 [66] 0 [106] 0 [103] 1.1 [89] 3.4 [86] 
SDREE[KNEx2][KYDx1]D[KYEx3]E[KYDx1] 1.5 [66] 0.9 [106] 0 [103] 1.1 [89] 1.1 [86] 
SDREE[KNEx2][KYDx2]D[KYEx2]E[KYDx2] 1.5 [66] 0 [106] 0 [103] 0 [89] 0 [86] 
SDREE[KNEx2][KYDx3]D[KYEx3]E[KYDx1] 1.5 [66] 0.9 [106] 1.9 [103] 0 [89] 0 [86] 
SDRGE[KNEx2][KYDx2]D[KYEx2]E[KYDx1] 1.5 [66] 0 [106] 0 [103] 0 [89] 0 [86] 
SDREE[KNEx2][KYDx2]D[KYEx1]E[KYDx1] 0 [66] 1.8 [106] 0 [103] 0 [89] 0 [86] 
SDREE[KNEx2][KYDx4]D[KYEx2]E[KYDx1] 0 [66] 1.8 [106] 1.9 [103] 0 [89] 0 [86] 
SDRE-[KNEx2][KYDx1]D[KYEx2]E[KYDx1] 0 [66] 0.9 [106] 1.9 [103] 3.3 [89] 0 [86] 
SDREE[KNEx1][KYDx3]D[KYEx2]E[KYDx1] 0 [66] 0.9 [106] 0 [103] 0 [89] 1.1 [86] 
SDREE[KNEx2][KYDx2]D[KYEKYV]V[KYDx1] 0 [66] 0.9 [106] 0 [103] 0 [89] 0 [86] 
SDREE[KNEx2][KYGKYD]G[KYEx3]E[KYDx1] 0 [66] 0.9 [106] 0 [103] 0 [89] 0 [86] 
SYREE[KNEx2][KYDx2]D[KYEx2]E[KYDx1] 0 [66] 0.9 [106] 0 [103] 2.2 [89] 0 [86] 
YDREE[KNEx1][KYDx2]D[KYEx3]E[KYDx1] 0 [66] 0.9 [106] 0.9 [103] 0 [89] 0 [86] 
SDRE-[KNEx2][KYDx4]D[KYEx2]E[KYDx1] 0 [66] 0 [106] 1.9 [103] 0 [89] 0 [86] 
SDREE[KNEx2][KYDx2]D[KYEKYDKYE]E[KYDx1] 0 [66] 0 [106] 1.9 [103] 0 [89] 0 [86] 
SDREE[KNEx1][KYDx2]D[KYEx3]E[KYDx1] 0 [66] 0 [106] 0.9 [103] 1.1 [89] 0 [86] 
SDRE-[KNEx2][KYDx2]D[KYEx2]E[KYDx1] 0 [66] 0 [106] 0 [103] 1.1 [89] 2.3 [86] 
SDHEE[KNEx2][KYDx2]D[KYEx3]E[KYDx1] 0 [66] 0 [106] 0 [103] 0 [89] 1.1 [86] 
The following were used to define haplotypes: 12 polymorphic sites, including codons 1472, 1484, 1499, 1504, 1508, 
1514, 1520, 1522, 1526, 1531, 1532 and 1575. The haplotypes marked with an * indicate the 3D7 haplotype. “-“ in some 
of the haplotypes indicates a deletion. Frequency is presented as the percentage of sequences that contributed to the 
haplotype out of the total number of sequences [n]. In grey are zero SNP frequencies. 
 
4.3.3 Genetic markers associated with CQ, SP and lumefantrine resistance 
Three polymorphic codons (M74I, N75E and K76T) were identified in the crt gene in 2015/16 
and 2017/18 and all were found to be in high LD (D’ = 1). Mutant alleles at codons 74I, 75E 
and 76T dominated during the pre-ACT period and there was a distinct shift to the wild-type 
alleles (M74, N75 and K76) in the post-ACT period, almost reaching fixation (99%) (χ2 = 181, 
p-value <0.001, Table 4.11). There was a significant decline in the frequency of the CQ-





the frequency of the CQ-sensitive (CQS) haplotype (CVMNK) from 7% in 1998/99 to 99% in 
2017/18 (χ2 = 181, p-value <0.001, Figure 4.5A, Table 4.12). 
Five polymorphic codons were identified in mdr1 in 2015/16 and 2017/18 including N86Y, 
G102G, G182G, F184Y and D1246Y. mdr1 codons 86Y and 1246Y also showed a distinct shift 
from mutant alleles in the pre-ACT period (~40-70%), to wild-type alleles N86 and D1246, 
nearly approaching fixation (99%) (χ2 = 103, p-value <0.001 and χ2 = 85, p-value <0.001, 
respectively) post-ACT introduction. In contrast, the mutant 184F allele increased in 
frequency during the post-ACT period (33-54%, χ2 = 15.8, p-value <0.001, Table 4.11). Codons 
N86Y and F186Y as well as N86Y and D1246Y were found to be in high and low LD, respectively 
(D’ = 0.9 and D’ = -1, respectively). There were notable changes in frequency of both the 3D7 
haplotype (NYD) and the mutant NFD haplotype. NYD increased sharply to 64% in 2012/13, 
decreased to 40% in 2015/16 and later rose to 55% in 2017/18 to become the dominant 
haplotype. The mutant haplotype NFD followed an opposite pattern rising to 55% in 2015/16 
and later decreasing to 41% in 2017/18. The triple mutant haplotype YYY was no longer 
detected in the population post-ACT (Figure 4.5B, Table 4.12) and there was no significant 
temporal trend observed for the haplotype frequencies. 
S436A, A437G, K540E and A581G dhps polymorphic codons were identified across all time 
points and the I431V mutation was not identified. The mutant (437G and 540E) alleles 
dominated in the post-ACT period (68-91%, χ2 = 82.7, p<0.001 and χ2 = 153, p<0.001, 
respectively). Moreover, codons A437G and K540E were found to be in high LD (D’ = 1). The 
SP sensitive haplotype (SAKA) decreased in frequency over time and was no longer detectable 
in 2015/16 (Table 4.11), while the single mutant haplotype (SGKA) decreased gradually to 9% 
in 2015/16 and the double mutant haplotype (SGEA) rose in frequency from 10% to 85% in 
2015/16. (Figure 4.5C, Table 4.12). There was a significant temporal trend between the two 
dominant haplotypes, SAKA and SGEA (χ2 = 91, p-value <0.001). 
Table 4.11. crt, mdr1 and dhps SNP frequencies 
Gene Codon NT Codon [NT] Mutant Frequency % [n] Wildtype Mutant 1995/96 1998/99 2005/06 2012/13 2015/16 2017/18 





75 225 N [T] E [A] 62.03 [80] 93.2 [103] 50.98 [102] 18.29 [82] 3.16 [94] 1.1 [92] 
76 227 K [A] T [C] 62.03 [80] 93.2 [103] 50.98 [102] 18.29 [82] 3.19 [94] 1.1 [92] 
mdr1 
86 256 N [A] Y [T] 57.14 [57] 72.84 [81] 57.45 [47] 2.08 [48] 2.8 [107] 1.22 [82] 
102 306 G [T] G [C] ND ND ND ND 1.9 [105] 7.41 [81] 
182 546 G [T] G [G] ND ND ND ND 2.56 [78] 0 [89] 
184 551 Y [A] F [T] 30.56 [57] 13.58 [81] 29.79 [47] 33.33 [48] 54.43 [79] 42.5 [80] 
1246 3736 D [G] Y [T] 37.5 [57] 64.2 [81] 38.3 [47] 0 [48] 2.8 [107] 1.14 [88] 
dhps  
436 1306 S [T] A [G] 0 [85] 2.42 [124] 0 [80] 0 [21] 0 [24] NA 
437 1310 A [C] G [G] 32.94 [85] 37.9 [124] 86.49 [74] 78.57 [28] 0 [26] NA 
540 1618 K [A] E [G] 10.42 [196] 28.12 [128] 83.17 [101] 68.29 [41] 91.3 [45] NA 
581 1742 A [C] G [G] 0 [93] 0 [120] 0 [89] 0 [54] 3.03 [32] NA 
The number samples successfully genotyped per timepoint include: crt – 103 in 2015/16 and 91 in 2017/18 and no sequences 
with mixed bases identified. mdr1 – 130 in 2015/16 and 88 in 2017/18 and no sequences with mixed bases identified. dhps – 
99 in 1995/96, 137 in 1998/99, 130 in 2005/06, 80 in 2012/13 and 72 in 2015/16 with two sequences having mixed bases in 
1998/99. For dhps 2017/18 and crt (codons 102 and 182 in 1995/96, 1998/99 and 2005/06, respectively) no data (NA) was 
available because they were not genotyped. NT – Nucleotide, (*) one-sided, 97.5% confidence interval. In grey are zero SNP 
frequencies. 
 
Table 4.12. crt, mdr1 and dhps haplotype frequencies 
Gene Haplotype 
Frequency % [n] 
1995/96 1998/99 2005/06 2012/13 2015/16 2017/18 
crt CVMNK* 37.9 [79] 6.8 [103] 49.0 [102] 81.7 [82] 96.7 [91] 98.8 [90] CVIET 62.0 [79] 93.2 [103] 50.9 [102] 18.2 [82] 3.3 [91] 1.1 [90] 
mdr1 
NYD* 14.2 [56] 12.3 [81] 12.7 [47] 64.5 [48] 40 [60] 55.7 [70] 
NFD 28.5 [56] 7.4 [81] 12.7 [47] 33.3 [48] 55 [60] 41.4 [70] 
YFY 1.7 [56] 0 [81] 0 [47] 0 [48] 0 [60] 0 [70] 
YYD 19.6 [56] 16.0 [81] 31.9 [47] 2.0 [48] 3.3 [60] 1.4 [70] 
YYY 35.7 [56] 56.7 [81] 21.2 [47] 0 [48] 0 [60] 0 [70] 
NFY 0 [56] 6.1 [81] 12.7 [47] 0 [48] 0 [60] 1.4 [70] 
NYY 0 [56] 1.2 [81] 4.2 [47] 0 [48] 1.6 [60] 0 [70] 
YFD 0 [56] 0 [81] 4.2 [47] 0 [48] 0 [60] 0 [70] 
dhps  
SGEA* 10.7 [84] 31.6 [115] 84.2 [57] 76 [25] 85.7 [21] NA 
SAKA 66.6 [84] 59.8 [115] 14.0 [57] 16 [25] 0 [21] NA 
SGKA 22.6 [84] 5.9 [115] 1.7 [57] 8 [25] 9.5 [21] NA 
AAKA 0 [84] 2.5 [115] 0 [57] 0 [25] 0 [21] NA 
SGEG 0 [84] 0 [115] 0 [57] 0 [25] 4.7 [21] NA 
The following were used to define haplotypes: crt – 3 polymorphic sites, including codons 74, 75 and 76. Mdr1 – 3 
polymorphic sites, including codons 86, 184 and 1246 and dhps – 4 polymorphic sites, including codons 436, 437, 
540 and 581. The haplotypes marked with an * indicate the 3D7 haplotype. For dhps , there was no data for the 
2017/18 timepoint as it was not genotyped. Frequency is presented as the percentage of sequences that 







Figure 4.5. crt, mdr1, dhps haplotypes frequencies over time. (A) The crt sensitive haplotype (CVMNK) 
decreased from 1995/96 to 1998/99 and increased onwards to almost fixation in 2017/18 while the 
crt resistant haplotype (CVIET) followed an opposite pattern. (B) The 3D7 mdr1 haplotype NYD had 
was the least prevalent in comparison to the mutant haplotypes, NFD, YYD and YYY pre-ACT 
introduction. The triple mutant YYY was undetectable after 2005/06 while the 3D7 NYD and mutant 
NFD haplotypes started to increase in the population after 2005/06. Mutants YYD and NFY haplotypes 
decreased to almost zero in 2017/18. (C) The SP sensitive haplotype (SAKA) was on a decline from 
1995/96 and was undetectable in the population after 2012/13. The SP resistant double mutant 
haplotype (SGEA) was on the increase from 1995/96 and reached >80% frequency in 2015/16. The 
single mutant haplotype (SGKA) was the least prevalent throughout the sampling period. In grey are 
the 95% confidence intervals. 
 
In nfs, only codon K65Q was found to have a significant, albeit marginal, trend pre- and post-
ACT introduction (χ2 = 4.4, p-value = 0.04). It was also in high LD (D’ = 1) with codons S62N 





wild-type 65K diverge in frequency in opposite directions with the latter decreasing and the 
former increasing in frequency (Figure 4.6 and Table 4.13).  
 
Figure 4.6. nfs codon K65Q frequencies over time. The two nfs K65Q alleles appear to have stable 
frequencies from 1995/96 to 2005/06 but the frequency of K65 starts to drop after 2005/06 while that 
of 65K starts to increase after 2005/06. In grey are the 95% confidence intervals. 
 
Table 4.13. nfs SNP frequencies 
Codon Nucleotide 
Codon [Nucleotide] Mutant Frequency % [n] 
Wildtype Mutant 1995/96 1998/99 2005/06 2012/13 2015/16 2017/18 
44 131 S [C] C [G] 0 [73] 0 [64] 2.0 [48] 4.4 [68] 6.1 [97] 4.2 [70] 
62 185 S [G] N [A] 37 [74] 33 [64] 36 [47] 28 [73] 25 [99] 20 [71] 
65 193 K [A] Q [C] 62 [74] 66 [64] 40 [47] 70 [74] 74 [99] 80 [70] 
67 200 E [A] G [G] 62 [74] 66 [64] 40 [47] 70 [74] 74 [79] 80 [70] 
 201 E [A] G [T] 62 [74] 66 [64] 40 [47] 70 [74] 74 [79] 80 [70] 
110 328 Q [C] E [G] 5.4 [74] 10 [65] 8 [50] 1.2 [78] 16 [79] 5.7 [70] 
116 347 S [G] I [T] 0 [74] 1.5 [66] 0 [51] 0 [79] 0 [100] 98 [70] 
119 355 G [G] C [T] 0 [74] 3.0 [67] 0 [51] 1.2 [79] 0 [100] 0 [70] 
120 359 S [G] I [T] 14 [74] 27 [66] 37 [51] 30 [79] 41 [100] 32 [70] 
126 376 P [C] S [T] 0 [74] 0 [65] 1.9 [51] 0 [79] 0 [100] 0 [70] 
130 389 E [A] G [G] 0 [74] 0 [65] 0 [51] 1.2 [79] 0 [100] 0 [70] 
 390 E [G] D [C] 13 [74] 18 [65] 15 [51] 18 [79] 25 [25] 22 [70] 
188 562 E [G] K [A] 0 [24] 0 [57] 0 [44] 0 [60] 0 [92] 5.9 [67] 
274 822 G [T] G [C] 0 [76] 0 [66] 0 [57] 0 [82] 0 [100] 1.4 [70] 
283 847 N [A] Y [T] 0 [76] 0 [66] 0 [58] 0 [82] 0 [100] 1.4 [70] 
288 864 N [T] N [C] 0 [76] 0 [66] 1.7 [58] 0 [82] 0 [100] 0 [70] 
308 922 E [G] Q [C] 0 [76] 0 [66] 0 [57] 0 [82] 0 [100] 1.4 [70] 





338 1013 K [A] R [G] 0 [75] 0 [66] 0 [56] 0 [82] 0 [100] 1.4 [70] 
379 1137 G [C] G [T] 0 [74] 0 [66] 0 [54] 0 [82] 0 [100] 1.4 [70] 
409 1225 N [A] Y [T] 0 [74] 0 [66] 0 [53] 0 [82] 0 [102] 2.9 [69] 
The number of samples successfully genotyped per timepoint include: 81 in 1995/96, 71 in 1998/99, 73 in 
2005/06, 86 in 2012/13, 114 in 2015/16 and 77 in 2017/18. There were a total of 4, 3, 3, 4, 11 and 7 sequences 
with mixed bases in 1995/96, 1998/99, 2005/06, 2012/13, 2015/16 and 2017/18, respectively. Frequency is 
presented as the percentage of sequences that carried a mutation out of the total number of sequences that had 
data for that locus [n]. In grey are zero SNP frequencies. 
 
The 3D7 nfs haplotype was the seventh most dominant of all the 24 haplotypes and there 
were no significant temporal trends in haplotype frequencies (Table 4.14).  
Table 4.14. nfs haplotype frequencies 
Haplotype 
Frequency % [n] 
1995/96 1998/99 2005/06 2012/13 2015/16 2017/18 
SNQGQSGIPE 27.2 [22] 7.1 [56] 17.0 [41] 15.2 [59] 9.7 [94] 12.8 [70] 
SSKEQSGSPD 22.7 [22] 3.5 [56] 2.4 [41] 5.0 [59] 4.3 [94] 2.8 [70] 
SNQGQSGSPD 13.6 [22] 10.7 [56] 0 [41] 6.7 [59] 3.2 [94] 8.5 [70] 
SNQGQSGSPE 13.6 [22] 37.5 [56] 31.7 [41] 37.2 [59] 28.2 [94] 41.4 [70] 
SNQGESGIPE 9.0 [22] 7.1 [56] 4.8 [41] 0 [59] 6.5 [94] 1.4 [70] 
SNQGQSGIPD 9.0 [22] 3.5 [56] 2.4 [41] 8.4 [59] 13.0 [94] 5.7 [70] 
SSKEQSGSPE* 4.5 [22] 10.7 [56] 12.2 [41] 5.0 [59] 8.7 [94] 7.1 [70] 
SSKEQSGIPE 0 [22] 7.1 [56] 7.3 [41] 8.4 [59] 4.3 [94] 5.7 [70] 
SNQGESGSPE 0 [22] 3.5 [56] 2.4 [41] 1.6 [59] 6.5 [94] 4.2 [70] 
SSKEQSCIPE 0 [22] 3.5 [56] 0 [41] 1.6 [59] 0 [94] 0 [70] 
SSKEESGSPE 0 [22] 1.7 [56] 0 [41] 0 [59] 0 [94] 0 [70] 
SSKEQIGIPD 0 [22] 1.7 [56] 0 [41] 0 [59] 0 [94] 0 [70] 
SSKEQSGIPD 0 [22] 1.7 [56] 7.3 [41] 3.3 [59] 5.4 [94] 4.2 [70] 
CSKEQSGSPD 0 [22] 0 [56] 2.4 [41] 0 [59] 0 [94] 0 [70] 
SNKEQSGSPD 0 [22] 0 [56] 2.4 [41] 0 [59] 0 [94] 0 [70] 
SNKEQSGSPE 0 [22] 0 [56] 2.4 [41] 0 [59] 0 [94] 0 [70] 
SNQGQSGSSE 0 [22] 0 [56] 2.4 [41] 0 [59] 0 [94] 0 [70] 
SSKEESGIPE 0 [22] 0 [56] 2.4 [41] 0 [59] 2.1 [94] 0 [70] 
CNQGQSGIPD 0 [22] 0 [56] 0 [41] 1.6 [59] 0 [94] 1.4 [70] 
CNQGQSGIPE 0 [22] 0 [56] 0 [41] 1.6 [59] 2.1 [94] 1.4 [70] 
CNQGQSGSPE 0 [22] 0 [56] 0 [41] 1.6 [59] 4.3 [94] 1.4 [70] 
SNQGQSGSPG 0 [22] 0 [56] 0 [41] 1.6 [59] 0 [94] 0 [70] 
SNQGESGIPD 0 [22] 0 [56] 0 [41] 0 [59] 1.0 [94] 0 [70] 
SNQGQNGSPE 0 [22] 0 [56] 0 [41] 0 [59] 0 [94] 1.4 [70] 
The following were used to define haplotypes: 10 polymorphic sites, including codons 44, 62, 65, 67, 
110, 116, 119, 120, 126 and 130. The haplotypes marked with an * indicate the 3D7 haplotype. 
Frequency is presented as the percentage of sequences that contributed to the haplotype out of the 





4.3.4 serine-tRNA ligase, putative 
serine tRNA ligase, a marker not associated with resistance or dug selection, had only one 
polymorphic codon observed across all time points (L84V), with frequencies ranging between 
2- 5% while the rest were rare and no SNPs were found to be in LD (<5%, Table 4.15). 
Table 4.15. serine-tRNA ligase SNP frequencies 
Codon Nucleotide 
Codon [Nucleotide] Mutant Frequency %[n] 
Wildtype Mutant 1995/96 1998/99 2005/06 2012/13 2015/16 
31 92 N [A] S [G] 0 [95] 0 [120] 0 [105] 0.8 [114] 3 [127] 
71 211 D [G] N [A] 2 [105] 0 [133] 0 [121] 0 [121] 0 [142] 
84 250 L [T] V [G] 3 [106] 3 [133] 5 [120] 4 [122] 2 [142] 
86 258 I [A] M [G] 0 [106] 0 [133] 0 [121] 0 [122] 1 [142] 
88 264 E [A] D [T] 0 [106] 6 [133] 0.8 [121] 1 [122] 2 [142] 
94 280 Q [C] E [G] 0 [107] 0 [133] 0 [121] 0.8 [122] 2 [142] 
133 399 T [A] T [G] 0 [106] 2 [132] 0.8 [121] 0 [120] 0.7 [142] 
140 418 L [C] F [T] 0 [105] 0.7 [132] 0 [118] 0 [119] 0 [142] 
155 463 V [G] L [T] 0 [105] 0 [133] 0 [120] 1 [118] 0 [142] 
175 524 I [T] K [A] 0 [95] 0 [128] 0.9 [108] 0 [114] 0 [139] 
199 596 A [C] V [T] 0 [91] 0 [116] 0 [190] 0 [113] 0.7 [134] 
221 662 A [C] G [G] 0 [94] 0.8 [124] 0.9 [111] 1 [120] 0.7 [138] 
267 799 T [A] P [C] 0 [93] 0 [126] 0 [113] 5 [118] 1 [136] 
284 851 A [C] V [T] 0 [95] 0.7 [128] 0 [110] 0 [117] 0 [136] 
318 952 E [G] K [A] 0 [94] 0.7 [130] 0 [107] 0 [115] 0 [139] 
372 1116 F [F] F [T] 1 [89] 0 [127] 0 [107] 0 [115] 0 [139] 
417 1249 S [T] A [G] 0 [92] 1 [126] 0 [105] 0 [117] 0.7 [139] 
430 1290 N [T] N [C] 0 [92] 1 [129] 0 [107] 0 [120] 0 [139] 
528 1584 Y [C] Y [T] 0 [99] 0 [126] 0 [110] 1 [101] 0 [139] 
The number of samples successfully genotyped per timepoint include: 118 in 1995/96, 136 in 1998/99, 130 
in 2005/06, 123 in 2012/13 and 118 in 2015/16. No sequences with mixed bases were identified. Frequency 
is presented as the percentage of sequences that carried a mutation out of the total number of sequences 
that had data for that locus [n]. In grey are zero SNP frequencies. 
 
A total of 15 serine-tRNAligase haplotypes were observed and only the 3D7 haplotype 
occurred across all time points and with frequencies >80% with the rest of the haplotypes 
being rare (<5%) (Table 4.16). 
Table 4.16. serine-tRNAligase haplotype frequencies 
Haplotype 
Frequency % [n] 
1995/96 1998/99 2005/06 2012/13 2015/16 
NDLIEQLVAATAES* 93.2 [74] 85.2 [102] 95.8 [72] 86.1 [101] 84.6 [117] 
NNLIEQLVAATAES 4.0 [74] 0 [102] 0 [72] 0 [101] 0 [117] 





NDLIDQLVAATAES 0 [74] 4.9 [102] 0 [72] 0.9 [101] 3.4 [117] 
NDLIEQLVAATAEA 0 [74] 1.9 [102] 0 [72] 0 [101] 0.8 [117] 
NDLIDQLVAATAKS 0 [74] 0.9 [102] 0 [72] 0 [101] 0 [117] 
NDLIDQLVAATVES 0 [74] 0.9 [102] 0 [72] 0 [101] 0 [117] 
NDLIEQFVAATAES 0 [74] 0.9 [102] 0 [72] 0 [101] 0 [117] 
NDLIEQLVAGTAES 0 [74] 0.9 [102] 0 [72] 1.9 [101] 0.8 [117] 
NDLIEQLVAAPAES 0 [74] 0 [102] 0 [72] 5.9 [101] 1.7 [117] 
NDLIEQLLAATAES 0 [74] 0 [102] 0 [72] 1.9 [101] 0 [117] 
NDLIEELVAATAES 0 [74] 0 [102] 0 [72] 0.9 [101] 0.8 [117] 
SDLIEQLVAATAES 0 [74] 0 [102] 0 [72] 0 [101] 3.4 [117] 
NDLIEQLVVATAES 0 [74] 0 [102] 0 [72] 0 [101] 0.8 [117] 
NDLMEQLVAATAES 0 [74] 0 [102] 0 [72] 0 [101] 0.8 [117] 
The following were used to define haplotypes: 14 polymorphic sites, including codons 31, 71, 
84, 86, 88, 94, 140, 155, 199, 221, 267, 284, 318 and 417. The haplotypes marked with an * 
indicate the 3D7 haplotype. Frequency is presented as the percentage of sequences that 
contributed to the haplotype out of the total number of sequences [n]. In grey are zero SNP 
frequencies.  
4.4 Discussion 
The withdrawal of CQ in Kenya (Shretta et al. 2000) has resulted in the rapid decline in CQR 
alleles, namely crt-76T and mdr1-86Y and 1246Y, to 1% and the complete absence of the triple 
mutant mdr1-YYY, that modulates sensitivity to CQ and AQ (Reed et al. 2000; Humphreys et 
al. 2007), in the Kilifi population. Additionally, there has been a near complete reversion to 
the wild-type alleles crt-K76 (99%), mdr1-N86 (97%) and D1246 (99%). This is contrary to the 
neutral marker evaluated, serine tRNA ligase, which showed a dominance of the wild-type 
allele (>90%) and haplotype (NDLIEQLVAATAES, >80%) across the entire sampling period with 
no significant temporal differences. It is unclear whether this trend will continue so that the 
frequency of the crt-76T mutant allele approaches zero, or if this allele will persist at a new, 
very low steady state frequency. This observed trend supports a previous study that predicted 
it would take an additional 13 years to restore CQ clinical efficacy in Kilifi based on sampling 
between 1993 to 2006 (Mwai et al. 2009b). This near complete reversion to crt-CVMNK in 
Kilifi might be taken to suggest that after 2019, CQ could be re-introduced as a treatment 
option for malaria. Nationally, a decline in CQR has previously been observed in Kwale on the 
South Coast of Kenya, crt-K76 was on the rise at 36% in 2008 from 22% in 1999 (Mang’era et 
al. 2012), Kisumu, Kisii and Kericho in the Western region of Kenya (Eyase et al. 2013; Achieng 





and 2014, crt-76T dropped from 86% to 2%, mdr1-86Y from 92% to 1% and mdr1-1246Y from 
67% to 6%. Therefore, a national re-roll out of CQ in the next few years is a possibility, such 
as in a combination therapy, however careful consideration needs to be taken to determine 
the best modality for its re-introduction. As for mdr1, the NFD haplotype appears to oscillate 
in frequency with the NYD (wild type) haplotype and both have gone on to be the dominant 
mdr1 haplotypes post-ACT introduction. The NYD haplotype is likely to have risen in frequency 
due to the absence of CQ, restoring the wild type parasite population while the increase in 
the NFD haplotype frequency may be attributable to AL pressure (Humphreys et al., 2007). 
The mdr1-G102G and G182G identified in 2015/16 and 2017/18 were not genotyped in an 
earlier study (Okombo et al. 2014) hence their associations with changing anti-malarial drug 
policy could not be described. 
The introduction of SP in 1998 led to a rapid increase in the frequency of the dhps mutations 
(437G/540E) associated with resistance to sulfadoxine. This upsurge is in accordance with the 
previously observed increase in dhfr mutations (51I/59R/108N) associated with 
pyrimethamine resistance in the same population (Okombo et al. 2014) and the high 
frequency of SP resistance markers in Kenya may be attributable to the continued distribution 
of SP for malaria case management in the private sector (Musuva et al. 2017). Even though 
SP is no longer the first line treatment for malaria, similar observations have been made in 
others regions of SSA (Okell, Griffin and Roper 2017). Still, SP maintains its utility in IPTp but 
the loss of IPTp efficacy has been noted when the prevalence of sextuple-mutant parasites 
(dhfr 51I/59R/108N and dhps 437G/540E/581G) exceeds 37% (van Eijk et al. 2019), as seen in 
some SSA settings. Consequently, the dhps-581G mutation needs to be monitored given that 
it first occurs in our population in 2015/16 at 3%. The dhps I431V allele was not detected and 
its distribution appears to be restricted to West Africa (Oguike et al. 2016). 
The decline in the nfs-K65 wild-type allele in the Kilifi population draws attention to the 
potential causes of its decline since the introduction of AL in 2004. Recent findings from The 
Gambia (West Africa) implicated lumefantrine as a selective pressure, showed an increase in 
nfs-K65 allele frequencies over time and described its association with a higher lumefantrine 





that there is an opposite trend of the K65 allele in this East African population. The Gambian 
parasites have shown increasing tolerance to lumefantrine in a study conducted between 
2013 and 2015 (Amambua-Ngwa et al. 2017). However, drug trials with AL in Western Africa, 
including The Gambia, show that AL is still highly efficacious (Dieye et al. 2016). This is despite 
sporadic reports of AL treatment failure in Swedish and UK travellers to SSA that may be an 
early indication of falling AL efficacy (Sondén et al. 2017; Sutherland et al. 2017). It’s worth 
noting that Sondén et al. (2017) attributed the treatment failures to lower lumefantrine 
concentrations during the initial AL treatment. On the other hand, Sutherland et al. (2017) 
mentioned that the patients with treatment failures were not observed to ensure adherence 
to AL regimen nor did they measure lumefantrine blood levels at day 7, to rule out any 
problems with malabsorption, as this may have resulted in failure to clear parasites. However, 
Of equal interest is the increase in the 65Q allele in the Kilifi population compared to the 
apparent stable frequency in the Gambia. Perhaps these discordant observations are due to 
differences in allele frequencies of other loci such as pfmdr1 between East and West Africa 
(Okombo et al. 2013), or the differences in drug policy (such as the extensive use of 
amodiaquine in West Africa compared to East Africa) (Okell et al. 2018) or perhaps the inverse 
relationship between LM and CQ resistance (Mwai et al. 2009a). 
The common k13 A578S mutation that has been found to be prevalent in Africa (Kamau et al. 
2015; MalariaGEN Plasmodium falciparum Community Project 2016; Ménard et al. 2016) was 
also observed in our population at lower frequencies <2% across all time points. In contrast, 
the K189T mutation was the only SNP with a stable, >10%, frequency across all time points 
and it appears to be prevalent globally (MalariaGEN Plasmodium falciparum Community 
Project 2016). Notably, a recent study confirmed that the A578S mutation does not confer 
artemisinin resistance by carrying out genome editing to confirm its phenotypic effect 
(Ménard et al. 2016), consistent with limited field data (Muwanguzi et al. 2016). This 
observation was comparable to serine-tRNA ligase, the neutral marker that was not under 
drug pressure. Moreover, similar to parasites from SSA (MalariaGEN Plasmodium falciparum 
Community Project 2016), the N-terminal region of k13 had higher Ka/Ks ratios than the C-





the gene. This is not the case in SE Asia where the C-terminal region that harbours artemisinin 
resistance SNPs shows higher Ka/Ks ratios, which is most likely the result of artemisinin 
selection pressure. Similar to previous studies (MalariaGEN Plasmodium falciparum 
Community Project 2016), the artemisinin resistance predisposing mutations were not 
identified, apart from a high frequency SNP (I492V) in mdr2 that did not show evidence of 
selection over time. This mutation (I492V) has also been identified at 100% frequency (n = 38) 
in Suriname (Chenet et al. 2017). 
The distinct patterns of selection observed with crt, mdr1 and dhps were not seen in the other 
genes evaluated including ap2-mu, falcipain-2a, nfs and ubp-1. Notably, the ap2-mu-160N 
mutation was observed across all time points at stable frequencies, showing no evidence of 
selection. However, the ap2-mu-S160N mutation has previously been found to be selected 
for after ACT treatment although it was not associated with treatment failure in a Western 
Kenya population (Henriques et al. 2014). in vitro work has further shown that transgenic Dd2 
parasites that harboured the 160N allele had significantly higher dihydroartemisinin IC50 
values compared to those harbouring the wild type S160 allele (Henriques et al. 2015). Of 
interest, the ap2-mu-160N mutation was not observed in the MalariaGEN dataset 
(MalariaGEN Plasmodium falciparum Community Project 2016), particularly in the SE Asian 
parasites where parasites carry both the CQR crt allele and have a multicopy mdr1 locus. This 
suggests that this marker may be specific to the African population, even though from the 
population data there is no evidence of selection. Further evidence showed that transgenic 
parasites carrying an ap2-mu-I592T mutation (not detected in this population), but not those 
gene-edited to harbour the S160N mutation, had increased ring-stage survival (an in vitro 
proxy for artemisinin resistance) compared to the 3D7 wild type allele after 
dihydroartemisinin pressure (Henrici, van Schalkwyk and Sutherland 2019). Further work is 
required to evaluate the potential role of ap2-mu mutations on ACT response. 
Previous work has shown that artemisinin activity is dependent on haemoglobin uptake and 
digestion. falcipain-2a encodes a cysteine protease that is involved in this pathway and its 
deletion has been significantly associated with decreased artemisinin sensitivity (Klonis et al. 





identified in vitro (Ariey et al. 2014), this mutation was not identified in our population. 
However, a significant temporal trend in codon S59F (χ2 = 6.9, p-value = 0.01) was found and 
it showed that there was an increase in the wild type S59 allele post-ACT introduction, 
potentially due to AL pressure. Of note, this mutation is not observed globally (MalariaGEN 
Plasmodium falciparum Community Project 2016). falcipain-2a was the most polymorphic 
gene in this study and this can be attributed to drug pressure as it is a target of antimalarials 
(Ponsuwanna et al. 2016). Crucially, there were no mutations in codons 185 and 187, two 
residues within the falcipain-2a that are important for binding to haemoglobin (Pasupureddy 
et al. 2019). Recently, Siddiqui et al. (2018) showed that mutant falcipain-2a haplotypes 
together with k13 artemisinin resistance mutations were associated with elevated survival in 
the ring-stage survival assay. Some of the mutations identified in that study including N4H, 
A8I, H10N, Q15H, V51I, S59F, K255R, N257E, T343P, D345G, V393I, A400P and Q414E were 
identified in this study as well. Though falcipain-2a was highly polymorphic, k13 did not 
contain artemisinin resistance mutations, thus the role of falcipain-2a in modulating 
artemisinin resistance remains to be understood. 
The ubp-1 1528D mutation was not identified, contrary to Henriques et al. (2014) and a more 
recent study conducted in Ghana that found it at a prevalence of 7.4% (Adams et al. 2018). 
Additionally, a recent study identified, among other polymorphisms, a ubp-1 SNP (R3138H) 
outside the region genotyped in this study, that was associated with artemisinin resistance 
on the Thai-Myanmar border (Cerqueira et al. 2017). ubp-1 was first shown to modulate 
artemisinin resistance in P. chabaudi (Hunt et al. 2007) and later in P. falciparum (Borrmann 
et al. 2013; Henriques et al. 2014). Notably, the frequency of mutant 1528D allele in P. 
falciparum increased after ACT treatment in Western Kenya, although this mutation was not 
associated with recrudescence (Henriques et al. 2014). A recent study demonstrated that 
death of malaria parasites following artemisinin treatment is achieved through the damage 
of proteins as well as inhibiting the proteasome (Bridgford et al. 2018). Given that ubp-1 may 
play a crucial role in ubiquitination and degradation following protein damage, mutations in 





ubiquitination and degradation reduce the accumulation of damaged proteins. Evidently, this 
calls for further work to understand the role of ubp-1 as a marker of ACT resistance. 
Notably, while there were virtually no significant temporal frequencies in genes other than 
crt, mdr1 and dhps, a distinct pattern was detected from 2005/06 through to 2012/13 and 
2015/16. This pattern involved 2-fold increases or decreases in the frequencies of alleles and 
haplotypes from 2005/06 to 2012/13 and a shift back to the original or similar frequency in 
2015/16 and they include: ap2-mu-S160N (9.1 - 24 - 16.5%) and E163E (8.51 - 16.36 - 4.55%), 
falcipain-2a N4H (19.2 - 9.2 - 16.5%), H10N (17.6 - 7.1 - 14.6) and E11E (18.9 - 7.1 - 15.3%), 
ubp-1 KNE-repeat at codon 1514 (5.5 - 11.6 - 5.41%) and N1518N (5.6 - 11.7 - 5.5%), the 
second most dominant k13 haplotype (PK[N6]MAISTLQ, 9.6 - 19.6 - 8.8%) and finally mdr1-
NFD haplotype with a pattern that goes onto the 2017/18 time point (12.7 - 33.3 - 55 - 41.4 
%). This could probably have resulted from the sudden change of drug-policy from SP to ACTs 
and hence the selection of random SNPs across the genome as the parasite population was 
adapting to changes in drug-pressure. These SNPs may have been eliminated over time due 
to a fitness cost. 
The major limitation of this study is that factors such as complexity of infection and its role in 
the evolution of drug-resistance was not studied. The availability of longitudinal samples 
prompted this study into carrying out a surveillance of anti-malarial drug-resistance markers 
during periods where first line antimalarials were switched, hence other questions were not 
explored. 
4.5 Conclusion  
Following the introduction of ACTs in 2004, there has been a rapid increase in the CQ sensitive 
population to near fixation and this reignites the debate on the use of CQ for malaria 
treatment, such as in combination therapy. On the other hand, there is still a need for careful 
monitoring of the dhps A581G locus since SP has proved useful in IPTp, significantly reducing 
morbidity in pregnant women (van Eijk et al. 2019). The decline in the novel marker (nfs) 
which potentially confers resistance to LM, contrary to the observations made in The Gambia, 





resistance-conferring SE Asian mutations in k13, such as C580Y, have not been identified in 
Kilifi and many of the SNPs occurred in the N-terminal region of the gene with no evidence of 
drug selection. Consequently, due to lack of the validated molecular markers of artemisinin 
and lumefantrine resistance, there appears to be no threat to ACT efficacy from resistance in 
the population, however, continued surveillance remains a requirement. 
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Chapter 5 : General Discussion 
The renewed efforts to eliminate malaria mean that more research is required to inform 
malaria interventions. Among the impediments to malaria elimination are asymptomatic 
infections and antimalarial drug-resistance. Asymptomatic infections have been associated 
with adverse health effects and particularly, provide a constant source of parasites that fuel 
malaria transmission. This is compounded by the fact that individuals with asymptomatic 
infections do not present with symptoms of malaria and hence do not seek treatment. In turn, 
such individuals are often not targeted by malaria interventions such as the use of 
antimalarial drugs and, hence, remain chronic for long periods. Recent studies have therefore 
emphasized the need to include asymptomatic infections in malaria interventions and 
additional research is needed to inform this.  
On the other hand, by rendering drugs ineffective, antimalarial drug-resistance makes it 
difficult to clear malaria infections. Worryingly, drug resistance has constantly emerged 
against widely used antimalarial drugs and has, in the past, been associated with a significant 
increase in clinical cases of malaria and mortality. Children under the age of 5 years bear the 
greatest burden of malaria and antimalarial drug resistance is a problem that does not seem 
to go away, however, it can be mitigated with informed decisions. Such decisions involve 
efforts such as carrying out the surveillance of drug resistance using molecular markers. This 
method has gained prominence given that it is less resource-intensive compared to other 
methods such as TES and in vitro culture of parasites. Additionally, it can include hundreds of 
samples with ease because dried blood spots can be used and these are easy to collect, ship 
and store. Thus, the analysis presented in this thesis focussed on characterising P. falciparum 
asymptomatic infections as well as carrying out the surveillance of drug resistance markers in 
Kilifi, Kenya. 
In characterising P. falciparum asymptomatic infections, the first objective in chapter 2 
focussed on evaluating whether age and malaria transmission intensity impact on 
asymptomatic infections, hence, predicting the risk of developing febrile malaria. This work 
was informed by preceding studies that showed divergent outcomes. In some studies, 
asymptomatic infections were associated with an increased risk of febrile malaria while in 
others, the inverse was observed. An inspection of these earlier studies revealed that they 





and with participants of varying age groups. Living in regions of high transmission intensity 
and increasing age have been associated with increasing NAI, which reduces the number of 
clinical episodes that an individual presents with. For this reason, it would be justified to 
hypothesize that both transmission intensity and age might have modified the risk of 
developing febrile malaria in individuals with asymptomatic infections. However, this 
assumption needed confirmation. To achieve this, malaria monitoring data spanning 19 years 
was obtained from three cohorts in Kilifi of varying malaria transmission intensities (Ngerenya 
– low, Junju – moderate to high and Chonyi - high) and with participants ranging between one 
month to 15 years. In this cohorts, children were recruited from birth until they reached 15 
years of age and underwent both active and passive surveillance to detect asymptomatic and 
febrile infections. Accordingly, over 11,000 person-years of follow up were used to evaluate 
whether asymptomatic infections predict subsequent febrile malaria infections and whether 
age and transmission intensity modified this risk.  
In the low transmission setting, it was revealed that asymptomatic infections were associated 
with an increased risk of febrile malaria across all ages, implying that asymptomatic infections 
are detrimental in this setting, as such individuals are expected to have lower NAI. In the 
regions of moderate to high transmission, asymptomatic infections were associated with a 
reduced risk of febrile malaria episodes in older children, however, there was no association 
in younger children. This implied that asymptomatic infections are protective from malaria 
episodes and this pointed to a role of higher levels of NAI in such individuals to predict 
protection. However, regarding the role of premunition or acquired immunity in protecting 
asymptomatic individuals against illness, this study was not designed to elucidate this. 
Premunition in asymptomatic individuals would involve a host response that protects against 
illness due to an ongoing infection, without eliminating the infection. On the other hand, 
acquired immunity would involve protection against illness due to past infections, still without 
eliminating the infection. The impact of this is that clearing asymptomatic infections would 
increase the risk of febrile episodes in the case of premunition but not acquired immunity. 
Either way, a better understanding of these mechanisms would be instrumental in the design 





Given that this analysis used data from varying transmission intensities and with participants 
of varying ages, these findings provided a unifying explanation on the role of asymptomatic 
infections on the risk of developing febrile malaria. Not only do asymptomatic infections 
predict subsequent febrile malaria infections, but it appears this risk is modified by both 
transmission intensity and age. As previously mentioned, asymptomatic infections have 
serious adverse health effects and fuel malaria transmission. Also, while it appears that 
asymptomatic infections can protect one from malaria in regions of high transmission 
intensity, they increase one’s risk of malaria in regions of low transmission intensity. Finally, 
there is ample evidence that curing school children of chronic and asymptomatic infections 
with targeted MDA improves school attendance, cognition and educational attainment 
(Clarke et al. 2017). Therefore, it is crucial that malaria intervention efforts also target 
asymptomatic infections. 
Targeting asymptomatic infections is presented with two main challenges. Firstly, infected 
individuals do not experience symptoms, hence do not seek treatment and this makes these 
infections both undetected and likely to become chronic. Secondly, some asymptomatic 
infections harbour sub-microscopic parasitemia that is below the detection levels of 
microscopy, the gold standard for malaria diagnosis. Accordingly, this makes the estimation 
of the burden of asymptomatic infections a major challenge. MDA interventions avoid the 
detection problem by treating everyone, and some studies have found it to be effective in 
clearing these infections. However, for long-term impact, it appears that MDA needs to be 
sustained for longer periods and this may be a challenge in resource-limited settings such as 
those in SSA. Still, MDA is an attractive method for tackling asymptomatic infections and more 
research is needed to better deploy MDA. Additionally, MDA is recommended in areas 
approaching interruption of transmission where there is good access to treatment, effective 
implementation of vector control and surveillance, as well as regions with minimal risk of re-
introduction of infection. Many regions of SSA are yet to achieve significant reductions in 
levels of malaria transmission, implying that MDA might not be effective in such regions. 
Therefore, efforts should be geared towards reducing the levels of transmission before MDA 





The second objective, addressed in chapter 3, was informed by earlier studies that showed 
that the risk of subsequent febrile malaria episodes following an asymptomatic infection, was 
due to the introduction of new clones not detected before. However, the characterisation of 
the genetic diversity of malaria parasites has for a long time relied on msp1/msp2/glurp 
genotyping. These methods, devised in the 1990s, are limited in their sensitivity and are 
laborious to conduct. Additionally, they are hampered by technical problems such as the use 
of gel electrophoresis to discriminate parasite clones, something that can be subjective when 
the bands being analysed overlap. For this reason, earlier studies may have been limited in 
their ability to fully characterise asymptomatic infections, thereby missing minority clones. If 
this was the case, the finding that the transition from an asymptomatic episode was due to 
the introduction of a new clone, may have been hampered by the lack of detection of the 
same clone in the preceding asymptomatic episode, but at lower frequencies. Amplicon deep 
sequencing was therefore used to characterise the genetic diversity of parasites in 
asymptomatic infections as it is a more sensitive tool to detect minority clones and sample 
pooling allows genotyping of hundreds of samples. Asymptomatic and febrile samples were 
obtained from the Junju cohort described in the first objective and the ama1 gene was used 
to determine COI to characterise parasite diversity as well to characterise the transition from 
an asymptomatic to febrile malaria episode. 
It was revealed that asymptomatic infections harboured more diverse parasites compared to 
febrile malaria infections similar to previous studies. Markedly, a study conducted in Tanzania 
found that individuals with asymptomatic infections had higher NAI based or higher antibody 
titres to merozoite antigens compared to those with febrile infections (Rono et al. 2013). In 
turn, asymptomatic individuals may be expected to harbour more diverse parasites, a proxy 
of higher NAI. In the transition from an asymptomatic to febrile malaria episode, the results 
in Chapter 3 suggest that many of the febrile malaria infections were due to a new clone. This 
finding resonated with earlier studies, implying that the shift from an asymptomatic to febrile 
malaria episode is caused by a parasite clone to which the host is yet to encounter and hence 
a higher probability that the parasite will escape the host’s immune response. Immunity to 





the targets of these antibodies impedes the acquisition of sterile immunity. The P. falciparum 
parasite takes full advantage of this diversity to continuously cause clinical episodes and it 
has been hypothesized that for one to be fully protected from malaria, they would have to 
encounter multiple diverse parasites. The findings in chapter 3 add weight to this hypothesis 
and emphasize the need for further studies that will determine the correlates of immunity to 
malaria. Consequently, such studies will inform the design of a malaria vaccine, a much-
needed intervention that could significantly protect from malaria and greatly reduce the 
human reservoir of disease, as has been observed with the eradication of diseases such as 
smallpox, due to vaccines.  
Another take home point from chapter 3 was the utility of amplicon deep-sequencing to 
determine COI from a large pool of samples. Previous methods used to characterise malaria 
transmission intensity such as the use of spleen rate, EIR, annual parasite incidence and 
parasite prevalence are met with methodological challenges such as being resource-
intensive. COI has been shown to be a proxy for malaria transmission intensity and such data 
can be obtained from hundreds of samples using amplicon deep sequencing. An assessment 
of the population level COI can help to detect active transmission foci if an increase in COI is 
detected in an area and it can also be used to detect the introduction of parasites in an area 
by characterising parasite relatedness. While amplicon deep sequencing is expensive to set 
up, the cost of sequencing has been decreasing rapidly and the usefulness of this method can 
be realised in a few years given that hundreds of samples can be pooled for analysis. Notably, 
one recent review suggested that the high cost of sequencing can be alleviated by creating 
genomic Centres of Excellence in Africa, which will receive and process samples from a 
network of smaller laboratories (Apinjoh et al. 2019). Consequently, such consortia could 
create networks and build capacity in SSA for genomics to track and monitor malaria 
elimination.  
If asymptomatic infections were a threat to malaria elimination, then antimalarial drug 
resistance presents an even bigger threat. The use of drugs to treat malaria, in addition to 
vector control, has become a cornerstone in malaria control. In the past, the use of CQ and 





due to malaria. Thus, lives have been saved, notably those of children under 5 who bear the 
greatest burden of malaria. Unfortunately, P. falciparum has developed resistance to both CQ 
and SP as well as second-line drugs such as MQ and AQ and this hampers malaria intervention 
efforts. In the wake of failing CQ, the world changed to SP as the first-line antimalarial drug 
and later to ACTs after resistance to SP spread widely. Thus, surveillance of antimalarial drug 
resistance is employed to detect resistance as well as characterising its spread in space and 
time. The emergence of resistance to artemisinin, a component of ACTs, in SE Asia means that 
the world is yet again at risk of losing the usefulness of a major first-line antimalarial drug to 
resistance. Moreover, there is now widespread resistance not only to artemisinin but 
resistance to ACT partner drugs in SE Asia. This has resulted in countries such as Cambodia to 
switch from DHA-PPQ to AS-MQ, due to widespread failure of DHA-PPQ to treat malaria 
infections. From 2000 to 2015, both vector control and the use ACTs have had a major impact 
in reducing clinical cases of malaria especially in SSA and resistance to ACTs poses a major 
threat to fighting malaria in SSA.  
The identification of a molecular marker of resistance for artemisinin has made it possible to 
carry out surveillance of artemisinin resistance. Studies have shown that the geographical 
spread of mutations that correlate with artemisinin resistance in the propeller domain of k13 
overlap with cases of slow clearing parasites. The malaria world has hence moved to contain 
resistance in SEA, eradicate it and prevent its spread to other malaria endemic regions. K13 
has proven to be a valid marker for achieving this, however, there is a growing concern that 
k13 may not be applicable in tracking artemisinin resistance outside SEA. Recent studies have 
reported cases of parasites that are resistant to artemisinin but lacking k13 mutations, while 
other studies have reported mutations in genes other than k13. In chapter 4, a temporal 
analysis of drug resistance was carried out using P. falciparum positive samples collected in 
Kilifi during the pre-ACT period (at a time when CQ and SP were in use) and post-ACT 
introduction. The main objective was to determine whether the validated SNPs of artemisinin 
resistance in k13 exist and whether there has been any selection of mutations in the k13 gene 
post-ACT introduction. Additionally, eleven other genes that have been associated with CQ, 





The validated SNPs of artemisinin resistance in k13 were not detected. Also, a k13 mutation 
that is prevalent in SSA was found not to be under selection as it was prevalent in the 
population in the pre-ACT and post-ACT period. Similarly, for the ap2-mu S160T that was 
selected for in children treated with ACTs in Western Kenya, no changes in allele frequencies 
were observed in the pre- and post-ACT periods. A falcipain-2a mutation that was detected 
in a lab strain that was cultured under artemisinin pressure, was not detected hence in this 
population there is no evidence of artemisinin resistance from evaluation of known markers. 
Multiple studies across Africa have continually found the efficacy of ACTs to be high, despite 
the looming threat of artemisinin resistance in SEA. This is important because it means for 
now, Africa can continue to rely on ACTs for the treatment of malaria, but should continue to 
monitor for the emergence of artemisinin resistance. Several theories have been proposed as 
to why artemisinin resistance is yet to be detected in Africa including (i) high parasite diversity 
and low linkage disequilibrium which would continually break resistant haplotypes due to 
parasites of diverse background interbreeding. The high efficacy of ACT partner drugs 
prevents the emergence of resistant parasites since they effectively mop-up the last 
remaining parasites preventing the exposure of parasite to sub-optimal doses of artemisinin. 
(iii) There is higher acquired immunity to malaria in Africa compared to SEA which would 
mean that individuals rarely develop illness and hence no need to take drugs and this would 
substantially reduce drug-pressure then reduce risk of selecting for artemisinin resistance 
parasites. In line with this theory of immunity, a recent study showed that naturally acquired 
malarial immunity was associated with reduced anti-malarial treatment failure in malaria 
endemic populations (O’Flaherty et al. 2017). Consequently, it was hypothesized 
that naturally acquired immunity may accelerate the clearance of artemisinin-resistant 
parasites and hence immunity may also play an important role in the emergence and 
transmission potential of artemisinin-resistant parasites. This, however, presents a challenge 
in that early signs of the emergence of artemisinin resistance parasites may be missed 






The findings in chapter 4 are in line with multiple other studies conducted in SSA that are yet 
to report the existence of validated artemisinin resistance markers. However, there have 
been two reports of artemisinin resistant parasites in Equatorial Guinea and Uganda, but 
these parasites did not have the k13 SNPs that have been associated with artemisinin 
resistance. Still, continued surveillance of artemisinin resistance is called for in SSA especially 
given that there is no immediate replacement for ACTs. Such efforts should involve laboratory 
studies that aim to generate parasites that are resistant to two widely used ACTs in SSA (AL 
and AS+AQ) followed by genome-wide association studies to try and detect SNPs under 
selection that may be involved in resistance. This may help to understand artemisinin 
resistance in parasites with a SSA genetic background, given that recent studies have reported 
that artemisinin resistance required a particular genetic background to emerge in SEA.  
In conclusion, malaria elimination offers a path to eradicating one of the deadliest diseases 
known to man. Many gains in tackling malaria have been realised including eliminating 
malaria in several countries, the deployment of vector control measures and antimalarial 
drugs that have been key pillars in malaria control as well as substantial increases in global 
investment in fighting malaria. Still, significant challenges persist, as many regions continue 
to experience high malaria transmission, insecticide resistance, drug-resistance and chronic 
asymptomatic infections. In this thesis, I have presented work on the epidemiology and 
genetic epidemiology of asymptomatic infections and revealed the extensive diversity of 
parasites that negatively impacts malaria elimination efforts such as the design of a malaria 
vaccine. Additionally, no evidence of artemisinin resistance was detected in Kilifi, but the 
foundation for carrying out continuous genetic epidemiology of antimalarial drug resistance 
in this and other populations continues to be laid. Going forward, baseline data on 
antimalarial drug-resistance markers from Kilifi are now available and this can be used as the 
benchmark for continually monitoring the impact of ACTs on the diversity of these markers. 
Consequently, such data can aid in the detection of early signs of artemisinin resistance. 
Regarding asymptomatic infections, like previous studies, the current study has shown that 
parasite diversity is higher in asymptomatic infections compared to febrile infections. Other 





in asymptomatic infections which has also been associated with protection from febrile 
illness. Future work should look to improve our understanding of the mechanisms of 
protection as this can be used in the design of a malaria vaccine. Given the opportunity, I 
would incorporate amplicon deep-sequencing into malaria monitoring studies to characterise 
parasite diversity as well as carry out surveillance of drug-resistance markers. In 
characterising parasite diversity, a proxy for malaria transmission, studies can evaluate 
whether malaria interventions efforts are working since they are expected to reduce parasite 
diversity. Accordingly, such efforts can evaluate whether gains are being made in tackling 
malaria as we target to eliminate the disease. Secondly, the current study has used Sanger 
sequencing in the surveillance of drug-resistance markers, however, amplicon deep-
sequencing offers a more sensitive, robust and resourceful alternative. With deep-
sequencing, many more samples can be incorporated due to pooling, many markers and 
samples can be included from across Kenya. With this pipeline, routine surveillance can be 
conducted since the platform is already available at the KEMRI-Wellcome Trust laboratories 
as well as other sites across Kenya. Such data will keep Kenya ahead of the impending threat 
of artemisinin resistance since early signs of the emergence of resistance can be detected and 
mitigated in time. 
I hope that the findings presented in this thesis will play a significant role in informing malaria 
elimination, notably, the utility of genetic epidemiology of malaria and that future studies will 
further this work to improve our understanding of parasite origins, gene flow between 
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